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CHAPTER 1 
INTRODUCTION 
Narrowing of the aortic valve by calcified deposits has been recognized for about 
500 years, as seen in drawings by Leonardo da Vinci (1). The physiologic implications 
of such aortic valvular calcified deposits were only appreciated in the last 100 to 200 
years. It was James Hope who in his " A Treatise on the Diseases of the Heart and 
Great Vessels", recognized that the contraction of the aortic valve must be very great 
to influence the vigor of the peripheral pulse (2). 
At the beginning of this century, Tuftier attempted to treat aortic valvular stenosis by 
digitally invaginating a portion of the aortic wall through the opening of the stenotic 
aortic valve, thus creating a truly closed commissurotomy (3). Eleven years after this 
attempt the patient was reported living and his condition improved. 
Beginning with Smithy and Parker (4) in 1947, a number of experimental operations 
have been reported, using a hooked blade initially, which was inserted into the 
ascending aorta, and, after passage through the stenotic valve, this thin-bladed knife 
was retracted, in order to lacerate one or more aortic valve cusps. Bailey and 
coworkers (5) used punchcutters, Goodell uterine dilators and a Brock-like 
valvulotome. This last instrument had an umbrella like configuration with three blades, 
which was advanced retro or antegradely through the stenotic aortic valve, opened 
and retracted. These investigators later developed a pencil-like instrument with a blunt 
point which could be opened and forced through the stenotic aortic valve. They felt 
that this instrument had insufficient dilating force, and that the forcible passage of the 
dilator head was unduly traumatic. Therefore they replaced the umbrella-like spring 
blades, by three parallel dilating bars with wedge like cross sections, to dilate the valve, 
without retracting the instrument. The results left Bailey reflecting that " .... we do not 
accomplish much opening of the stenotic valve by any closed method. It is not 
surprising that many of our surviving patients are beginning to show evidence of 
recurrence of the stenosis" (6). 
For this reason Bailey proposed an exclusive open method to remove the extremely 
calcified layer of the aortic cusps (6). This technique was initially hampered due to the 
time needed to perform a satisfactory "debridement". With the introduction of general 
hypothermia, which considerably extended the time available for a cardiac operation, 
more extensive and accurate sculpturing of the stenotic aortic leaflets became 
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possible, and was performed by Lewis and Shumway (7). Another milestone was 
attained with the introduction of extracorporeal circulation and the pumpoxygenator (8), 
which allowed surgeons ample time to perfect the debridement technique, and to attain 
more satisfactory results (9). At the same time, however, more definite alternatives 
came into vogue to completely replace the diseased aortic valve, and halted the era 
of operative valvuloplasty (10). Although surgical pioneers developed in the course of 
time many different prosthetic heart valves to improve durability and reduce 
thrombogenecity, no prosthesis proved ideal once subjected to the test of time. 
As a result of these imperfections, techniques were developed to replace the aortic 
valve with homo and heterografts initially procured from post mortems and sewn into 
the descending aorta without the use of extracorporeal circulation (11). Later D. Ross 
(12) and Barratt Boyes (13) used freeze-dried aortic valve homografts, inserted below 
the coronary ostia. Heterografts, mainly consisting of pig or calf aortic valves were also 
employed in the same time period (14). Later Carpentier perfected these valves by 
employing a support ring (15), instead of suturing these valves directly to the aortic 
ring. Other biomaterials have been used to reconstruct or replace the diseased aortic 
valve, such as autologous fascia lata (16, 17), heterologous pericardia! tissue (18) and 
homologous dura mater tissue (19), with or without a supporting frame. 
Nowadays aortic valve replacement or reconstruction is a widely accepted operation, 
which can be performed with an overall in hospital mortality of about 5% and an 
excellent life expectancy after the operation for the survivors (20). However several 
preoperative variables have been recognized that increase the operative risk of aortic 
valve replacement (21). Among these factors are age over 70 years, female gender, 
poor left ventricular function, concomitant coronary artery disease and emergency 
operation. Accumulation of several of these risk factors might lead to such a high 
expected operative risk, that patients, however severely symptomatic, are denied 
operation. Moreover the high age of some patients with severe aortic stenosis, can be 
a prohibitive factor in performing cardiac surgery. 
In 1985, Cribier and coworkers from Rauen in France, extended the area of the 
interventional cardiologist, by applying percutaneously introduced balloon catheters to 
dilate acquired aortic valve stenosis in three elderly patients (22). Immediate results of 
these procedures appeared very encouraging, so that the authors subtitled their first 
publication with: "an alternative to valve replacement?". This balloon procedure had 
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been considered until then inconceivable for application in patients with longstanding, 
calcified stenotic aortic valves, although it had been preceded by the introduction of 
the balloon dilatation technique in young patients with congenital aortic valve stenosis 
for several years. This was the direct reason for the investigation laid down in this 
thesis. 
On March 19, 1986, Cribier assisted Patrick Serruys and myself with our first 
percutaneous balloon valvuloplasty procedure in a male patient of 75 years old, with 
severe aortic stenosis. Till January 1, 1990, thirty seven other patients have been 
treated. The results obtained in these patients constitute the main topic of this thesis. 
In chapter 2 we describe the pathology and etiology of the various forms of aortic 
valvular stenosis. 
In chapter 3 we review the initial surgical attempts to relieve aortic valve stenosis 
with the help of remarkable instruments and later endeavors to replace the aortic valve, 
ultimately with prosthetic materials. 
In chapter 4 we report our immediate and medium term results in elderly patients 
who underwent percutaneous balloon aortic valvuloplasty. Complications of the 
procedure and symptomatology of the patients after valvuloplasty were assessed 
systematically, by asking specifically about anginal symptoms, syncope or dizziness, 
dyspnea and daily activities. 
In chapter 5 we describe the measurements obtained with echo Doppler techniques 
before and after valvuloplasty in these patients and we compare these data with 
catheter derived values. 
In chapter 6 we describe experimental post mortem balloon aortic valve dilatations, 
evaluated with Computer Tomographic scans. We extrapolated these experimental 
data to actual relations between balloon design and valve anatomy. 
In chapter 7 we report about the merits of a long introducer sheath inserted during 
the valvuloplasty procudure. 
In chapter 8 we report the results of aortic valve replacement in patients with 
previous percutaneous balloon dilatation of the stenotic valve, and we describe the 
histologic changes in these valves excised during operation. 
We conclude in chapter 9 with an inventarization of present and future indications 
for the procedure and some reflections on technical improvements to make the 
procedure safer and eventually more efficient. 
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CHAPTER 2 
ISOLATED AORTIC VAlVE STENOSIS: 
HISTORY, ETIOlOGY, PATHOlOGY, PHYSIOlOGY 
SUMMARY 
Isolated aortic valvular stenosis has been recognized for about half a millennium. 
Many of the disputes around the etiology of this disease which have raged since, can 
be ascribed to changing prevalence of the different disease entities and gradual ageing 
of the population in general. While, only 40 years ago rheumatic fever was the principal 
cause of aortic valvular stenosis, nowadays this is only found in a small minority of 
patients in western countries. Thus the proportion of congenital aortic stenosis, or 
congenitally bicuspid aortic valves, which become gradually stenotic, has increased, 
and most of all the degenerative form prevalent in elderly patients is now the main 
cause. Calcification of aortic valves can occur in a congenitally abnormal aortic valve, 
after rheumatic valvulitis or as a degenerative process in an otherwise normal tricuspid 
aortic valve. This process of fibrosing and calcification of the valve leaflets regardless 
of cause, creates a resistance to ejection of blood from the left ventricle, which leads 
to cellular hypertrophy, hyperplasia and wall thickening in an effort to normalize wall 
stress. However sustained pressure overload eventually leads to a depression of the 
contractile state of the myocardium, usually late in the course of the disease, and then 
is attended by left ventricular dilatation. Thus symptoms usually appear late in the 
course of aortic valvular stenosis, and consist of angina pectoris, syncopal attacks, 
sudden death or dyspnea when patients enter the stage of cardiac failure. The onset 
of symptoms is an indicator of moderately severe aortic valvular stenosis, with an 
aortic valve orifice restricted to i .0-0.7 cm2. Sudden death is uncommon as a first 
symptom of aortic valve stenosis, and most patients remain asymptomatic until this 
critical value of an aortic valve area of less than 0.7 cm2 is attained. Angina pectoris 
may occur earlier and is explained on the basis of subendocardial hypoperfusion. 
Syncope and sudden death are interpreted as a consequence of a malfunctioning 
baroreceptor mechanism rather than critical stenosis percentage. Dyspnea is caused 
by left atrial pressure elevation and pulmonary venous congestion in turn preceded by 
cardiac hypertrophy, dilatation and dysfunction in diastole. Evaluation of the natural 
course of aortic valve stenosis has become difficult because efforts at the objective 
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measurements of its severity over time by means of sequential left heart catheterization 
have been thwarted by operative treatment. Most studies on the natural history of this 
disease are therefore either based on early symptoms or on post mortem 
examinations, assessing retrospectively the symptoms of the deceased. Yet it is 
generally accepted that life expectancy in patients with critical aortic stenosis of :::o.7 
cm2 is low, with more than 80% of patients dying within five years. Upon the 
occurrence of angina pectoris life expectancy is usually limited to three or four years, 
after syncope to three years or less and after signs of cardiac failure to one year. 
The most important coexisting condition in aortic valve stenosis is coronary artery 
disease, which has a high prevalence among elderly people, the population 
predominantly affected by isolated aortic valve stenosis. Incidences of 24 to 52% of 
obstructive coronary artery disease have been reported in patients with severe aortic 
valve stenosis, the highest percentage being demonstrated in those over 80 years. As 
the absence of angina pectoris does not always indicate absence of coronary artery 
disease, selective coronary angiography should routinely be performed as part of a 
preoperative invasive evaluation in all patients. 
HISTORY 
The earliest description of aortic valvular stenosis is probably that of Riverius in 164 7 
who correlated the anatomic changes of aortic valvular stenosis, with the clinical 
features of a weak pulse and diminished arterial pulsations (1). Carolus Rayger (1672), 
annotated by Bonetus in his Sepulchretum, also contributed to the recognition of this 
disease (2). He noted that the aortic valves in a middle aged Parisian taylor who 
dropped dead on the street, had the consistency of bone. Many physicians, beginning 
with Corvisart, Napoleon's physician, recorded their impressions of the clinical 
manifestations ofthe disease (3). These early recordings led to various misconceptions 
about the physical signs of aortic valve stenosis. It was James Hope in his " A Treatise 
on the Diseases of the Heart and Great Vessels" who corrected these to a large extent. 
He noted that the "contraction of the aortic valves must be very great to render the 
pulse small, weak, intermittent and irregular". He also wrote that "irregularity of the 
pulse is not necessarily or usually produced by contraction of the aortic valves, unless 
extreme; nor are the size and strength of the pulse materially diminished by moderate 
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contractions"(4). 
ETIOLOGY 
Valvular aortic stenosis may be a congenital or acquired malformation (Table 1). 
Age 
years 
0-30 
30-70 
> 70 
Table 1 
Disease prevalence 
listed in decreasing frequency 
Unicuspid valve 
Bicuspid valve 
Bicuspid valve 
Rheumatic valvulitis 
Unicuspid valve 
Degenerative calcification 
Bicuspid valve 
Rheumatic valvulitis 
Etiology of isolated aortic valve stenosis (after Hurst (22)). 
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The pathogenesis and etiology of isolated aortic stenosis has long been a subject 
of great controversy. This controversy followed Monckeberg's attempt to determine the 
pathogenesis of aortic stenosis in 1904 (5). He studied 32 cases between 26 and 84 
years and concluded that either inflammation or degenerative calcification was the 
cause of aortic stenosis. This concept was the basis for numerous studies summarized 
by Karsner and Koletsky in 1947 (6). However, they concluded that out of 200 patients 
with aortic stenosis, 196 exhibited signs of rheumatic valvulitis (6), which view was 
supported by other cardiologists (7-9). Rheumatic fever is generally considered to be 
caused by an unusual response to a B hemolytic streptococcal infection. Cross-
reactivity between membrane antigen determinants of B hemolytic streptococci 
(following a throat infection) and certain proteins present in the heart, may produce an 
immune- conveyed injury to cardiac tissues, evoking inflammation. This inflammatory 
reaction, in its acute stage, is dominated by edema. Fibrinoid necrosis of connective 
tissues and cellular reaction occur next. When the inflammatory process is located in 
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the heart valves, this valvulitis leads to verrucous fibrin deposits along the line of 
closure of the leaflets. Organization of the acute inflammatory reaction will go together 
with fibrosis and retraction or thickening. Recurrent attacks of rheumatic fever may 
thus produce repeated episodes of injury and repair leading to fibrosis of the valves 
and commissural fusion (10,11, 12). This process may affect all three commissures, but 
is occasionally confined to only one cusp, leading to acquired bicuspidy of the aortic 
valve. Calcifications in the valve affected by rheumatic disease are as a rule a 
concomitant finding in patients over the age of 40. Campbell and Kauntze pointed out, 
that among congenital bicuspid aortic valves, aortic stenosis was more prevalent at a 
later age, observations which were confirmed by others (3, 13-17). This association, 
however, had already been recognized in 1858 by Peacock who indicated that 
bicuspid valves could develop 11Chronic inflammation II and become thick, unyielding and 
often ossified (18). Patients developing aortic stenosis over the age of 70, usually 
manifest degenerative calcifications of an in origin tricuspid aortic valve (19,20). 
Many of the disputes around the etiology of valvular aortic stenosis can be ascribed 
to two causes. First of all the prevalence of several disease entities has changed over 
the years with for example a dramatic decrease in rheumatic fever especially in 
developed countries. While Karsner and Koletsky in 1947 described in 200 cases of 
autopsied aortic valve stenosis a 74% incidence of cases with commissural fusion (6), 
Petersen in 1985, found only a 10% incidence of the same phenomenon in 109 
surgical patients with aortic valve stenosis (21). Secondly the longer survival of the 
population in general has had a great impact on the distribution of the different disease 
entities. As can be concluded from Table I, proposed by Willis Hurst (22), ageing of 
a population in general might favor the incidence of degenerative calcification as a 
cause of aortic valve stenosis. 
PATHOLOGY 
Calcific aortic stenosis is a term applicable in a broad sense to all varieties of adult 
aortic stenosis, but is now generally reserved for aortic stenosis with pure calcification 
of the valve leaflets. It is now clear that aortic stenosis does not have a single etiology, 
and in almost all cases can be attributed to one of three processes: calcification in a 
congenitally abnormal aortic valve, calcification following, usually rheumatic, valvulitis 
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and degenerative (or senile) calcifications in an otherwise initially normal tricuspid aortic 
valve (i9, 23-25). 
Congenital malformation of the aortic valve, includes unicuspidy, bicuspidy and 
tricuspidy. Unicuspid valves are usually the most common anatomical base for severe 
valvular aortic stenosis under the age of one year (26-28). Moreover, calcific aortic 
stenosis seen in children, teenagers and young adults will likely be due to either a 
unicuspid aortic valve or one with no obvious commissure (acommissural valve). 
Bicuspid valves may be stenotic at birth, but more commonly are initially not a serious 
impediment for aortic valve flow (29-3 i). Their abnormal architecture induces turbulent 
flow, which leads to trauma of the leaflets and later to rigidity of all cusps due to 
fibrosis, combined with calcification of the valves and narrowing of the valve orifice 
(32). The calcification usually develops at the free edges first, and then progresses to 
the base. If infective endocarditis develops on a calcified bicuspid aortic valve, the 
destructive inflammatory process renders the valve incompetent, leading to aortic 
regurgitation. However regurgitation is a rare finding in congenital bicuspid aortic 
valves without preceding infection. Also severe deposits of calcium do not occur in 
purely incompetent congenitally bicuspid aortic valves. Based on this observation 
Roberts states that valvular stenosis seems to be a prerequisite for the development 
of heavy deposits of calcium at this site. However, the inverse seems to be more 
plausible, i.e., only heavy calcifications cause stenotic aortic valves (33). Edwards (34), 
offers an attractive alternate explanation for a congenital bicuspid valve to become 
stenotic. In his view it is not mechanically possible for a congenitally bicuspid valve to 
open and close properly. The free margins of normal tricuspid valvular cusps are 
curved lines. Here the extra length allows the cusps to move freely during opening and 
closing of the valves. In contrast the distances between the lateral attachments of 
congenitally bicuspid valves are almost straight lines. Indeed if they were completely 
straight the valve could not even open during ventricular systole. Consequently at least 
one cusp is larger than the other, producing abnormal contact between the cusps. 
This in turn causes abnormal fibrous thickening, in the course of time progressing 
into calcification. Such an explanation does not elucidate why one congenital bicuspid 
aortic valve becomes stenotic, another incompetent, and yet another remains free of 
complications. Furthermore the congenitally bicuspid aortic valve induces calcific aortic 
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stenosis in patients 40 to 70 years old, yet also tricuspid valves may be congenitally 
misformed, with cusps of unequal size, which may lead, as in the case of bicuspid 
valves, to turbulent flows and fibrosis of the valve leaflets. In 20 percent of cases of 
aortic stenosis between the age of 15 and 65 years, tricuspid valves were found at 
autopsy, without signs of rheumatic fever. These cases must be considered to have 
been either congenital tricuspid malformed valves, or degenerative tricuspid valves, or 
a combination of both (35). 
Rheumatic valvular disease is seen in the 30 to 50 age group, especially in 
women. The aortic lesion is almost always combined with mitral rheumatic valvular 
disease. Isolated aortic stenosis is a rare manifestation of rheumatic heart disease, 
accounting for only 5% of cases. Combined mitral and aortic disease occurs in about 
one third of patients with rheumatic heart disease often leading to the misrecognition 
of the other valve involvement (36). The stenosis of the aortic valve in this condition is 
initiated by recurrent episodes of valvulitis in due time leading to fibrosis of the valve 
leaflets and to fusion of commissures (10, 11). 
The fusion occurs most often between the left and right aortic leaflet converting the 
aortic valve into a bicuspid configuration, subjected to the same stresses as congenital 
bicuspid aortic valves (37). Thus, both for the pathologist and the surgeon it may be 
problematic to differentiate congenital bicuspid aortic valves from acquired bicuspidy. 
Osler (38), deduced characteristics to make this differentiation by macroscopic 
inspection. The raphe (false commissure or ridge) is located where the true 
commissure normally would be. The length of the free margin of the conjoint cusp, is 
slightly larger than the margin of the cusp without a raphe. The border of attachment 
of the conjoint cusp viewed from the ventricular aspect, presents either the contour of 
a single semilunar cusp or a shallow groove, indicative of the junction of two cusps. 
The raphe may be located on the aortic wall alone or extend onto the cusp for variable 
distances. According to Lewis and Grant (39) the subdivided cusp is larger than one 
normal cusp, but smaller than two normal cusps. As pointed out by Edwards (40) the 
raphe might also display macroscopic features suggesting fusion of two distinguishable 
separate cusps in infants with congenital bicuspid stenotic aortic valves. Lewis and 
Grant (39) considered gross examination to make a distinction between congenital and 
acquired bicuspid aortic valves unreliable, and supported their macroscopic 
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observations with histologic examination. They noticed that microscopically a "true" 
raphe is similar to the media of the aortic wall containing elastic fibres, while fused 
commissures lacked elastic fibres and consisted mainly of fibrous valvular tissue. 
Koletsky (24) pointed out that congenital raphes were devoid of vascular channels and 
inflammatory cells, whereas both were seen in acquired, fused commissures. However 
helpful these histologic criteria might seem, the experience is that by the time the 
patient suffers from the complications of his valve anomaly and the valves can be 
examined either after surgical excision or at autopsy, they will be so heavily scarred 
and calcified that histologic examination is often fruitless (33). 
Primary degenerative calcification of otherwise initially normal tricuspid aortic 
valves. It appears that tricuspid aortic valves are rarely stenotic at birth. Possibly minor 
abnormalities in the size of the aortic valve cusps induce abnormal contact of the 
leaflets with one another, resulting in fibrosis and finally stenosis (41). According to 
Vollebergh and Becker three aortic valve cusps of equal size are the exception rather 
than the rule (42). Approximately 5 percent of aortic tricuspid valves show some 
degree of calcification by the age of 55, with an increase in incidence of 1 percent per 
year, up to 30% at the age of 85 (25). These degenerative changes were already 
recognized by M6nckeberg (5), but are not due to atherosclerosis as he suggested. 
In atherosclerosis the early lesion includes fatty macrophages, which are absent in the 
early stages of degenerative valvular calcification, the primary change in the latter 
condition being an alteration of connective tissue with extracellular droplets of neutral 
fat occurring within the collagen. This material serves as a precursor for calcium 
deposition. The bases of the cusps are the first sites to be affected with this alteration 
of the collagen, which later extends to the free margins of the cusps with progressive 
calcification. The calcification is entirely on the aortic side of the cusps, without fusion 
of commissures. Calcifications may also extend to the aortic wall while these three 
phenomena are rarely encountered in rheumatic aortic valve disease (15, 19,37,43). The 
described changes are the same as those which occur at an earlier age in many 
bicuspid valves and are in the case of bicuspid valves ascribed to simple wear and tear 
as described.earlier in this chapter. Support for the traumatic nature of the valve 
stenosis is found in the presence of the histologic counterpart of fatty deposits within 
the collagenous tissue and secondary calcifications in the supraspinatus tendon in 
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cases of subdeltoid bursitis (43). Although there is an overlap in the different age 
groups, the basic architecture of the aortic valve in general correlates with the age of 
the patient. Roberts noticed that there is a definite relationship between the number 
of cusps present at birth and the age at which aortic stenosis becomes manifest (33). 
Below the age of i 5 years 60% of isolated aortic stenosis is due to unicuspidy and 
only i 5% of these patients have tricuspid aortic valves. On the other hand 90% of 
patients above the age of 65 years with aortic stenosis manifest tricuspid valves, while 
none of these elderly patients have unicuspid valves. Aortic stenosis with underlying 
bicuspid anatomy was found in 20% of patients below the age of i 5 years, 60% in 
patients between i 6 and 65 years old, and in i 0% of patients over the age of 65. (see 
Table 1). We conclude therefore that congenital aortic stenosis is most frequently 
encountered with congenital unicuspidy. 
INCIDENCE OF VALVULAR AORTIC STENOSIS 
Unicommissural, unicuspid aortic valve stenosis 
This type of valve is generally considered to be stenotic from birth on, and one of 
the common forms in very young children. Exceptionally this form of valve stenosis can 
be free of symptoms for a long period. The oldest reported patient with this type of 
lesion was 69 years old (i2). The incidence of this congenital malformation is not 
known. 
Bicuspid aortic valve stenosis 
Congenital bicuspid aortic valves are not intrinsically stenotic (34). Campbell (25) 
stated that a bicuspid aortic valve occurred in 0.4% of live births, males dominating 
females in a ratio of 4 : i. One quarter of these valves became calcified by the age of 
40, and one half over the age of 50. Roberts (44) in i800 autopsied hearts, without 
preexistent cardiac disease, found i 7 congenitally bicuspid valves with normal 
appearance (i %). The same author concluded that the frequency of this malformation 
is as high as 2% of all human births (i6). This incidence suggested by Roberts is far 
higher than that encountered by Becker (i 2) although he did not mention a specific 
percentage. Fenoglio reported that among children born with a bicuspid aortic valve 
one third will have normal function throughout life, one third will have calcific aortic 
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stenosis, and one third will have aortic regurgitation (29). 
Rheumatic aortic stenosis 
The incidence of isolated rheumatic aortic stenosis in a general population is not 
known. Of all patients affected with rheumatic heart disease, only 5% manifest isolated 
aortic valve stenosis (36). While the proportion of stenotic aortic valves with all 
commissures fused has been reported to be as high as 74% in autopsied hearts in 
1947, in two recently reported series, from 1984 and 1985, it was only 27 and 10% 
(6,21,45). 
Primary degenerative calcific aortic stenosis 
This condition is now reported as accounting for 30% of surgical cases (21 ,45). As 
this disease affects the oldest people, the true incidence of the disease might be 
underestimated, because many patients are not candidates for surgery. 
PATHOPHYSIOLOGY 
Stenosis of the aortic valves creates resistance to the ejection of blood from the left 
ventricle. During systole a pressure difference develops between the left ventricle and 
the ascending aorta. The left ventricle adapts by hyperplasia and hypertrophy. 
Hypertrophy by definition is characterized by an increase in volume of the myocytes 
(12), but initially there is also hyperplasia, an increment in the number of cells. The 
cellular hypertrophy leads to a regular increase in thickness of the wall and left 
ventricular mass, known as concentric hypertrophy. This concentric hypertrophy 
without chamber dilatation normalizes the wall stress, and preserves normal left 
ventricular ejection function (46). Dilatation of the left ventricle does not occur until, in 
the more advanced stage of the disease, the contractile state of the myocardium is 
severely depressed. Eventually the increase in left ventricular volume and mass result 
in an elevation of the left ventricular end-diastolic pressure. Additionally atrial systole 
contributes more to the volume ejected by the left ventricle in severe aortic stenosis, 
as compared to the normal ventricle and so further raises end-diastolic left ventricular 
pressure (47). Such increases in end-diastolic pressure stretch the myocardial muscle 
fibres and so evoke a larger stroke volume by the Frank-Starling effect. Initially this will 
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aid left ventricular emptying (48). However, sustained pressure overload eventually 
leads to a depression of the contractile state (49). In turn the declining mechanical 
performance is attended by further dilatation of the left ventricle. This extra left 
ventricular dilatation will increase the left ventricular radius, and elevate wall stress to 
unsustainable degrees. Such consistently uncompensated and elevated wall stress 
jeopardizes coronary perfusion, leading to myocardial ischemia, especially in the 
subendocardial region. This event can be reinforced by the lengthening of the coronary 
capillaries in the dilated heart. Moreover, myocardial hypertrophy impairs oxygen 
delivery to the myocytes even more by increasing the diffusion distance from the 
capillaries to the center of the enlarged myocardial fibres. For all reasons stated above, 
myocardial fibres will suffer from ischemia, which not only will lower their performance, 
but may lead to cell death and fibrosis. This sequence of cellular events also occurs 
in patients with aortic stenosis without coronary sclerosis. However, it will be clear that 
in the case of even minor atherosclerotic narrowing of the coronary arteries the 
effective perfusion pressure of the coronary artery distally from the stenosis will decline 
even further, increasing the risk of developing ischemic damage to the myocytes. 
Cellular malfunctioning can lead to a decline in ejection fraction, which implies a 
reduction in cardiac output. Reduced cardiac output will increase the left ventricular 
end-diastolic pressure, causing a rise of the effective left ventricular filling pressure, in 
its turn leading to left atrial pressure elevation. These events give cause for pulmonary 
venous dilatation and congestion, going together with dilatation of lymph vessels and 
edema of the intralobular septa. To protect the pulmonary capillary bed, temporarily 
a vasoconstriction of the arterial side of the pulmonary circulation will occur, leading 
to an increase in pulmonary resistance. Eventually this process will lead to structural 
changes in the pulmonary veins as well as in the pulmonary arteries and overload of 
the right ventricle. 
Histologically myocardial hypertrophy is characterized by myocytes that have an 
enlarged cross sectional diameter, far exceeding the mean normal myocyte diameter 
of 12 microns. The nucleus of the hypertrophied cell is also increased in size and often 
shows a bizarre contour. Dilatation of the left ventricle leads to attenuation of the 
myocardial fibers and the cytoplasm of the cells is stretched along the enlarged 
nucleus leading to a discrepancy between nuclear size and fiber diameter. Myocardial 
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ischemic damage eventually may cause loss of myocytes. This goes together with a 
scarring reaction in which the lost myocytes are replaced by connective tissue (50). 
A variety of ultrastructural changes in the myocardium have been documented in 
patients with aortic stenosis. However, it must be kept in mind that these changes are 
by no means specific for aortic stenosis, and can also be found in other cardiac 
diseases. Loss of cellular elements, such as myofibrils and mitochondria, and 
proliferation of fibroblasts and collagen fibers in the interstitium, as part of the scarring 
reaction, have been described (51) in coronary artery disease and other inflammatory 
disorders. 
Symptoms appear late in the course of aortic valve stenosis, and consequently 
patients may have severe stenosis, unrecognized for years. During this asymptomatic 
period a small percentage of the patients die suddenly (52,53). However the onset of 
angina pectoris, syncope or symptoms of left ventricular failure are the usual indicators 
of critical aortic stenosis. Critical in this sense, is commonly used by most authors as 
an aortic valve area of less than 0.7 cm2, i.e. less than one quarter of the normal aortic 
orifice (54). 
Angina pectoris is the most common initial symptom of severe aortic stenosis. The 
incidence of this symptom has been reported to be as high as 70 percent. The 
average life expectancy when this symptom appears is 5 years, with longer survival 
(1 0-20 years) noted only in 5 percent of the patients (7). This symptom can also occur 
in the absence of obstructive coronary lesions. It is explained on the basis of 
subendocardial hypoperfusion due to diminished coronary reserve, as described earlier 
(55,56). 
Syncope and an increased risk of sudden death have long been considered to be 
unique features of aortic stenosis. Three hypotheses are being offered to explain the 
mechanism of syncope: arrhythmia, abrupt failure of the overloaded left ventricle and 
a faulty baroreceptor mechanism, leading to peripheral vasodilatation. In the series of 
patients with syncope observed by Schwartz, the first sign was always an abrupt fall 
in arterial pressure, followed by ventricular rhythm disturbances (57). It seems therefore 
that arrhythmias are secondary to a drop in pressure. It was Johnson who offered the 
hypothesis of baroreceptor mechanism malfunctioning in 1971, as the cause of 
syncope (58). He explained that an abrupt rise in pressure during exercise without a 
concomitant rise in aortic pressure, may stimulate left ventricular baroreceptors, to 
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produce a severe depressor effect. Very little support for the theory of abrupt left 
ventricular failure has been found in literature. One observation was published in 1967 
by Flamm (59). Moreover Lombard (60) stated that syncope usually occurs at the time 
when left ventricular function is still normal. So it seems that up to now Johnson's 
hypothesis of baroreceptor mechanism malfunction is the most plausible explanation 
for syncope in patients with aortic stenosis. Sudden death has been related more to 
syncopal attacks which become irreversible, rather than to primary ventricular 
fibrillation (61). 
Left ventricular function is well preserved in most patients, not only in the 
asymptomatic stage, but also in the patients with angina or syncope. Depression of left 
ventricular function may be caused by inadequate left ventricular hypertrophy and 
progression of the severity of aortic stenosis. Correction of the stenosis usually 
reverses hypertrophy and restores left ventricular function, mediated by regression of 
myocardial cellular hypertrophy. But even 6-7 years after valve replacement the 
regression of structural abnormalities of left ventricular hypertrophy is still incomplete, 
as recently demonstrated by left ventricular biopsies by KrayenbOhl and co-workers. 
(62). 
When left ventricular dysfunction is such that cardiac output is depressed, outflow 
obstruction becomes relatively more severe. These events might explain the rapid 
deterioration of patients with aortic stenosis, who enter the stage of cardiac failure (63). 
Progression of the severity of aortic stenosis can be accomplished either by a further 
reduction of the orifice size, or by restricting the mobility of the cusps. In congenital 
aortic valve stenosis the size of the orifice is determined at birth. The degree of 
stenosis may remain unchanged, progress, due to secondary degenerative changes, 
or possibly regress with the growth of the heart (64-66). 
Rheumatic aortic stenosis develops in its early stages from cusp fibrosis and 
commissural fusion. Bland and Jones indicate that the stenotic process in the aortic 
valve is slower than in the mitral valve (67). A further decrease in the mobility of the 
movable portion of the cusps is achieved by calcium deposition, furthering progression 
of stenosis. This hypothesis is supported by findings at autopsy and surgery, where 
patients with rheumatic aortic valve stenosis show postinflammatory fibrosis and 
usually extensive calcifications (68). 
In calcific aortic stenosis, a term usually applied to calcified bicuspid and tricuspid 
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aortic valves, the commissures are usually unaffected. The valve becomes more 
stenotic as the mobility decreases by fibrosis and deposition of calcium, as 
demonstrated by Wagner and Seizer in a serial study of 50 patients. Progression of 
stenosis was more rapid in older patients with calcific aortic stenosis (63). As stated 
by these authors, calculation of aortic valve area by means of cardiac output and mean 
transvalvular pressure gradient, constitutes a more reliable measure of progression of 
disease than the pressure gradient alone, because a decrease in valve opening force 
might reduce both cardiac output and transvalvular pressure gradient. 
NATURAL COURSE 
Evaluation of the natural course of aortic stenosis has been difficult because the 
objective assessment of its severity by means of left heart catheterization, and the initial 
attempts at correction by operative treatment, occurred almost simultaneously (52). 
Therefore most information on the natural history of aortic valve stenosis must be 
assembled from clinical and postmortem studies of the pre-surgery era. As mentioned 
earlier, the course of valvular aortic stenosis is characterized by a long asymptomatic 
stage. The normal aortic valve area in adults varies between 3 and 4 cm2. Resistance 
to flow, manifesting itself by a transvalvular pressure gradient, appears when the aortic 
orifice is reduced to 1 to 1.5 cm2. Symptoms seldom develop before the stenosis is 
at least moderately severe (0.7 to 1.0 cm2), but even patients with critical aortic 
stenosis(< 0.7 cm2) may remain asymptomatic (60). 
Angina and syncope are early warning symptoms, present in about two thirds of 
patients with aortic valve stenosis. In the remaining one third congestive heart failure 
is the initial presentation (60). Also the age at which clinical symptoms present has 
changed. Ross and Braunwald in an overview of aortic stenosis collected several 
studies between 1934 and 1967, and found a mean age of clinical presentation of 
symptoms of 48 years (52). In the more recent study (1987) of Lombard and Seizer 
the age at presentation in symptomatic patients was 61.1 years (60). Many patients are 
not even considered for presurgical evaluation, due to other concomitant life 
expectancy limiting disease, so that the mean age at presentation might even be 
higher nowadays. 
Only a few prospective clinical studies about the natural course and mortality in 
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aortic valve stenosis are available. Most of these studies, however, are based on 
symptoms, without evaluating the actual severity of the disease. Grant reported a 65% 
mortality in symptomatic patients at the end of.10 years follow up {69). Wood followed 
32 patients, who were considered clinically to have severe aortic disease, for periods 
of one to seven years. Eighteen of these patients died during the observation period 
(7). Of Takeda's series of 60 patients admitted to the hospital with a diagnosis of 
isolated aortic valve stenosis, 82% were dead after 4 to 15 years (53). In the only 
reported series of 12 patients with critical aortic valve stenosis (valve orifice :::o. 7 cm2), 
assessed by cardiac catheterization, without subsequent operation, 10 were dead, at 
the end of five years (70). 
In various studies based on data obtained at post mortem examination the average 
duration of various symptoms was as follows: angina pectoris three years, syncope 
three years, dyspnea two years and congestive heart failure 1.5 to 2 years (52). Olesen 
and Wartburg showed a mean survival in the presence of angina of 4. 7 years, in the 
presence of syncope of 3.2 years, and with concomitant cardiac failure of less than 
one year (71). The prognosis extracted from the literature might nowadays be more 
favorable, because the fatal outcome might have been modified by modern therapeutic 
measures. This is especially valid in the case of bacterial endocarditis, which counted 
for 15 to 20% of all deaths with isolated aortic valve stenosis in post mortem studies 
(52). Seizer recently stated that infective endocarditis is a rare complication of aortic 
valve stenosis, its incidence being known only for congenital aortic stenosis, and 
estimated to be 1.8 per 1000 patients-years {61, 72). 
COEXISTING CONDITIONS 
The most important coexisting condition is coronary artery disease, which has a high 
prevalence among older people, which also happens to be the population 
predominantly affected by aortic stenosis. Roberts found a 48% incidence of a severe 
obstruction in at least one major coronary artery in 21 autopsied patients with severe 
aortic stenosis over the age of 65 years (20). Exadactylos et al. reported in 1984 a 34% 
incidence of coronary artery disease in a consecutive group of 88 patients with a mean 
age of 58 years requiring aortic valve replacement for isolated aortic valve stenosis. 
Interestingly, in view of current findings, they did not find significant coronary artery 
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disease when patients were free of angina (73). Bessone recently in a group of 219 
patients, with a mean age of 7 4.8 years, identified 112 patients with concomitant 
coronary artery disease (52%) (74). In the same year, an incidence of only 24% was 
reported in a comparable population but with a lower age of 59 years (75). In another 
report from Emory, comprising 152 patients over the age of 70 who underwent aortic 
valve replacement, 41% of patients over the age of 70 underwent concomitant 
coronary bypass grafting, while under the age of 70 this figure was 31% (76). Although 
there is already a relatively high incidence of coronary artery disease in aortic stenosis, 
there is a tendency to an even higher incidence in older people. Angina pectoris is not 
always present in these patients. A study of Hancock revealed that, in a series of 45 
patients with aortic stenosis without anginal complaints, 33% had significant coronary 
artery disease ! (77). Since coronary artery disease occurs so frequently in patients 
with aortic stenosis and may even exist without angina it is advisable to perform 
coronary arteriography in all patients with severe aortic valve stenosis, in need of 
aortic valve replacement. 
An association between aortic stenosis and idiopathic gastrointestinal bleeding has 
been postulated for the first time in 1958 (78, 79). Later reports more specifically related 
aortic stenosis to intestinal angiodysplasia (80,81). Although several case control 
studies on this subject have been reported (82-86), Imperiale and Ransohoff (87) 
recently concluded, after a critical review of the literature, that, due to methodological 
inadequacies, an association between aortic stenosis and angiodysplasia has not 
been demonstrated. 
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CHAPTER3 
SURGICAL INTERVENTIONS FOR THE TREATMENT OF AORTIC 
VALVULAR STENOSIS 
SUMMARY 
In 1913 for the first time an attempt was made to dilate an aortic valve by digitally 
invaginating the aortic wall. Since then, the attention of, surgeons was initially more 
directed to dilating stenotic mitral valves, but around 1950 several instruments were 
developed to dilate, or separate stenotic aortic valves, without much success. In 1951 
Hufnagel implanted an artificial valve in the descending aorta. With the introduction of 
cardiopulmonary bypass and the pumpoxygenator in 1954, techniques for surgical 
debridement of calcified aortic valves were developed, some of which still persist. 
Between 1950 and 1960 aortic cusp substitution, cusp extension and valve replacement, 
both by Starr - Edwards caged ball prostheses, as well as by homologous and later 
heterologous aortic valve grafts were the techniques used. These techniques were 
complemented by the use of auto and heterologous allografts, such as pericardium and 
dura mater. Homografts after cryopreseNation appear to provide better results than 
nutrient medium preseNed homografts. Some hospitals predominantly use aortic 
homografts for all age groups, with fairly good results, also in the long-term. Despite 
several large studies comparing biological valves with prosthetic valves, mainly Starr -
Edwards and Bjork - Shiley prostheses, the evidence is not yet decisive concerning 
failure rates into the second decade after implantation. For the first five years biological 
valves are superior, but in the second five year period results are equal for both valve 
types. Biological valves seem especially indicated in older patients, because they do not 
require anticoagulation, and results are better than in younger patients. 
The evolution of prosthetic heart valves revolved around improvements of 
hemodynamic characteristics and durability, together with reduction of thrombogenicity. 
Caged-ball, disc-valve and bileaflet valve prostheses, are the valves most often 
employed. All patients need anticoagulation after implantation of these valves. There is 
also still a place nowadays for surgical valvuloplasty, which evidently does not need 
anticoagulation afterward. 
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Operative risk of aortic valve replacement has declined over the years, mainly due to 
better myocardial preservation techniques, but also by operating on patients earlier. 
Nevertheless there is an increasing demand for aortic valve replacement in the elderly, 
as the general population ages and because patients are better informed, and more 
often referred to cardiosurgical centers. Increasing age, advanced functional class, poor 
left ventricular function, female gender, urgent operation and the presence of coronary 
artery disease all are important independent predictors of operative mortality. It is 
advisable to calculate the operative risk, before discussing the options with the patient 
involved. After aortic valve replacement survival is improved in all age groups, especially 
if compared with a group of patients who were deferred or refused the operation. 
Linearized mortality rates were the same after aortic valve replacement for both 
mechanical and biological valves. 
Hemorrhage and thromboembolism are the most frequent valve related causes of 
morbidity after aortic valve replacement. It is concluded that age alone should not be a 
contraindication for surgical treatment of aortic valve disease, but that all factors 
pertinent to the operative risk and postoperative course should be included in the 
weighing process, before discussing the risks and potential benefits with the patient 
and his/her relatives. 
A HISTORICAL REVIEW OF NOW DEFUNCT TECHNIQUES AND DESIGNS 
Valvulotomy and debridement 
The first referral to surgical repair of the aortic valve is by Allen and Graham who in 
1922 divided the aortic valves in dogs by means of a cardioscope (1). Tuftier in 1913 
made the first attempt to dilate a stenotic aortic valve in a patient, digitally invaginating 
the aortic wall (2). In 1924 this patient was reported to be still improved. In 1947 Smithy 
and Parker reported an animal study of aortic valvulotomy with open chest dogs using 
a hooked blade introduced through a sheath, which was inserted into the ascending 
aorta. They intended to perforate the normal aortic cusps in order to achieve a complete 
division of the free margin of the valve leaflet by retracting the barbed blade. More than 
one third of the animals died of bleeding from the ascending aorta, while division of the 
cusp could only be achieved in 30% of all surviving dogs (3). Bailey and coworkers 
stated that "only an entirely new valve could offer a reasonable solution" (4) and 
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continued the experiments of Smithy. To test this hypothesis they resected part of the 
aortic valve in mongrel dogs and replaced the valve action by inserting either an inverted 
vein graft, or direct valve grafts, or free aorta grafts between the left ventricle and the 
aorta. Later they redirected their attention towards punch resection of the aortic valve 
by a punchcutter either, from the left ventricle, retrogradely, or from the ascending aorta. 
As these methods produced an impressive amount of regurgitation they were 
abandoned. The same investigators later developed a Brock-like type of valvulotome, 
which had been used for division of the pulmonic valve in congenital pulmonary valve 
stenosis (5). The valvulotome has an umbrella like configuration, with three blades. They 
intended to cut through the posterior cusp and through the commissure between both 
anterior cusps. For this purpose the instrument was inserted in the left ventricle via the 
left ventricular apex and advanced through the aortic valve with retracted blades. Once 
the aortic valve was passed the instrument was opened and withdrawn into the left 
ventricle. On March 9, 1950, they performed this procedure for the first time in a 26 year 
old woman with severe aortic stenosis. Although they encountered problems crossing 
the valve, they ultimately succeeded in pulling back the partially opened instrument into 
the left ventricle. Directly after this manoeuvre, the patient died however. Autopsy 
revealed that the knife had been properly inserted, cutting the posterior valve leaflet for 
about one centimeter. Appreciable aortic regurgitation must have been produced by 
division of this cusp, leading to the fatal outcome. After this disappointing experience 
they devised an instrument shaped like a large pencil with a blunt point. This instrument 
was guided into the left ventricle via an incision in the left common carotid artery. After 
arriving in the left ventricle, the dilating mechanism was opened, to gradually dilate the 
narrowed orifice. Bailey and coworkers performed this procedure in 2 patients, and both 
withstood the procedure well. A third patient, however, died as a result of the procedure. 
This last event led to a change in approach to the aortic valve (4). In a later 
communication (6) they reported the use of this instrument in 11 patients, entering the 
aortic valve via an apical ventriculotomy. Two of these patients died in the hospital, one 
of them during operation. At autopsy this case manifested the degenerative type of valve 
stenosis, without any commissural fusion. The other patient died at day 13 of multiple 
peripheral arterial emboli. Two other patients died respectively at 12 days and one month 
after discharge, one due to cardiac failure the other due to septicemia. One further 
patient had, after several months, recurrence of anginal pain and myocardial 
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insufficiency. They felt that this instrument had insufficient dilating force and that forced 
passage of the opened, umbrella like dilatorhead back and forth through the valve 
orifice, was unduly traumatic (6). 
By April 1952, a much superior instrument was developed to dilate stenotic aortic 
valves. The original umbrella spring type blades, had been replaced by three parallel 
dilating bars with wedge like cross sections. It contained a beaded guidewire at the distal 
tip, and an operating control mechanism at the proximal end (7). The beaded wire was 
inserted into the left ventricular apex under purse string control, and advanced into the 
stenosed aortic valve. After setting of the control mechanism, so that the open diameter 
of the instrument would be slightly less than that of the aortic ring, and after aligning the 
instrument, so that the triradiate arms fitted into the commissures, the instrument was 
opened. In their first publication, 23 patients underwent aortic commissurotomy. In 13 
patients this was combined with mitral commissurotomy. Only one patient died as a 
result of the operation (7). Aortic valve surgery had come of age. 
In 1956, applying general hypothermia, Lewis and Shumway for the first time 
performed aortic valvulotomy under direct vision, after occluding the inflow of blood to 
the right heart. In their description of the first three patients, of whom one died due to a 
technical error, they state that an accurate separation of all three cusps was achieved 
under direct vision. They thought this would be a better operation than blind transaortic 
or transventricular procedures, especially in non calcified stenotic valves, with fused 
commissures (8). In the discussion of this paper, the superiority of "seeing being better 
than feeling" was questioned by Harken, who stated that lightly fused tricuspid aortic 
valves may best be managed by finger fracture. In the same discussion Larzelere 
showed an improved Donaldson instrument. This dilating instrument had about the same 
features as the one introduced by himself (7), but was advanced retrogradely, using a 
pouch or tunnel sewn onto the ascending aorta to control bleeding (9). The instrument 
was fingertip guided through the aortic valve and then opened (8). 
With the introduction of cardiopulmonary bypass and the pumpoxygenator in 1954, 
a still more effective approach to the surgical treatment of aortic valve disease became 
possible. 
Lillehei was one of the first to use total bypass of the heart and lungs together with 
retroperfusion of the coronary sinus, to retain a healthy pink color of the myocardium 
(1 0). The next logical step was to combine the advantages of extracorporeal circulation 
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with aortic valvulotomy and removal of calcareous deposits form the leaflets 
(debridement), a technique advocated by Bailey (11). Kirklin and Mankin described 14 
patients operated upon in 1959, using extracorporeal circulation and valvulotomy 
combined with debridement for both isolated aortic stenosis and aortic stenosis 
combined with aortic incompetence (12). Thirteen out of 14 patients survived the 
operation; one died later, and another one was unimproved at short term follow-up. The 
debridement and other sculpturing techniques for restoring aortic valve anatomy were 
largely superseded by techniques involving valve replacement. However, already in 1967 
Hurley et al reported their very disappointing results with debridement operations in a 
group of 76 patients. Thirteen out of the 61 patients with isolated aortic valve stenosis 
died during, or directly after the operation (21%), while another 6 died at follow-up. 
Although the majority of the surviving patients felt improved (60%), objective evaluation 
of this group at a mean of 46 months after operation, revealed a good or satisfactory 
result in only 5 patients (13%). They felt that debridement valvulotomy should no longer 
be considered as a suitable treatment (13). McGoon et al., however, had concluded two 
years earlier, that the method might have limited application, in patients where 
restoration of valve mobility could be anticipated (14). Indeed this surgical method has 
up to the present not been abandoned. Recently Mindich et al reported an increase in 
valve area from 0.55 cm2 to 1.56 cm2, using improved surgical valvuloplasty techniques 
in 23 patients with a mean age of 75 years. Follow-up ranged from 6 months to six years, 
in which period two patients died and two required reoperation. These authors conclude 
that aortic valvuloplasty, carefully performed, may be an excellent alternative in a select 
group of patients with aortic stenosis (15). Patients with a trileaflet valve, a small aortic 
valve annulus, a contra indication for oral anticoagulation and without significant aortic 
regurgitation are in their view candidates for this procedure. 
Aortic valve replacement for aortic valve incompetence 
In 1951, Hufnagel in Washington, developed a ball valve prosthesis for rapid insertion 
into the descending aorta just distal to the left subclavian artery to palliate severe aortic 
incompetence (16, 17). Although palliation was observed in some patients, signs of aortic 
incompetence in the upper body became very severe (17,18). Some years later in 1961 
a cusp-type valve prosthesis was developed by Hufnagel and Conrad, and was used 
widely after being commercially available (19). These authors introduced the technique 
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of topical cooling of the myocardium, combined with cardiopulmonary bypass. They 
stated that if the myocardial temperature could be reduced to between 5 and 8°C, 
periods of cardiac arrest of at least 1 00 minutes would be safe. A complete prosthetic 
valve consisted of 3 separate leaflets, made of terylene cloth impregnated with silicone 
rubber, while the free edge was sealed to prevent ingrowth of fibrous tissue. In over 100 
patients with aortic incompetence, operated upon with replacement of the incompetent 
valve by this prosthesis, all except one resumed satisfactory cardiac output following 
topical cooling. 
McGoon, also in 1961, employed a single unit prosthesis, consisting of a Teflon 
sleeve, fashioned from a piece of ordinary woven Teflon aortic prosthesis. Three of the 
first seven patients died in hospital (20). Further application of this valve in the Mayo 
Clinic proved to be rather unsuccessful because initial competence was sometimes not 
achieved, leading to an appreciable hospital mortality (21). 
After several rather unsuccessful attempts to reduce aortic incompetence by 
circumclusion (narrowing of the aortic base by a woven silk band from the outside) and 
direct plastic procedures to provide a better apposition of incompetent valve cusps, 
Harken and coworkers directed their attention to cusp substitution, cusp extension and 
valve replacement (22). Teflon cloth used initially was subsequently abandoned for fear 
of ingrowth of fibrous tissue. A stiff woven Teflon patch for the cusp extension proved 
unsatisfactory. 
They subsequently constructed a caged-ball valve, of stainless steel, with a Lucite ball, 
used since 1955 in human beings (23). This valve was quiet, atraumatic, competent, 
offered little resistance to flow (25 mm Hg pressure difference at a continuous flow of 20 
ljmin) and produced normal pulse contours, under laboratory conditions. However from 
the first five patients with massive aorta incompetence, only one survived implantation 
of this valve. The fatalities were ascribed to the preoperative grossly dilated left ventricles 
(22). 
About one year later Starr and Edwards used a slightly modified caged-ball prosthesis 
with a silicone rubber ball and a vitallium like alloy cage. Out of their five first patients 4 
died in hospital, one from valve suture dehiscence, one from hemolysis, one from 
cerebral thrombosis and one from preexistent left main coronary artery disease. The fifth 
patient died at 8 months due to a thrombus formed on the Teflon coated prosthesis ring 
and extending into the left coronary ostium. Afterwards they changed the sewing ring 
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from the rigid short Teflon cloth sleeve to a semirigid more compressible sewing margin. 
In 1962 this new type of valve was implanted in 11 patients. One patient died during 
operation, and there was one late death (24). 
These efforts at replacing incompetent valves have strongly influenced the designs of 
valves utilized in replacing the stenotic valve. 
Homo and heterologous aortic valve transplants 
In 1956 Murray from Toronto reported the use of homologous aortic valve segments 
in three patients with severe aortic incompetence. Aortic valve segments were obtained 
from human postmortems and kept in saline gauze. Without extracorporeal circulation 
the segment was sewn into the descending aorta, just distal to the left subclavian artery. 
Circulation to the descending aorta was interrupted in the first case for 37 minutes. All 
three patients improved considerably following the operation (25). Six years after 
operation the first patient was reported to do well, while his cardia-thoracic ratio had 
decreased. Another 8 patients had been operated since 1956, of whom 3 died in the 
immediate post-operative period (26). 
In Europe, D. Ross was the first to insert a freeze-dried aortic homograft below the 
coronary ostia. The patient did well after operation with a medication of anticoagulants 
and hydrocortisone (27). Barratt - Boyes from New-Zealand reported a series of 57 
patients operated upon in 1962 and 1963, with the same technique as used by Ross. 
Four patients died in the post-operative phase, while three others died during follow-up. 
He used sterilized, freeze-dried valves, removed within 15 hours from the donor hearts 
(28). 
The first use of a heterograft in a human being was reported in 1965 by Binet, Duran, 
Carpentier and Langlois. In their preliminary communication 5 patients were discussed 
who all had their stenotic or incompetent valves replaced by pig or calf aortic valves, all 
with good immediate results (29). A year earlier Duran and Gunning had transplanted a 
heterologous aortic valve in a very ill patient, who died 24 hours later from causes 
unrelated to the heterograft (30). 
Carpentier used a support ring, instead of direct suturing of the heterologous valve 
graft; the support was subsequently modified into a frame on which the graft was 
mounted. He also modified the mode of preservation, from sterilization to electrodialysis, 
oxidation and cross linkage. These two combined changes improved the immediate as 
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well as long-term functioning of the graft. Grafts were stored in a gluteraldehyde solution 
{31). 
Senning in Zurich used a strip of autologous fascia lata tissue to form three cusps. 
From his first series of 90 patients, 13 died within two months, most of them due to 
myocardial failure, coronary air embolism or myocardial infarction. Another 10 patients 
died 3 to 45 months postoperatively with a high incidence of endocarditis, while 4 
patients were reoperated on due to valvular incompetence (32). Although no signs of 
fascia lata calcification or thromboembolism were found in Senning's patients, the high 
incidence of post-operative bacterial endocarditis led to the abandonment of this 
method. 
From 1969 on lonescu and Ross implanted autologous fascia lata valves, attached 
to a supporting frame {33). lonescu later introduced heterologous pericardia! tissue, 
also mounted on a frame as aortic valve replacement. In his first 80 patients with aortic 
stenosis, a 10% operative mortality is mentioned. Causes of death were heart failure, 
endocarditis, cerebral infarction and necrosis of the ileum. Another 8 patients died 2 to 
15 months postoperatively, 3 of infective endocarditis, two of cardiac failure and one of 
mesenteric artery thrombosis {34). In two patients no cause of death was found. 
Because there is only limited time available in the operation theatre to construct these 
valves meticulously, lonescu and coworkers later preferred stent mounted homologous 
fascia lata, or heterologous stent mounted pericardia! tissue valves. These were 
prepared beforehand in the laboratory, sterilized and preserved, according to 
Carpentier's method {31). 
Puig and Zerbini from Sao Paulo employed homologous dura mater tissue, prepared 
according to lonescu's method. Dura mater was obtained at most 12 hours after the 
donor's death, and preserved in 98 per cent glycerin at room temperature for at least 12 
days. After construction of the valve under aseptic conditions, it was preserved in a 
solution of physiologic saline with kanamycin and cephalothin, and stored at 4°C. Their 
initial results were satisfactory, but with a follow-up period of only 7 to 14 months no 
definite conclusions could be drawn as to the durability of these valves (35). 
CHAPTER3 
CURRENTLY USED SURGICAL TECHNIQUES FOR AORTIC VALVE 
REPLACEMENT OR RECONSTRUCTION 
Aortic valve reconstruction 
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Although debridement was already described in 1967 by Hurley {13), with very 
disappointing results, McGoon stated that there still might be a very limited use of this 
method (14). In a well preserved three leaflet aortic valve, without commissural fusion, 
debridement of the individual leaflets might be performed, if for example the patients 
condition or age precluded valve replacement (15). In our own institute debridement 
has been conducted in 3 patients during the last year, with good direct results, a 
reduction of the maximal flow velocity measured with Doppler over the aortic valve, and 
good functional improvement (E. Bas, personal communication). 
Homo and heterografts to replace the aortic valve 
Homografts 
After freshly procured aortic valves by Ross and Barratt - Boyes in the early sixties 
(27,28), preserved and sterilized valves came into use. However, irradiated and 
chemically sterilized valves showed a high incidence of cusp rupture, necessitating 
reoperations in a third of all patients within 6 years {36). In a later period valve failure 
was reduced when homografts were sterilized with antibiotics, and preserved in a 
nutrient medium (37). O'Brien recently compared the results of 124 allograft (nonviable) 
aortic valves, preserved by antibiotic sterilization and nutrient medium preservation at 
4°C with 192 viable allografts cryopreserved at -196°C in liquid nitrogen. A total of 316 
aortic valve replacement operations were performed from 1969 through 1986. Operative 
mortality was 6.0% while survival at 4 and 15 years was respectively 83 and 60%, without 
differences between the two groups (mean age at operation 51 years). Thirty eight 
patients underwent reoperation, 84% of the fresh valve group being at ten years without 
reoperation, while this was 92% for viable cryopreserved valves. Freedom from a 
thromboembolic event was the same between the two groups, being 97% at ten years 
and 96% at 15 years (38). 
Aortic valve replacement with an aortic homograft sewn freehand in the aortic ring, 
is in some institutions, like the Green Lane Hospital in New Zealand, routinely used in 
all ages when no contraindications are present. The only real contraindications are 
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circumstances that predispose the patient to progressive dilatation of the aortic sinus, 
or aortic root, like aneurysms and media-necrosis, leading to aortic incompetence (21). 
Heterografts 
Since the introduction of the glutaraldehyde preservation technique by Carpentier, 
bioprostheses have provided an appealing alternative for mechanical valves, primarily 
because no long-term anticoagulant treatment is needed. A recently published 
randomized collaborative trial of 13 Veterans Administration hospitals compared 198 
mechanical valves (Bjork- Shiley), with 196 biological valves (Hancock) implanted in 
the aortic position. After a relatively short follow-up period of, on average, 5 years with 
a maximum of 8 years, a significantly higher proportion of patients with a biological valve 
proved to be free from all valve related complications, compared with the patients with 
mechanical valves, 63 vs 53%. This difference was entirely due to a higher hemorrhage 
rate with the mechanical valves (85 vs 67%). Thromboembolism rates were comparable 
with 9 and 1 0% respectively for mechanical and biological valves. No failure of one or 
another valve type had yet occurred at a relative short follow-up period of 5 years. 
Operative mortality was respectively 9.2 and 6.1% for implantation of a biological valve 
or mechanical valve in this group of patients with a mean age of 60.2 and 59.1 years 
respectively (39). 
Another study compared three valve types implanted in the aortic position in 207 4 
patients in 3 different institutions. Results with the Starr - Edwards Silastic ball valve 
(Oregon), the Hancock (Stanford) and Carpentier - Edwards (Vancouver) porcine valves 
are compared with respect to treatment failure, defined as a valve-related death or 
permanent patient disability. Using this definition, biological valves are superior at 5 
years; at 10 years the results are comparable. Structural failures of implanted valves 
had occurred at 7 years in 0% of Starr - Edwards prostheses, 5% of Hancock valves 
and 3% of Carpentier - Edwards valves. At 10 years no structural failure had occurred 
in the Starr - Edwards valves, while in 21% of Hancock valves a structural failure did 
occur. In the widely used Stanford definition of structural failure, which includes any 
valve related complication causing death or requiring valve removal, at 5 years 
respectively 95, 93 and 98% of all implanted aortic Starr - Edwards, Hancock and 
Carpentier - Edwards valves, were free of failure. At 1 0 years these numbers were 88 
and 72% for Starr- Edwards and Hancock valves respectively, while follow-up time for 
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Carpentier valves was still less than 10 years (Table 1) {40). 
Aortic 
Variable Starr Hancock Carpentier 
Patient-years 3,310 4,747 2,532 
Treatment failure-free 
At 5 years 93 (1) 96 (1) 97 (1) 
At 7 years 91 (2) 94 (1) 93 (2) 
At 10 years 90 (2) 87 (3) 
Structural failure-free 
At 5 years 100 (0) 98 (1) 99 (1) 
At ?years 100 (0) 95 (1) 97 (3) 
At 10 years 100 (0) 79 (4) 
Valve failure- free 
At 5 years 95 (1) 93 (1) 98 (1) 
At 7 years 94 (1) 88 (1) 95 (4) 
At 10 years 88 (2) 72 (4) 
Table 1 Actuarial comparison of % of patients free from treatment, structural or valve failure at 5, 7 
and 10 years after implantation of Starr- Edwards, Hancock or Carpentier- Edwards valves 
in the aortic position (Standard error percentage) 
Another analysis of biological versus mechanical valves, comparing total morbidity and 
valve related mortality significantly favored the biological valves in the first 5 years after 
implantation, and the mechanical valves in the ensuing five years, but the net 10 years 
results were not significantly different (41 ). This study included four different biological 
and five different mechanical types of valves, implanted in three different positions. These 
authors also noted an increased failure rate of biological valves in younger patients, as 
stated earlier by several authors {42-44). 
A Spanish report compared long-term survival in 85 patients in whom 38 Bjork - Shirley 
and 47 Hancock valves were implanted in 1975. Hospital mortality was 13 and 6% 
respectively. Unfortunately these authors did not state the age at which these patients 
were operated, as they only gave global figures of mean ages of the total group, which 
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also included mitral and double valve replacement. Mean survival at 10 years was 94 ± 
4.2% and 89 ± 4.9% in patients with mechanical and biological valves respectively, a 
difference which is not significant. However in the 10 year follow-up freedom of 
reoperation was statistically significant higher in the Bjork - Shirley valves than in the 
Hancock valves implanted in the aortic position, being 90 ± 5.2 and 63 ± 8.3% 
respectively (45). 
Two studies from Scotland compared a mechanical valve prosthesis (Bjork - Shiley) 
with a porcine aortic bioprosthesis (Hancock or Carpentier - Edwards) (46,47). 
Bloomfield et al randomized patients to a mechanical disc valve, or a porcine heterograft 
prosthesis. In hospital mortality was 7.6% for all patients undergoing aortic valve 
replacement, without significant differences between the three types of valves implanted. 
At a follow-up of 7 years no significant differences in actuarial survival were noted, 
survival being 69.6 ± 9.golo after 7 years for the whole group with aortic valve replacement. 
In the same follow-up period no significant differences in thromboembolic events were 
noted, all patients with a mechanical valve prosthesis and some of the patients with a 
porcine heterograft receiving anticoagulation therapy. Likewise reoperation was evenly 
distributed between the three types of valves being associated with a high operative 
mortality of 30%. The risks of anticoagulation in this trial were low with an overall 
incidence of complications of one per 100 patient years. These authors concluded that 
after a median follow-up period of 5.6 years no significant advantage of the use of any 
of the three prostheses studied had yet appeared, but that important differences might 
emerge later. 
The other Scottish study, reported by Nashef et al, compared 169 Bjork- Shiley aortic 
valves with 205 Carpentier - Edwards valves implanted in the same position. Hospital 
mortality in this study in patients with a mean age of 51 years was not statistically 
different being 5.9 and 4.9% respectively. At a mean follow-up of 3.2 and 3.5 years 
respectively no significant differences were found in overall incidence of 
thromboembolism, endocarditis, periprosthetic leak, anticoagulant related complications, 
incidence of reoperation, or late mortality. 
Less information is available regarding the bovine pericardia! valve implanted in the 
aortic position. At 10 years follow-up lonescu et al found an actuarial survival of 85.8 ± 
8.7%. In this group 83.0 ± 9.1% of all patients were valve failure free, and 72.5 ± 13.2% 
were free from all major complications. The linearized rate of embolism without 
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anticoagulant treatment is 0.55% per annum, with no deaths related to embolism (48). 
It is possible that newer generations of porcine and pericardia! valves might improve the 
durability of these valves (49-51). 
The evidence presented above establishes the fact that for the first five years tissue 
valves are superior to mechanical valves. They thus present an alternative choice when 
life expectancy is limited and anticoagulation problematic. In the second five year period 
results are equal for biological and mechanical valves, while beyond 10 years antibiotic 
treated homografts are definitely inferior compared to mechanical prostheses. Thus in 
younger patients and in areas where anticoagulant therapy is well controlled, this type 
of valve is preferred. Cryopreserved homografts show the same effectiveness as 
mechanical grafts, with 83% being free from intrinsic tissue disruption at 13 years (52). 
In children this appears to become the favoured approach. Another approach to treat 
valvular aortic stenosis in younger patients, introduced by D. Ross in 1967, is aortic valve 
replacement by pulmonary autograft (53). This technique, has also shown good results 
with an actuarial event free rate of 74.2% at 19 years. For the porcine valves no decisive 
figures concerning failure rates into the second decade are available. 
Prosthetic heart valves 
As pointed out earlier, Hufnagel and associates were the first to implant a caged ball 
prosthesis in the descending aorta in September 1951 (10). The subsequent history of 
prosthetic valves revolved around modification of the basic ball valve design, alteration 
of construction material and introduction of new valve designs. 
The first caged ball valves to be widely used were the Starr - Edwards prostheses, 
which have undergone several refinements (54). The caged ball principle is also applied 
in the Smeloff- Cutter and Braunwald -Cutter valves, designed to diminish the stenotic 
nature of ball valves and problems associated with cloth covering (55,56). 
Disc prostheses (Kay- Shiley, Kay- Suzuki and Cross- Jones) were developed to 
overcome problems of poppet inertia, by employing a light weight disc as an occluder 
and reducing the length of the cage (57,58). However, the incidence of 
thromboembolism remained high in these prostheses and led to the development of 
the Beall valve, a cloth covered disc prosthesis (59). However pressure gradients across 
these valves remained high as the valve orifice remained small (60). 
50 SURGICAL INTERVENTIONS 
To enlarge effective valve area, eccentric, monocusp, central flow prosthetic devices 
were introduced. First of these new types was the Wada - Cutter prosthesis which 
suffered intermittent fixation of the valve disc in an open position (61). One year later 
the Bjork- Shiley design was introduced with a free floating and rotating disc (62). 
Although this model has been utilized in numerous patients, recently fracture of the 
struts restraining the disc has been reported in the convexo-concave valve types CC60 
and CC70, especially with a 70 degree opening angle, leading to embolization of the disc 
and immediate massive aortic incompetence (63). The last two valves mentioned have 
an opening angle of 60°- 70°, while a third pivoting disc valve, the Lillehei- Kaster has 
an opening angle of 80°, which hopefully would lessen the incidence of 
thromboembolism (64). 
The St. Jude bileaflet valve contains two valve discs which open vertically, and 
approach most closely normal physiological conditions. Haemodynamically superior, 
this valve also has a lower incidence of thromboembolic complications ranging in various 
reports from 0.3 to 2.5% per year and valve thrombosis between 0 to 1.2% per year. 
Rates are higher when anticoagulation is not given (65-70). 
INDICATIONS FOR OPERATION IN PATIENTS WITH AORTIC STENOSIS 
Patients with calcific aortic stenosis usually present because of symptoms, and when 
in such patients the presence of an important stenosis is confirmed by catheterization 
or echo Doppler measurements, i.e. a valve area of ,:::0.7 cm2, operation is clearly 
indicated. Signs and symptoms of left ventricular failure make the operation urgent. 
When symptoms are absent or trivial, and the stenosis is clearly important with a residual 
aortic valve area of ,:::0.7 cm2, operation is advisable. A positive exercise test lends 
weight to the decision to operate. In patients with predominantly anginal symptoms, 
who are found on cardiac catheterization to have a moderate to severe aortic stenosis 
(valve area 0. 7 - 1. 0 cm2) and severe coronary artery disease, coronary artery bypass 
grafting should be performed, and the aortic valve replaced at the same time. Moderate 
to severe stenosis alone can also be a reason to replace the aortic valve, depending on 
the patients physical activities, and the diminished quality of life experienced. 
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OPERATIVE MORTALITY OF PROSTHETIC AORTIC VAlVE IMPlANTATION AND 
MORBIDITY AFTER IMPlANTATION 
The risk of aortic valve replacement depends on several, sometimes interrelated 
factors. Recognized risk factors are: 
Operation decade 
Acar reported a i 9% early mortality in patients operated for aortic stenosis with or 
without aortic incompetence over the age of 65 in the period from i968 to i979 (7i). 
Jamieson collecting his data in the same period found a 4.7% thirty day hospital mortality 
in aortic valve replacements for all causes in the age group over 65 (72). In his oveNiew 
of the literature an overall operative mortality in the sixties was found of i 3.3% for aortic 
valve replacement over the age of 60. In the seventies this figure dropped to 7% for the 
same condition in the same age group. Cormier reported a 8. i% operative mortality in 
a group of patients, with a majority having aortic valve replacement for aortic stenosis, 
before i983, while this was 3.7% after i983 (73). The year of operation was not a 
predictor for hospital mortality in Craver's review on operated aortic stenosis from i 975 
to i987, the overall death rate being 4.6% (74). So it seems reasonable to state that 
operative mortality for aortic valve replacement for mainly aortic stenosis is around 5% 
in i989 taking all patients together, an experience matched by that of The Thoraxcenter. 
Age at operation 
Older age at the time of operation seems to contribute substantially to operative 
mortality. Deloche reported a i2% operative mortality in a group of iOi patients over 
the age of 70 with aortic valve replacement for aortic stenosis, between i970 and i980 
(75). DOren showed a iO% hospital mortality in a comparable group of 20 patients, 
operated between i977 and i985 (76). Sethi found in male patients with comparable 
disease and operation, a 10.2% mortality in the age group between 60 and 70 years, 
and an i8.2% mortality in patients over 70 years (77). More recently Magovern reported 
a 5.9% operative mortality for elective valve replacement in the age group over 70 (78), 
while in the age group over 80 a 28% early mortality ( < 90 days) was seen (79). Craver 
found an in hospital mortality of 11.0% for aortic valve replacement for aortic stenosis 
above the age of 70, while this risk was 3.9% below the age of 70 years (74). Kay 
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reported earlier in i98i an in hospital mortality of i4 and 6% in patients with aortic valve 
replacement over and under the age of 70 (80), while Rioux found a ; 0. i % operative 
mortality in the same age group over 70, treated with aortic valve replacement mainly for 
aortic stenosis (8i). In patients over 75 years, who underwent aortic valve replacement 
from i982 to i985 the same authors found an 8.8% mortality, while Teply gave a 23% 
operative mortality from i964 to i980 in the same age group (82). Most recently 
Levinson found a 9.4% in hospital mortality for the age group over 80, treated with aortic 
valve replacement for aortic stenosis (83). 
It is concluded that the operative risk for patients over the age of 70 for aortic valve 
replacement for aortic stenosis ranges from 5.9 to i8.2%, over the age of 75 it is 
estimated as 8.8 to 23%, while in octogenarians the operative mortality risk varies from 
9.4to 28%. 
Preoperative functional status and left ventricular ejection fraction 
Although Rediker reported no mortality in 42 patients with ejection fractions less or 
equal to 45% undergoing aortic valve replacement of isolated aortic valve stenosis (84), 
impaired left ventricular function has been an independent predictor of operative 
mortality in patients over 70 years of age. In a recent report on 469 patients of whom 
67% had aortic valve replacement New York Heart Association class IV was associated 
with increased risk of operative mortality compared with classes I, II and Ill (85). The 
group from Stanford also reported advanced functional class and the presence of 
congestive heart failure as univariate determinants of a higher operative mortality in 
patients with aortic valve replacement (86). In their multivariate analysis advanced 
functional class remained statistically the most significant independent determinant of 
operative mortality, although congestive heart failure was not a significant predictor. In 
a smaller group of 64 patients over the age of 80 who underwent aortic valve 
replacement for aortic stenosis, left ventricular ejection fraction was not a significant 
univariate predictor of a complicated postoperative course, nor of unfavorable outcome 
such as hospital death or permanent severe neurological deficit (83). 
Functional status of the patient preoperatively also was an important determinant of 
mortality after aortic valve replacement in the experience from La Pitie Hospital in Paris 
between i98i and i984 (87). Another French study also showed a linear relationship 
between functional class and operative mortality, varying from 3.3% for patients in NYHA 
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class I or II to 16.4% for class IV patients (73). In the earlier mentioned series from 
Stanford, a collection of 1479 patients, with aortic valve replacement, a tendency to 
operate on patients in a lower functional class has been noted. While NYHA class Ill or 
IV patients constituted more than 60% of all patients operated on before 1974, this was 
about 10% less after 1974 (86). This difference in preoperative functional class, might 
account partly for the higher operative mortality noted before 1980,(see decade of 
operation), while improvement in surgical techniques in recent years, might also have 
lowered operative mortality. 
Gender 
Although female gender increased the risk for operative mortality in the series reported 
by the University of Toronto, which included 469 patients over 70 years, it is not clear 
from this report whether this was the case for all preoperative diagnoses, as only about 
60% of all patients had isolated aortic valve procedures (85). The Stanford experience 
by univariate analysis did not reveal female gender to be associated with a higher 
operative mortality (86). In fact in the group with aortic valve replacement over the age 
of 80, women had a better chance to have an uncomplicated in hospital course than 
men, 56 vs 32% (83). On the other hand in the data reported by Lytle, female gender was 
the most important variable predictive of operative mortality for combined aortic valve 
replacement and coronary artery bypass grafting (88). The same factor has been 
identified as having a negative influence on operative mortality for isolated coronary 
artery surgery (89). So if there is an excess in mortality in female patients undergoing 
aortic valve replacement this could be due to a less favorable concomitant bypass 
operation result or to smaller aortic roots requiring smaller prostheses. The suggestion 
from the Coronary Artery Surgery Study (CASS) which compared medical and surgical 
treatment for relief of angina pectoris is, that small stature may be more important than 
female gender (89). Yet Sethi's large study analyzing predictors for operative mortality 
after valve replacement did this in males only (77). It confirmed however that a smaller 
body surface is independently related to a higher operative mortality. 
Concomitant coronary artery disease 
In Magovern's study, univariate analysis selected patients having combined aortic 
valve replacement and coronary artery bypass grafting as a high risk group, whereas 
54 SURGICAL INTERVENTIONS 
multivariate analysis did not (78). Here, unlike emergency operation and age greater 
than 70 years, the need for coronary bypass grafting in addition to aortic valve 
replacement had no independent effect on the mortality rate of the operation. Also in 
Scott's study concomitant coronary bypass grafting had no independent predictive value 
for operative mortality (86). Yet, in Fremes' experience, aortic valve replacement, with 
concomitant surgery for coronary artery disease, showed an elevated risk of operation. 
However this risk was lower when coronary arteries with significant stenoses were 
grafted than when left alone (respectively 8.0 and 10% operative mortality)(84). The 
same finding has been reported by Cormier for all age groups for aortic valve 
replacement. He recorded the lowest operative mortality in patients without significant 
coronary artery disease, a higher risk in patients with significant coronary artery disease 
and revascularization and the highest risk in patients with significant concomitant 
coronary artery disease without additional bypass grafting (73). 
Urgent operation 
A definition of urgent surgery is not given in the reported study populations but most 
authors include in this category patients with unstable angina, rapidly progressive heart 
failure, bacterial endocarditis and severe rhythm disturbances. Urgent surgery in these 
studies was associated with a higher operative mortality in most of the reported larger 
patient groups both old and young (74,78,85). 
Urgent surgery was not, however, identified as a predictor of operative mortality in 
the Veterans Administration Cooperative Study (77), in the group over 80 years old 
reported by the Massachusetts General Hospital (83), in the Stanford University (86), 
or in the Cleveland Clinic study (88). 
All these studies are not quite comparable as some contained all age groups 
(74,77,78,86,88), others only older patients (83,85); some comprised all valve 
replacements and combinations of these (77,85), others only aortic valve replacement 
(74,78,83,86,88); all incorporated both sexes, except the Veterans Administration study 
which included only male patients (77). 
One study exclusively contained only older patients with aortic valve replacement 
comparing these two given data with urgent surgery as a variable (82). But the numbers 
in this last study were rather small: 54 patients undergoing elective and 10 patients 
undergoing urgent aortic valve replacement, so the absence of a predictive value of 
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urgent surgery for an unfavorable outcome in the last mentioned study is not very 
convincing. 
Most probably urgent aortic valve replacement in elderly patients increases the 
operative mortality only moderately and to a lesser extent than urgent mitral valve 
replacement (85). 
Combined valve surgery 
In the patient series from the University of Toronto (85), aortic valve replacement 
combined with mitral valve replacement influenced operative mortality adversely only 
in the old patient group(> 70 years). Jamieson and associates (72) reported the same 
correlation in their patient population over 65 years of age, while a combined valve 
replacement had already been recognized as a risk factor for operative mortality in 197 4 
by Barnhorst and associates (90). The risk of double valve replacement is estimated to 
be 3 to 9 times higher than for aortic valve replacement alone. 
Nature of underlying disease 
The type of underlying valve disorder i.e. predominantly aortic stenosis, aortic 
insufficiency or combined defect, has been postulated to have an influence on operative 
mortality. Earlier studies had reported that operative survival was influenced adversely 
by aortic regurgitation (91). This relation was still manifest in Scott's series, from 1967 
to 1981 (86). However in his latest publication, with patients undergoing surgery between 
1982 and 1986, this relation was no longer manifest (85). The use of cardioplegia instead 
of anoxic arrest, and referral of patients earlier for surgical treatment must have 
outweighed the excess mortality associated with aortic valve replacement when aortic 
valve insufficiency was predominant (88). 
Summarizing the previous data it is evident that, in the two largest series, comprising 
1479 and 1148 patients respectively, with aortic valve replacement, analysis of the data 
such as advanced New York Heart Association functional class, renal dysfunction, type 
of underlying physiopathology, atrial fibrillation, older age and urgent operation showed, 
that all had independent predictive value for operative mortality. Only age emerged as 
a common predictor in both studies (86,74). In Magovern's smaller series also age in 
excess of 70 years and emergency operation were identified as independent predictors 
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of operative mortality (78). In a male population of 661 subjects having isolated aortic 
valve replacement and three vessel coronary artery disease, a higher left ventricular 
systolic pressure, presence of prior cardiac operation, smaller body surface area and 
lower cardiac index were all factors contributing independently to higher operative 
mortality (77). These studies included analysis of the most pertinent preoperative, and 
in two studies also intraoperative variables, which all had, except the ones mentioned 
previously, no independent predictive value for operative mortality. 
Probability of operative mortality after aortic valve replacement based on logistic 
regression analysis. 
The probability of an event is represented by the formula: 
(p) 
In = ------------- = X 
(1-p) 
(p) X 
-------------- = e 
1-p 
ex 
p = --------------
1 +ex 
where p = the probability of an event and 
X = 80 + 81X1 + 82X2 + ..... 8nXn 
Where 80 represents a constant, 81, 82, ...... 8n represent coefficients for each of the 
risk variables x1, x2, ...... Xn. 
Fremes calculated factor adjusted odd ratios for the independent predictors of 
operative mortality (85). These factors are given in Table 2 for age groups below 70 and 
over 70. The probability of operative mortality ranges from 4.5 to 76% for patients below 
70 years and from 0.9 to 40% in patients over 70 years (85). 
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young patients old patients 
< 70 years > 70 years 
coefficient factor- adjusted coefficient factor -adjusted 
risk ratio risk ratio 
Intercept -3.2274 -4.6823 
Timing 
elective 1.00 1.00 
urgent 1.29312 3.664 0.7196 2.05 
NYHAclass 
I 1.00 
II -0.51659 0.60 
Ill -0.93906 0.39 
IV 0.35488 1.43 
Tricuspid valve disease 
no 1.00 
yes 1.13876 3.12 
Left venticular EF % 
> 60 1.00 1.00 
40-60 -0.02159 0.98 1.0598 2.89 
20-40 0.80239 2.23 0.7465 2.22 
< 20 0.77638 2.17 1.2553 3.51 
Redo valvular surgery 
none 1.00 
previous repair -0.59266 0.55 
previous replacement 0.75434 2.13 
Age 
< 40 years 1.00 
40-60 years 0.17364 1.25 
60-70 years 0.75965 2.15 
Position aortic 1.00 
mitral 0.8126 2.25 
double 1.5508 4.71 
Coronary artery disease 
no 1.00 
yes with CABG 0.7729 2.17 
without CABG 1.2829 3.61 
Gender 
male 1.00 
female 1.0042 2.73 
Table 2 Predictors of operative mortality in young and old patients, after aortic, mitral or double 
valve replacement. 
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Perioperative morbidity 
Morbidity is significantly increased in the older population. Perioperative morbidity 
including myocardial infarction, postoperative low output syndrome, intra aortic balloon 
counterpulsation and cerebrovascular accident has been reported in 36% of patients 
> 70 years and in 23% of younger patients. The incidence of operative mortality was 
28% after any major complication (85). 
In a group of 64 patients aged 80 to 89 years, the following perioperative 
complications were recorded: six patients with debilitating neurological events, 15 with 
temporary encephalopathy, 9 with major technical difficulties in the operating room of 
whom two died, while 11 patients required additional surgical procedures after aortic 
valve replacement, of whom 4 died. Another 24 patients had postoperative 
complications, leading to a mean hospital stay of 18 days, with 3.5 days in intensive 
care, but with ultimately good outcome, although 9 were discharged to rehabilitation 
facilities. Six patients had devastating central nervous system events, and were 
permanently unable to take care of themselves. These last six patients spent on average 
15 days in intensive care, with a mean total hospital stay of 48 days. Altogether 44% of 
the overall study group had no major complications and were discharged directly home 
after a mean hospital stay of 15 days, including 2.3 days in intensive care. So the mean 
stay in intensive care of the 58 operation survivors was 4.1 days, with a mean hospital 
stay of 19.7 days (83). Craver reported a 4.0% perioperative myocardial infarction rate 
in patients over 70 years after aortic valve replacement, while this complication occurred 
in 3.1% of younger patients. Neurological events in both age groups were recorded in 
7.5 and 3.0% respectively (74). Age was the only independent predictor of neurological 
events in this last study, while length of stay in the hospital after aortic valve replacement 
was significantly longer with increasing age at time of surgery, emergency of the 
operation and the year in which surgery was performed. It is clear that advanced age 
and aortic valve surgery form a complex combination with major morbidity and mortality. 
Survival after aortic valve replacement 
The data from the literature about survival after aortic valve replacement, including 
operative mortality are summarized in Table 3. Most authors used the actuarial survival 
method to calculate survival percentages (92). 
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Author 
(reference) 
Jamieson (72) 
Cormier (73) 
Rioux (81) 
Craver (74) 
Cabral (87) 
Levinson (83) 
Table 3 
age group 
(years) 
> 65 
> 65 
> 70 
> 70 
> 70 
> 80 
year of 
operation 
1966-1979 
1968-1986 
1971 -1985 
1975-1987 
1981 -1984 
1974- 1987 
number 
320 
272 
355 
322 
244 
64 
survival percentage 
1y 3y 5y 6y 8y 10y 12y 
68 56 
71 51 29 
83 76 71 60 57 
83 52 
73 
83 67 49 
Actuarial survival in elderly patients after aortic valve replacement 
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The results of aortic valve replacement on survival compare favorably with that 
recorded in 50 patients aged 60-89 years who while candidates for aortic valve 
replacement, did not undergo this procedure. The actuarial survival in these refusers 
was 57,37 and 25% after one, two and three years respectively (93). 
Turina recorded a 2 year survival of only one patient, out of a group of 18 patients 
who were denied operation (94). Irrespective of age Ross and Braunwald found a 
90% three year mortality in patients with unoperated aortic valve disease and angina or 
syncope, while those with heart failure died within two years (95). 
Survival percentages in these patients after aortic valve replacement approximate the 
survival of the total apparently healthy population in the same age group (81). Some 
series have reported a better long-term survival after aortic valve replacement, than in 
the unselected general population of the same age (83). These differences must be 
ascribed to the preoperative selection process and the small numbers of patients at risk. 
Linearized rates of mortality were the same in patients over 70 years for mechanical 
valves and bioprostheses, being 6.12 and 5.71 per 100 patient years respectively (81). 
Causes of death most frequently encountered are thromboembolism, infective 
endocarditis, valve dysfunction and hemorrhage (74). 
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Valve related morbidity after aortic valve replacement 
Thromboembolism and hemorrhage are the most frequent valve related causes of 
morbidity after aortic valve replacement. The linearized rate of non fatal 
thromboembolism for all age groups is reported as 0.96 and 1.14 per 100 patient years 
for bio and mechanical prostheses respectively, the latter with the use of oral 
anticoagulants (73). The incidence of non fatal bleeding of some importance was scored 
by the same authors as 0.3 and 1.06 per 100 patient years for bioprostheses and 
mechanical valves respectively. Hemorrhages in the mechanical valve group were twice 
as frequent with poor anticoagulation. Valve related morbidity in another French series 
in patients over 70 years was 1.5 and 1.3 per 100 patient years for mechanical and 
biologic aortic valve prostheses respectively (81). In an earlier series on results of aortic 
valve replacement in patients over 65 years, Jamieson reported a 2.63 and 2. 76 non fatal 
morbidity rate per 100 patient years in mechanical and porcine aortic valves (72). 
CONCLUSION 
Most authors conclude that aortic valve replacement can be performed in elderly 
patients with an acceptable operative mortality, and that advanced age alone should 
not be a contraindication for surgical management. However identification of appropriate 
patients for aortic valve replacement remains quite difficult. These decisions involve 
ethical and social issues as well as economic realities. Consideration of the desires of 
the patient and the family is a prime consideration while advice from the surgeon, the 
cardiologist and other involved medical personnel is essential. Preoperative risk factor 
analysis as proposed by Fremes and summarized in Table 3 may simplify some of these 
decisions (85), and can provide a background risk profile in these patients, which can 
serve as a comparative standard for other interventions. Open discussions both within 
and outside the medical community can furnish preliminary answers to questions such 
as those raised by Edmunds (79). Among these are: Can we afford to offer expensive 
operations to elderly patients at high risk (96)? Is there a level of risk that precludes 
operation, and if so, who will decide what it is? Is it ethical to refuse to perform high risk 
operations when the alternatives have higher risks? Are surgeons and cardiologists 
justified in exercising preoperative selection criteria without including the patient in the 
decision process (97)? Can patients demand operations against medical advice (98)? 
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Only ongoing analysis, preferably with systematic registration of aortic valve replacement 
will be able to provide a useful reply. 
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CHAPTER4 
PERCUTANEOUS BALLOON AORTIC VALVULOPLASTY FOR THE 
RELIEF OF ISOLATED AORTIC STENOSIS IN THE ELDERLY 
SUMMARY 
From March 1986 through December 1989 at the Thoraxcenter, 39 balloon aortic 
valvuloplasty procedures were performed in 38 patients. Mean age of these patients 
was 75.1 ± 7.1 years, male -female ratio was 15-23. Twenty five cases were considered 
as inoperable or high risk surgical candidates. lnoperability was judged to exist when 
poor left ventricular function, recently operated or unoperated carcinoma and severe 
pulmonary, neurological or renal disease were present. Very advanced age (_:::80 years) 
classified patients, in combination with other operative risk increasing factors, as high 
risk surgical candidates. Four patients died in hospital, two during the procedure and two 
within 8 days, one after dissection of the aortic base. In the remaining 35 cases, a 
satisfactory result (aortic valve area increase _:::25%) was obtained in 31. Mean aortic 
valve area increased from 0.47 ± 0.14 to 0.75 ± 0.19 cm2 in the hospital survivors. Three 
patients were operated early ( < 3 months), one for severe aortic incompetence, one 
after a failed procedure, and one for recurrence of symptoms. The other patients all 
experienced symptomatic improvement early after valvuloplasty, but thirteen had 
recurrence of symptoms and were then accepted for surgery, at a mean time of 15 
months after valvuloplasty. No patient died after aortic valve replacement. Eight patients 
died during follow-up, which now extends to 45 months. Death occurred at a mean of 
15 ± 5 months after valvuloplasty. The last eleven patients were alive and still improved 
at a mean follow-up time of 23 ± 12 months. Event free survival after one, two and three 
years was calculated as 62, 28 and 25% respectively. Total survival was 87, 68 and 68% 
after the same time intervals. 
We feel that balloon aortic valvuloplasty is a palliative procedure which supplements 
surgical aortic valve replacement. In our view this new therapy is indicated in patients 
where surgical risk is prohibitive, or carries an unduly high risk. 
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INTRODUCTION 
The use of a catheter for intracardiac therapeutic measures had appeared already 
in 1953, when Rubio-Aivarez and coworkers, used rigid catheters to dilate isolated cases 
of pulmonary valve stenosis (1). Charles Dotter in 1969 used rigid catheters of increasing 
size, to dilate acquired peripheral arterial stenoses (2). Apart from the isolated cases 
performed by Rubio-Aivarez, Rashkind was the first to introduce an intracardiac 
therapeutic procedure with a catheter to be used as a routine form of therapy. He 
published his atrial balloon septostomy, a crude, but often lifesaving procedure in the 
new born with transposition of the great arteries, in 1966 (3). After the introduction by 
Gruntzig in 1978 of small fixed diameter balloon catheters, which were inflated at high 
pressures to dilate coronary arteries (4) the same concept, but using larger balloons, 
was utilized in 1982 for the dilatation of pulmonary valve stenosis (5). 
Dilatation of valvular aortic stenosis in infants and children was first performed in 
October 1982 by Lababidi, Wu and Walls and reported in 1984 (6). They percutaneously 
introduced balloons, with maximal inflatable diameters of 10-20 mm, and with a length 
of 40 mm, and positioned these balloons over a 0.035 inch guide wire in the aortic orifice. 
Care was taken to select an inflated balloon diameter at least one mm smaller than the 
aortic annulus. The balloon catheter was sequentially inflated to pressures of 80, 100 and 
120 psi for 5 to 1 0 seconds. The results obtained in their first 23 patients, ranging in age 
from 2 to 17 years, were very promising. Peak systolic pressure differences between left 
ventricle and aorta ranged from 50 to 223 mm Hg before dilatation and from 11 to 80 
mm Hg after dilatation. Cardiac index did not change after dilatation. No severe 
complications occurred, although 8 balloons ruptured and 10 patients showed a mild 
increase of aortic incompetence after dilatation. Two patients underwent open aortic 
commissurotomy, because peak systolic pressure difference was still 80 respectively 65 
mm Hg after dilatation. At operation both aortic valves were bicuspid with small tears 
measuring 1 to 4 mm on the free ends of the commissures. Repeat catheterization in six 
patients 3 to 9 months after the procedure, showed no increase in pressure gradient 
over the aortic valve. The same favorable results were obtained by others, with increases 
in indexed aortic valve areas in children aged 10 days to 15 years from 0.48 to 0.65 
cm
2 jm2 (7) and 0.44 to 0.73 cm2 jm2 (8), the first authors using balloons always smaller 
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than the aortic annulus, while the second group employed sometimes larger balloons 
with a balloon/aortic annulus ratio, ranging from 0.67 to 1.1. 
In September 1985, Cribier et al first applied percutaneous transluminal balloon 
valvuloplasty in three inoperable elderly patients with calcific aortic stenosis (9). The 
amazingly good results in these patients led to an extension of the technique to other 
patients with high surgical risk. Since then Cribier and other groups have published their 
indications, immediate results and complications of this technique (I 0-19). Later reports, 
also from our department, indicated a high restenosis rate, limited hemodynamic results, 
with a still high mortality ·rate and need for subsequent interventions, a fairly high 
immediate risk and a high number of complications, leading to a reevaluation of the 
indications of this technique (20-23). In this chapter we report our elderly patient 
population, that has undergone balloon aortic valvuloplasty, between March 1986 and 
January 1990. 
PATIENTS AND METHODS 
Since March 1986, a total number of 38 patients have undergone balloon aortic 
valvuloplasty, with a gradual decrease in the number of patients over the years, and a 
decrease in the proportion of operable patients (Table I). 
year nr of male/female mean age range inoperable high risk operable 
patients ratio 
1986 10 6/4 72.4 (63- 88) 3 6 
1987 17 6/11 76.3 (60- 88) 9 7 
1988 8 3/5 74.8 (58- 85) 6 
1989 4 0/4 77.3 (72- 81) 2 2 0 
Total 39 15/24 75.1 ± 7.1 (58 - 88) 20 5 14 
Table 1 Characteristics of balloon valvuloplasty patients 
One patient underwent a second valvuloplasty, so 39 procedures were performed. All 
patients were discussed with the cardia-surgical team. 
Patients were considered acceptable for a balloon valvuloplasty procedure if they 
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fulfilled one of the following criteria: 
a) deemed inoperable after a combined cardia-surgical discussion 
b) classified as a high risk case for surgical intervention 
c) classified as a normal risk patient, but with preference of the patient for balloon 
valvuloplasty instead of surgical valve replacement or valvuloplasty. 
All patients and a relative had to give their informed consent, after explanation of the 
experimental character of the procedure, and the potential risks and benefits. No patient 
was acceptable if during diagnostic angiography aortic insufficiency more severe than 
grade II was demonstrated. 
The decision of inoperability was based on the following factors: 
severe cardiac failure (Ejection Fraction _::::0.30) in 6 patients, moderate cardiac failure 
combined with neurological or renal disease or advanced age (:::so years) in 5 patients, 
recently operated or unoperated carcinoma in 5 patients, severe primary lung disease 
in 2 patients and gangrene of the toes in 2 cases (same patient). Patients were classified 
as high risk surgical candidates if the age was over 80, but no strict contraindication for 
surgery existed. This was the case in 5 patients. The other patients were considered as 
operable although a variety of concomitant diseases existed in these patients, as is not 
unusual in this age group (Figure 1). 
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Figure 1: age distribution and estimated surgical risk of all aortic valvuloplasty patients 
Before valvuloplasty 14 patients were in New York Heart Association validity class IV, 
while 25 were in class Ill. Angina on effort or at rest was noted in 33 patients while i i 
patients reported syncopal attacks (fable 2). 
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Case Follow-up NYHAclass Angina Syncope Dyspnea Aortic valve 
No. time replacement 
(months) Before At FU Before AtFU Before AtFU Before AtFU AfterPBAV 
PBAV PBAV PBAV PBAV (months) 
1 45 Ill I +++ + 6 
2 45 Ill I ++ + 13 
3 44 Ill II ++ + 36 
4 18 Ill # +++ + 
5 39 Ill II ++ + + 1 
6 39 Ill I ++ + 10 
7 37 IV I + ++ 7 
8 23 IV # ++ ++ 
9 36 IV I ++ ++ 9 
10 36 Ill II ++ + + 
11 35 Ill II ++ + + 24 
12 34 IV I +++ 27 
13 34 Ill II ++ + + + + 8 
14 34 Ill I ++ 6 
15 34 Ill I ++ 20 
16 33 Ill II ++ + + + + 
17 33 Ill I ++ 13 
18 33 Ill II ++ ++ + 
19 19 Ill # + 
20 31 Ill Ill ++ ++ ++ ++ 
21 31 IV II +++ + + ++ 
22 31 Ill II ++ + ++ + 
23 15 IV # + +++ 
24 8days IV # +++ 
25 0 days IV # ++ +++ 
26 14 Ill # ++ + 
27 13 Ill # ++ + 
28 23 Ill I +++ 2,5 
29 22 IV II ++ + + +++ 
30 5 Ill # ++ ++ 
31 20 IV I ++ +++ 6 
32 16 Ill II ++ + + + 
33 16 Ill Ill ++ ++ ++ 13 
34 16 IV II ++ +++ + 
35 1 day IV # +++ 
36=26 Odays IV # ++ +++ 
37 10 Ill # +++ 
38 6 Ill I +++ 
39 10 days IV II +++ + + ++ + 
Mean 26.3 (hospital suNivors n = 35) 
.±. SD 11.9 
NYHA - New York Heart Association; PBAV - percutaneous balloon aortic valvuloplasty; 
At FU =at follow-up.#= Patient died 
Angina: - = absent; + = angina on strenuous effort; + + = angina on moderate effort; + + + = angina 
on minimal effort or at rest. 
Syncope: - = absent; + = present 
Dyspnea: - = absent; + = slight; + + = moderate; + + + = severe also at rest. 
Table 2 Validity class and severity of symptoms before and 0-45 months after balloon aortic valvuloplasty 
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Cardiac status of valvuloplasty patients 
The ejection fraction was calculated from a 30° right anterior oblique left ventricular 
angiogram in all but two patients. Two patients had undergone previous open heart 
surgery, one with mitral valve replacement, while the other patient underwent previous 
bypass operation for three vessel disease with invalidating angina pectoris. Three 
patients had undergone previous coronary angioplasty. 
The ejection fraction of the patients varied from 0.12 to 0. 72. Individual ejection 
fractions, the grade of aortic insufficiency as assessed from a pre valvuloplasty 
supravalvular, 60° left anterior oblique, aortic root contrast injection, and the severity or 
absence of coronary artery disease are summarized in Table 3. 
EF>0.55 
EF >0.40 - 0.54 
>0.20 -0.39 
<0.19 
not assessed 
Aortic incompetence 
grade 0 
grade I 
grade II 
Coronary artery disease 
Absent 
1 vessel disease 
2 vessel disease 
3 vessel disease 
left main disease 
Number of patients 
22 
6 
5 
4 
2 
10 
20 
9 
24 
7 
2 
5 
Table 3 Ejection fraction, severity of aortic incompetence and coronary artery disease in 39 valvuloplasty 
patients 
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Coronary artery disease was considered to be present if one of the three major 
coronary arteries i.e. right coronary, left anterior descending, left circumflex or the left 
main coronary artery showed a more than 50% diameter stenosis in one or more of 
multiple views. 
In seven patients a grade II mitral insufficiency was present while in two other patients 
a mitral stenosis of moderate severity (ostium 1.5- 2.0 cm2) was demonstrated. Three 
cases had suffered a previous myocardial infarction. Other prevalvuloplasty 
hemodynamic data will be presented later, together with post valvuloplasty 
measurements. 
Valvuloplasty procedure and hemodynamic evaluation 
All procedures were performed using the femoral route and under local anesthesia 
except in one case, where general anesthesia was applied. Left ventricular and aortic 
pressures, and mean systolic transvalvular gradients were averaged and calculated on 
line after acquisition periods of 20 seconds. Cardiac output was computed from 
duplicate thermodilution measurements. A computerized system also provided instant 
calculation of the mean systolic aortic valve flow to compute aortic valve area (24)(fig 
2) using the Gorlin formula (25): 
Aortic valve area (cm2) = systolic valve flow (ml sec-1) 
44.5 .;mean pressure gradient (mm Hg) 
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Figure 2: Example of computer output for 
calculation of cardiac output and aortic valve 
area. The 4 representative beats from which 
aortic valve area is calculated are marked under 
the respective beats, with small vertical bars, 
indicating beginsystole, endsystole and 
enddiastole. 
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Left ventricular end diastolic and endsystolic volume indices were calculated from the 
diagnostic left ventricular angiogram, either performed just before the valvuloplasty 
procedure, or during a separate session. Volume indices were calculated using the area 
length method from a 30° right anterior oblique projection angiogram (26). A 
supravalvular aortic root injection of contrast was performed to grade the amount of 
aortic valve insufficiency ranging from 0 to IV. Aortic incompetence was scored as 0 
when no contrast was visible in the left ventricle after supravalvular aortic contrast 
injection, as I when only minimal opacification of the left ventricle occurred, as II when 
the whole left ventricle was outlined with a density of contrast less than in the aortic root, 
as Ill when filling of the left ventricle was of the same density as the opacification of the 
aortic root and finally as grade IV when the contrast density of the left ventricle was 
higher than that of the aortic root. 
After femoral venous and arterial puncture, 5000 I.U. of heparin and 1.0 mg of atropine 
was administered intravenously. A Swan- Ganz thermodilution catheter was introduced 
through the venous sheath into the pulmonary artery for measuring right heart pressures 
and cardiac output. In the first 17 patients a straight 0.038 inch, 260 em long guidewire 
(Cordis Corporation, Miami), with its soft tip manually fashioned to a large J shape, was 
advanced into the left ventricle. In the remaining patients the distal part of a 0.035 inch, 
300 em long, "back-up" guidewire (Schneider- Shiley, Zurich) was introduced into the 
left ventricle, while over the proximal stiffer part of this guidewire a 16.5 French diameter, 
100 em long valvuloplasty introducer (Schneider - Shiley, Zurich) was positioned 
immediately above the aortic valve level, in an attempt to facilitate introduction and 
removal of multiple balloon catheters (see chapter 7). A balloon catheter was then 
pushed up along this wire and positioned across the aortic valve. Before insertion, 
particular care was taken to remove air from the balloon, by inflating and deflating the 
balloon before introduction with a mixture of contrast medium and saline (30/70). 
Inflations were performed by manual force, using a special 50 ml syringe with revolving 
piston, to increase the balloon pressure, under manometer control. Maximal inflation 
pressure ranged from 3 to 7 atmospheres. Single, double and trefoil balloons of 
increasing diameters and areas were used in an attempt to reduce the mean aortic 
transvalvular gradient to < 40 mm Hg, and to increase the aortic valve area to ,::::1.0 cm2. 
If this result was not accomplished oversized balloons (balloonjaortic annulus diameter 
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ratio> i.O) were employed. Each inflation duration ranged from i5 to 260 s (mean 40 
s) depending upon the individual tolerance. In most patients only a moderate decrease 
of systemic arterial pressure, continuously monitored throughout the procedure, was 
observed during balloon inflation (see also chapter 6). However, the maximal systolic 
pressure transiently fell to _::: 60 mm Hg in 20 patients, resulting in dizziness andjor 
promptly reversible syncopal attacks in 7 cases. We instructed our last i 4 patients to 
cough during balloon inflation to maintain minimal cerebral arterial flow. Since then only 
one patient fainted. 
In some of the first patients, 80 mm long balloons were used, in order to achieve a 
stable position during inflation, but with the inherent disadvantage of longer inflation 
durations to achieve adequate intra balloon pressures. In the more recent patients 
shorter balloons could be used because to and fro motion across the aortic valve during 
inflation was prevented by the long sheath positioned immediately above the inflated 
balloon (Fig 3). At the end of the procedure hemodynamic results and aortic valve 
regurgitation were systematically reassessed. 
Figure 3: A 3 x 12, 40 mm long trefoil balloon (Schneider Medintag, ZOrich) is inflated across the calcific 
stenotic aortic valve. The presence of the sheath (arrows) immediately above the balloon, prevents possible 
to-and-fro motion during inflation, allowing the use of shorter balloons. 
Percutaneous balloon aortic valvuloplasty immediately followed the diagnostic 
catheterization in 8 patients, while valvuloplasty was performed in a separate session in 
the remaining 3i patients. The decision not to perform valvuloplasty directly after the 
diagnostic procedure was mainly taken in view of the old age of the patients, for whom 
a long procedure time is very uncomfortable. 
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Echocardiographic and Doppler measurements 
These findings are detailed in chapter 5: Evaluation of percutaneous balloon aortic 
valvuloplasty in elderly patients with Doppler echocardiography. 
Follow-up 
Survival data and functional class of all patients discharged home were obtained 
mostly by telephone interview via general practitioners, referring cardiologists and the 
patients themselves. Follow-up coronary and left ventricular angiography was performed 
in 6 patients in five as a presurgery evaluation, and in one for assessment, before repeat 
valvuloplasty, after recurrence of symptoms. 
Estimation of surgical operative risk 
By means of the factor adjusted odds ratios for each risk variable, calculated by 
Fremes (27, see also chapter 3), the mortality probability of each patient as a surgical 
candidate was estimated. These risk variables included: gender, urgentjnon urgent 
operation, ejection fraction of the left ventricle, the presence or absence of coronary 
artery disease and age below or over 70 years. 
Statistical analysis 
Student's t-test for paired data was used whenever appropriate. 
Actuarial survival 
Life -table analysis was performed using the Kaplan - Meier method (28). Both 
eventfree survival after valvuloplasty i.e. survival without further interventions, such as 
aortic valve replacement or revalvuloplasty, as total survival were calculated. 
Analysis of risk factors for poor early or late outcome 
The following three untoward events were defined. 
1. Early mortality 2. Late mortality 3. Late events: revalvuloplasty or aortic valve 
replacement. 
Eighteen variables, including all13 hemodynamic parameters from Table 4, and age, 
gender, left ventricular ejection fraction, presence of coronary artery disease and 
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urgency of the procedure, were analyzed, to determine the relation between these 
preprocedural variables and untoward events. This relation between predictors and 
outcome was expressed as a relative risk or risk ratio, that is· as the ratio of the rate of 
the respective outcome event observed in patients belonging to one category relative 
to that observed in the other category. For instance the risk associated with an urgent 
procedure is the rate of the outcome event after an urgent procedure divided by that 
rate after a "routine" procedure. Continuous variables were dichotomized. The 95% 
confidence limits of the relative risk estimates are also given (29). 
RESULTS 
Immediate hemodynamic results 
Hemodynamic data before and after aortic balloon valvuloplasty are summarized in 
Table 4. In five cases no aortic valve area was calculated after the last balloon inflation. 
In cases 14 and 34 the aortic valve area could not be computed after aortic valve 
dilatation because of the development of grade Ill aortic insufficiency. In one case this 
complication occurred after a single 19 mm balloon inflation, in the other after inflation 
of a bifoil2 x 19 mm balloon. The first patient, who was operated on 6 days later, showed 
a bicuspid aortic valve, with heavy calcifications and scarring in one of these cusps, while 
the other cusp was less affected by the degenerative process and manifested a tearing 
off of the aortic wall of 7 mm. After inflation of a bifoil 2 x 19 mm balloon the second 
patient showed a dissection of the aortic wall just distal to the opening of the ·left 
coronary ostium, together with severe aortic incompetence (Fig 4). 
Figure 4: dissection of the aortic base (arrow) 
and aortic valve incompetence, (filling of the left 
ventricular cavity, after supravalvular contrast 
injection) after aortic valve dilatation with a bifoil 
2 x 19 mm balloon. 
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Case LVPSP LVEDP P-PSG MSG AF AVA %Increase 
No. B A B A B A B A B A B A AVA 
1 247 229 24 11 56 28 57 39 179 245 0.53 0.88 66 
2 275 222 31 16 98 68 78 56 234 270 0.59 0.81 37 
3 264 177 15 2 66 35 81 31 134 197 0.33 0.80 142 
4 230 188 16 19 73 22 67 28 136 166 0.37 0.71 92 
5 204 210 23 23 54 36 48 41 152 163 0.49 0.57 16 
6 238 212 12 2 105 70 80 58 136 120 0.34 0.36 6 
7 203 188 28 15 47 33 53 37 231 259 0.71 0.96 35 
8 275 240 17 12 119 66 118 64 198 230 0.47 0.65 38 
9 191 177 30 27 90 40 68 41 125 181 0.37 0.64 73 
10 197 223 27 17 58 23 50 31 193 258 0.61 1.04 70 
11 257 179 13 8 135 51 106 49 260 286 0.57 0.95 67 
12 232 154 29 3 121 52 93 52 166 229 0.39 0.71 82 
13 234 193 11 14 75 40 74 47 176 214 0.46 0.70 52 
14 190 140 13 22 65 54 60 nc 226 nc 0.66 nc 
15 211 188 5 4 48 32 60 39 215 238 0.62 0.85 37 
16 230 104 9 11 96 52 79 38 86 160 0.26 0.60 131 
17 204 nr 28 nr 89 nr 82 nr 236 nr 0.59 nr 
18 218 192 9 8 83 47 74 53 144 205 0.35 0.67 91 
19 219 164 7 6 103 83 67 60 238 253 0.65 0.72 11 
20 232 156 13 3 89 46 72 31 180 198 0.48 0.80 67 
21 207 199 28 12 96 24 75 54 119 140 0.31 0.44 42 
22 303 193 12 17 124 59 115 62 145 231 0.30 0.66 120 
23 180 181 11 11 72 37 89 49 139 151 0.33 0.49 48 
24 157 123 11 14 60 28 39 30 169 200 0.61 0.82 34 
25 105 nr* 27 nr* 35 nr* 36 nr* 90 nr* 0.34 nr* 
26 231 202 13 13 75 32 79 53 198 245 0.50 0.76 52 
27 240 173 13 8 107 23 91 28 161 250 0.38 1.06 179 
28 200 169 11 20 69 33 83 41 233 210 0.57 0.74 30 
29 233 164 4 0 70 33 70 36 127 152 0.34 0.57 68 
30 196 175 8 2 46 29 61 40 307 329 0.88 1.17 33 
31 188 133 8 4 106 37 80 46 163 213 0.41 0.71 73 
32 231 185 8 28 63 27 63 35 192 295 0.54 1.12 107 
33 232 205 12 17 69 28 74 39 204 216 0.53 0.78 47 
34 170 176 39 39 85 50 52 52 159 249 0.50 0.78 56 
35 153 77 20 27 67 13 51 nc 88 nc 0.28 nc 
36=26 197 nr* 25 nr* 55 nr* 69 nr* 159 nr* 0.43 nr* 
37 242 184 9 0 86 33 84 45 136 145 0.33 0.49 48 
38 231 148 11 3 108 44 95 46 228 193 0.53 0.64 21 
39 230 150 14 10 117 58 94 27 192 175 0.45 0.76 69 
Mean 217 177 16 12 82 41 74 43 176 214 0.47 0.75 63 
±so 37 34 9 9 24 15 19 10 50 49 0.14 0.19 38 
pvalue <0,05 <0.05 <0,05 <0,05 <0,05 <0,05 
AVA - aortic valve area (cm2); AF - systolic aortic valve flow (ml s-1); LVEDP - left ventricular end-
diastolic pressure (mmHg); LVPSP = left ventricular peak-systolic pressure (mmHg); MSG = mean systolic 
aortic gradient (mmHg); P-PSG = peak to peak systolic gradient (mmHg); nc = not computed because 
of significant aortic valve insufficiency after valvuloplasty; nr = not recorded at the end of the last balloon 
inflation; nr* = not recorded because of patient's demise immediately after the first balloon inflation. 
B = before; A = after. 
Table 4 Hemodynamic data before and after 39 balloon aortic valvuloplasty procedures. 
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This patient, deemed inoperable, died 24 hours later of cardiac failure. At autopsy the 
dissection of the aortic wall seen on the angiogram was confirmed, compromising the 
left main coronary artery. No tears in the tricuspid aortic valve were observed, the aortic 
incompetence probably being caused by loss of support of the three heavily calcified 
cusps. Two patients died immediately after the first balloon inflation (nrs 25 and 36). The 
first patient was in severe cardiac failure, managed with dopamine infusion, with a left 
ventricular systolic pressure of 105 mm Hg, a left ventricular end diastolic pressure of 27 
mm Hg, an ejection fraction of 0.14 and left main coronary artery disease. The second 
patient who died during the procedure (nr 36) had already undergone previous aortic 
valvuloplasty 14 months before, and previous coronary bypass operation 60 months 
earlier. During the first 25 mm balloon inflation the balloon "popped" out of the aortic 
valve possibly occluding the only remaining blood flow to the heart, i.e. the previously 
inserted jump graft with distal connections on 3 main coronary arteries. No autopsy was 
performed in these two last cases. In the last of the five patients without valve area 
calculation after the procedure, a severe epileptic fit occurred, with dislocation of the 
long wire from the left ventricle. In this patient no attempt was made to reposition the 
wire and measure the transvalvular aortic pressure gradient. 
Comparison between pre and post valvuloplasty values in the remaining patients 
revealed highly significant changes in left ventricular peak systolic and end diastolic 
pressures, mean and peak systolic aortic valve gradients, mean systolic aortic valve 
flow, and aortic valve area (Table 4, figs 5 and 6). 
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However, when the individual absolute values after valvuloplasty are considered, the 
presence of a mean systolic gradient of> 40 mm Hg in 19 patients (49%), and an aortic 
valve area < 0.70 cm2 in 12 patients (31%) should be emphasized. A less than 25% 
increase in valve area was obtained in 4 patients {10%). Increasing balloon sizes did not 
linearly affect the ultimate result of balloon aortic valvuloplasty, the increase in aortic 
valve area being 76 ± 37%, 52 ± 28% and 86 ± 53%, when a maximal single balloon size 
of 23 mm, trefoil 3 x 12 mm balloons or bifoil 2 x 19 mm balloons respectively were 
employed. 
Complications 
Mortality 
In patient nr 24, a 77 year old man, admitted to the intensive care unit in cardiogenic 
shock, mentally confused and an uric with a left ventricular ejection fraction of 15%, the 
valve area was increased from 0.61 to 0.82 cm2 as a result of valvuloplasty. Although 
temporary clinical benefit was observed for the first days after the procedure, all attempts 
at reducing the intravenous inotropic support were unsuccessful and the patient died 
in cardiogenic shock 8 days after the procedure. At autopsy no cardiac or vascular 
damage related to the procedure could be observed. Thus, in hospital mortality occurred 
in 4 patients or 10%. 
Neurological 
In patient nr. 10 a complete left hemiplegia developed at the end of the aortic 
valvuloplasty procedure, with persistent impairment of the mobility of the left arm at 
discharge from the hospital, but almost complete functional recovery at late follow-up. 
One patient developed complete left hemianopia during the procedure. At follow-up 
minimal residual defects were still present. Two patients (nrs 17 and 29) experienced 
syncopal attacks after balloon inflation. One of these patients had been known to have 
preexisting epilepsy, in the other patient syncope occurred after the balloon burst with 
possible air embolism in the cerebral circulation. Both patients recovered quickly and 
without sequelae. 
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Aortic valvular insufficiency 
Apart from the two patients described under immediate hemodynamic results and 
complications, no patient experienced an increase in the severity of aortic insufficiency 
of more than one grade. In the patients where aortic incompetence after the procedure 
could be reassessed (n = 32), a grade I increase in aortic valve insufficiency was noted 
in 11 patients, in 7 of these from grade 0 to grade I and in 4 from grade l to grade II. In 
three other patients minimal aortic insufficiency was no longer detectable after the 
procedure. 
Other cardiac complications 
One patient developed complete atrioventricular block immediately after insertion of 
a "back-up" guide wire in the left ventricle, requiring implantation of a permanent 
pacemaker. One other patient developed a complete left bundle branch block during 
the procedure, disappearing during follow-up. Two patients had temporary ventricular 
fibrillation in the catheterization department; this was managed by DC countershock. 
One patient had to be resuscitated for a short period after a prolonged fall in aortic 
pressure after balloon inflation, which led to an immediate fall in blood pressure to 20 mm 
Hg. One patient exhibited signs of severe pulmonary edema at the end of the procedure 
which was managed medically. 
Vascular 
Three patients required surgical interventions at the puncture site, two because of 
development of a femoral artery pseudo aneurysm, and one for the removal of a balloon 
remnant from the femoral artery after balloon rupture. Four patients developed large 
groin hematomata, requiring multiple blood transfusions in two cases. No hemorrhagic 
or other complications were observed at the puncture site in the last 21 procedures, after 
a long arterial valvuloplasty introducer was used (see chapter 7). 
For all patients the procedure was free of the above complications in 23 cases (59%), 
this number being 61% after the use of a long sheath, and 57% before that period. 
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Estimated risk of surgical operative mortality 
The patients that were deemed inoperable mainly on the basis of their cardiac 
condition (n = 16) had a calculated operative risk of 4 to 33% (mean 13.2 ± 7.4%). Three 
of these patients died in hospital for a calculated valvuloplasty risk of 18.8%. The other 
patients had a calculated mean risk of operative mortality of 4.4%. Eventually one died, 
i.e. a risk of valvuloplasty related mortality of 4.3%. Three other patients have died while 
waiting for their valvuloplasty procedure, which had already been planned in one case, 
while the other two were considered candidates and were evaluating the pro's and 
con's. 
In hospital stay 
Thirty five of the patients were discharged home, or referred to a rehabilitation center 
after a mean hospital stay of 6.1 ± 7.9 days. A prolonged hospital stay of more than six 
days was observed in 7 patients (range 7 to 37 days), mainly due to complications of the 
procedure or inability of these patients to take care of themselves and waiting for 
admittance to a recovery home. During this prolonged hospital stay also one pacemaker 
implant, one surgical aortic valve replacement and one surgical repair of a femoral artery 
pseudoaneurysm took place. 
Follow-up catheterization 
A total of six patients have been reinvestigated with left and right heart catheterization 
and left ventricular and aortic root angiography. Data obtained pre and post valvuloplasty 
and at follow-up catheterization are summarized in Table 5. 
Four patients (nrs 3, 12,26,33) had a return to pre valvuloplasty values, one had a 
moderate restenosis (nr 9) while one did not show signs of restenosis (nr 28). 
Nevertheless this last patient (85 years old) who had undergone angioplasty of the left 
anterior descending coronary artery one month before aortic valvuloplasty , and 
angioplasty of the left circumflex artery one month after valvuloplasty, was accepted for 
aortic valve replacement and a coronary bypass operation, due to persisting symptoms 
of angina pectoris. Four of the other patients underwent aortic valve replacement as well, 
while the last (inoperable) patient underwent revalvuloplasty. 
case LVPSP LVEDP MSG AF AVA 1-D EF AI Interval Coronary 
number 8 A FU 8 A FU 8 A FU 8 A FU 8 A FU I D 8 FU 8 A FU V-FU artery 
(months) disease 
3 264 177 273 15 2 16 81 31 93 134 197 151 0.33 0.80 0.35 142 128 0.63 0.60 I I I 33 1 VD 
9 191 177 215 30 27 30 68 41 72 125 181 199 0.37 0.64 0.53 73 30 0.19 0.38 I II I 9 none 
12 232 154 221 29 3 9 93 52 n.a. 166 229 n.a. 0.39 0.71 n.a. 38 n.a. n.a. 0.37 II II Ill 27 none 
26 231 202 197 13 13 25 79 53 69 198 245 159 0.50 0.76 0.43 52 77 0.51 0.37 II II II 14 3VD 
open jump graft 
28 200 169 181 11 20 21 83 41 56 233 210 257 0.57 0.74 0.77 30 -4 0.60 0.60 0 I I 1 2VD 
33 232 205 234 12 17 18 74 39 70 204 216 203 0.53 0.78 0.55 47 42 0.58 0.61 I I II 13 none 
LVPSP = left venticular peak systolic pressure (mm Hg); LVEDP = left venticular enddiastolic pressure (mm Hg); MSG = mean systolic aortic valve gradient (mm Hg); 
AF = systolic aortic valve flow (ml s-1); AVA= aortic valve area (cm2); 1-D = increase, respectively decrease; in AVA(%); EF =ejection fraction of the lett venticle; 
AI = grade of aortic incompetence; 8 = before valvuloplasty; A = after valvuloplasty; FU = at follow-up; 1-2-3 VD = single, double, triple vessel disease; 
V = valvuloplasty; n.a. = not assessed 
Table 5 Hemodynamic and angiographic data before and after balloon valvuloplasty and at follow-up catheterization 
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Clinical follow-up 
Mortality 
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Eight patients died 5 to 23 months after hospital discharge (mean 15 ± 5 months). 
With the exception of a 58 year old man, who was refused surgery on the basis of a 
pleural mesothelioma, and one other 70 year old male patient who rejected surgery, all 
other 6 patients were deemed inoperable on the basis of their age and cardiac and 
general condition (mean age 83 ± 5 years). They all experienced some relief of their 
anginal symptoms and dyspnea, while two patients with syncopal attacks did not report 
this complaint in the follow-up period before they died of natural causes. 
Aortic valve replacement 
A total of sixteen patients underwent aortic valve replacement, one after a complicated 
aortic valvuloplasty, two for failed valvuloplasty and thirteen for clinical, hemodynamic 
and echocardiographic signs of restenosis. All but one of these patients had been 
classified as inoperable or high risk cases. Six cases, previously deemed inoperable, 
were acceptable for surgery, after improvement of left ventricular function, or elimination 
of other diseases which had caused the decision of inoperability. Nine other patients, 
initially classified as high risk cases, were after a second discussion, when valvuloplasty 
had proved to be ineffective, accepted for surgical valve replacement. These 16 patients 
will be discussed in a separate chapter (chapter 8). At a mean follow-up of 34 (± 8) 
months after valvuloplasty and 22 ( ± 11) months after aortic valve replacement, none of 
these patients have died. Eleven patients are in New York Heart Association validity 
class I, four are in class II,_ while one is in class Ill. Thirteen patients are taking oral 
anticoagulants, three digoxin and six are on diuretics. 
Patients without further interventions 
Eleven patients were alive after a one-off balloon aortic valvuloplasty, at a follow-up 
time of 10 days to 35 months (mean 23 ± 12 months). One patient is in validity class I, 
9 are in class II and one is in class Ill. The last patient is 31 months after valvuloplasty 
in the same validity class as before valvuloplasty, and is now waiting for reevaluation 
and eventually revalvuloplasty. The other patients have experienced an increase in 
validity class of on average 1.5. Syncopal attacks which were present in 4 of these 
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patients before valvuloplasty, were not reported after valvuloplasty. Anginal symptoms 
and dyspnea improved as well after the procedure. The mean age of this group of 
patients was at the time of valvuloplasty 76.6 years. 
Symptoms and validity class before inteNention and at follow-up are summarized in 
Table 2. One patient is taking oral anticoagulants, nine are on diuretics, 5 on digoxin and 
three are taking long-acting nitrates. Table 6 summarizes some clinical and 
hemodynamic data of patients dying early (in hospital mortality), late deaths and long-
term suNivors with and without aortic valve replacement. 
Survivors operated 
(n = 16) 
Age 
(years) 
72.1 ± 5.6 
Male/Female Follow-up 
ratio (months) 
6/10 34 ± 8 
Aortic valve 
area (cm2) 
Before After 
Aortic valve area Validity class 
Increase (%) Before 
Ill IV 
0.51 ± 0.11 0.75 ± 0.15 52± 32 12 4 
Survivors not operated 76.7 ± 6.6 4/7 23 ± 12 0.42 ± 0.11 0.73 ± 0.19 77 ± 31 7 4 
(n = 11) 
Late deaths 
(n = 8) 
Early deaths 
(n = 4) 
Table 6 
78.7 ± 9.5 3/5 15 ± 5 0.49 ± 0.18 0.76 ± 0.23 67 ± 48 6 2 
76.2 ± 1.5 2/2 2 ± 3 days 0.42 ± 0.12 0 4 
Clinical and hemodynamic data at the time of percutaneous balloon aortic valvuloplasty 
in patients with early and late mortality and in survivors, with and without aortic valve 
replacement. Data are given as mean values ± standard deviation 
Figure 7, depicting the relation between aortic valve area increase and late outcome, 
indicates a trend for better long-term results if the aortic valve area is increased by at 
least 50%. 
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Actuarial survival for 38 patients was 87% after one year, and 68% after two as well 
as three years. Excluding patients who had a reintervention an eventfree survival of 62, 
28 and 25% after 1 ,2 and 3 years respectively was found (fig 8). 
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patients after percutaneous balloon aortic 
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treatment or aortic valvuloplasty is also shown 
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Predictors of early and late mortality and events after valvuloplasty 
Table 7 summarizes predictors for periprocedural and late mortality, as well as for 
late events. Procedural mortality was higher in patients with a left ventricular pressure 
< 200 mm Hg, a peak and mean systolic aortic gradient of < 75 mm Hg, an ejection 
fraction of less than 0.55 and in cases of an urgent procedure. The risk of aortic valve 
replacement during follow-up is higher in patients with a less than 50% aortic valve area 
increase after aortic valvuloplasty. 
Unfavorable outcome 
Early mortality 
Late mortality 
Late events 
Variable* 
Left venticular peak systolic pressure 
< 200 mm Hg 
Peak systolic gradient < 75 mm Hg 
Mean systolic gradient < 75 mm Hg 
Ejection Fraction < 0.55 
Urgent valvuloplasty 
none 
Aortic valve area increase < 50 % 
* only the significant variables are tabulated 
Risk ratio 95 % confidence 
limits 
1.5 1.0-2.2 
1.3 1.0- 1.6 
1.2 1.0-1.5 
1.3 1.0 -1.8 
1.4 1.0-2.0 
2.0 1.0-4.0 
Table 7 Univariate analysis to predict immediate and late unfavorable outcome after aortic 
valvuloplasty 
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Comparison of in hospital mortality rates following aortic valve replacement versus 
percutaneous balloon valvuloplasty, may be somewhat misleading, as all calculated 
risks for valve replacement are by definition obtained from operated patients only 
(27,30,31). In fact we do not know what the operative risk ofthese patients would have 
been, had they been accepted for surgery as a first choice. Also we do not know how 
the factors that make patients unsuitable candidates for aortic valve replacement, would 
influence operative mortality. Another part of the problem of estimating surgical risk is 
that results obtained in one hospital may not be applicable in another. Finally the 
calculated risk probabilities for operative mortality, were derived by Fremes (27) from a 
study group of 31 5 patients with aortic valve replacement who had a mean age of 7 4 ± 
3.4 years. Although the higher risk for operative mortality in patients over 80 is well 
recognized, compared to the age group over 70 (30,31), we could not adjust our 
calculated probabilities for patients over 80 years. In fact we have calculated the risk 
probabilities in these patients as those belonging to Fremes' group over 70 years old. 
With these limitations in mind operative mortality was found to be 8.0% for the whole 
group, while the actual valvuloplasty mortality was 10.3%. Other authors have reported 
valvuloplasty related mortalities in hospital to range from 3.5% (23) to 9.6% (32) in a 
series comprising 170 and 104 patients respectively. It might well be, that after the initial 
"Samson feeling, the Delilah of restenosis" (33) tempered the enthusiasm among 
interventional cardiologists, and the procedure is now reserved as palliation for patients 
with severe symptoms who are denied surgery, resulting in an inherent higher 
procedural risk. But the opposite could also be true, as pointed out by Cribier (34). He 
found in the French Registry a mortality of 13% in the first 215 patients, while this figure 
dropped to 4% in the following 237 patients. 
Other complications 
a) Vascular complications at the introduction site 
The most frequent complication of the procedure, is local trauma to the femoral artery 
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at the puncture site. In particular prior to the availability of introducer sheaths, and with 
balloons which had a high profile even when deflated, local vascular injury was 
encountered in about 1 0% of patients, while 23.5% of all patients required blood 
transfusion (23). Our vascular complication rate was 7.7%, while only 5% of patients 
were in need of blood transfusions. Vascular complications did not occur in our series 
in the last 21 procedures when a long introducer sheath was used (see chapter 7). 
Skillman et al found in 7333 patients undergoing percutaneous left heart catheterization 
75 operative repairs of catheterization related vascular complications (1%). For 
diagnostic heart catheterization, percutaneous transluminal coronary angioplasty and 
balloon valvuloplasty the percentages were 0.6, 0.9 and 5.2% respectively (35). 
b) Embolic complications 
Embolic events produced by calcific emboli, dislodged from the calcified leaflets 
during valvuloplasty are rare, but serious. In the French registry a 2";b incidence of stroke 
was noted (34). Embolization to the coronary arteries, with ensuing myocardial infarction 
is even more rare ( < 1%) (23). Neurological complications with residual impairment at 
follow-up, occurred in our series in two patients, in one a complete stroke occurred, 
while the other patient exhibited signs of hemianopia. Davidson et al systematically 
investigated the occurrence of emboli associated with percutaneous mitral and aortic 
valvuloplasty by computed tomography of the head, funduscopy and 
electrocardiography in 32 patients. They demonstrated signs of old cerebral infarction 
in nine patients, with three patients showing a new cerebral abnormality after 
valvuloplasty. Two of these three episodes were symptomatic, and occurred in patients 
with bicuspid aortic valves. Serial electrocardiograms were unchanged in all patients 
(36). Detachment of a large calcific fragment from the aortic valve was recently described 
in a case report. The calcific embolus was recovered from the abdominal aorta during 
operative aortic valve replacement (37). 
c) Aortic valve and aortic root complications 
Complications at the level of the aortic valve were observed in two patients, in both 
instances leading to severe aortic incompetence, one due to a tear in one of the leaflets 
of a bicuspid valve, the second caused by aortic root dissection (fig 4). Severe aortic 
incompetence has been reported previously but with a remarkably low incidence, mostly 
as case reports (38-40). In larger series the incidence of severe aortic valve 
incompetence ranged from 1 to 2% (23,34). Two papers addressing specifically the 
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problem of aortic valve insufficiency after aortic valvuloplasty came to the same 
conclusion in that the procedure neither produces significant increases nor decreases 
in aortic valve regurgitation (41 ,42). 
Although the use of balloons larger than the aortic annulus has been shown to lead 
to a greater increase in aortic valve area (43), a balloon -aortic annular area ratio of 
more than 1.21ed to aortic annular tears in 2 out of 100 patients, while this complication 
did not occur with ratios below 1.2 (44). If for example a trefoil balloon with 3 parallel 
balloons of 12 mm diameter mounted on a single catheter, is inflated, the radius is 14.2 
mm, the area occupied is 633 mm2, and the effective circumference 89 mm. If the aortic 
annulus diameter is 24 mm, the aortic annulus area is 452 mm2, and the circumference 
75 mm. So this balloon causes in a relatively large annulus diameter of 24 mm, already 
an overstretching of 19% of the aortic wall, where as a single balloon with a 25 mm 
diameter overstretches it by only 3%. Assuming a tricuspid valve, with equal cusp margin 
lengths in the previous example of a 24 mm diameter annular ring, the cusps are 
overstretched by 25%. In our patient whose aortic annulus was 20 mm with severe aortic 
incompetence after a single 19 mm balloon inflation, only one of the bicuspid leaflets was 
heavily calcified. The radial force of the inflated balloon must have been exerted 
eccentrically, overstretching the half of the annulus with the more supple valve by 56 %, 
which led to a tearing of the aortic attachment of this valve leaflet. 
Calculated circumferences, leaflet free margin lengths and annular areas are 
summarized in Table 8, for annular diameters varying from 20 to 26 mm in trileaflet 
valves. These values are compared with the same data derived from inflated balloons 
with increasing diameters. Leaflet length at the time of balloon inflation is derived from 
dividing the balloon circumference by 3. Maximal advisable balloon sizes are for annulus 
diameters of 20, 22, 24 and 26 mm: trefoil3 x 10 mm, single 25 mm, trefoil 3 x 12 mm 
and trefoil3 x 13 mm respectively. 
The application of double balloons for mitral valve dilatations, has also encouraged 
the use of this type of balloon in aortic valve stenosis (45-47). Calculations such as 
shown in Table 8 can also be performed for bifoil balloons. The circumferences of bifoil 
2 x 15, 2 x 17 and 2 x 19 mm balloons are respectively 77, 87 and 98 mm. By the nature 
of its design this balloon exerts more force on one leaflet than on the other two in 
tricuspid valves, so the result is more unpredictable. In bicuspid valves a 2 x 15 mm 
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balloon overstretches the leaflet edges in a 20 mm aortic annular ring by (30/20-1) x 
100 = 50%. The use of a bifoil2 x 19 mm balloon in patient nr 35 with an aortic annulus 
diameter of about 22 mm must have overstretched the wall circumference by 42%, 
causing fatal laceration and dissection of the aortic wall. 
Aortic annulus diameter 
20mm 22mm 24mm 26mm 
cf II area cf II area cf II area cf II area 
mmmm mm2 mmmmmm2 mmmm mm2 mm mm mm2 
63 20 314 69 22 380 75 24 452 82 26 534 
Balloons 
Single20 mm 63 21 314 
Overstretch(%) 0 5 0 
Single23mm 72 24 415 72 24 415 
Overstretch (%) 14 20 32 4 9 9 
Trefoil 3 x 1 0 mm 74 25 439 74 25 439 
Overstretch (%) 17 25 40 7 14 16 
Single25 mm 79 26 491 79 26 491 79 26 491 
Overstretch (%) 25 30 56 14 18 29 5 8 9 
Trefoil3x 12 mm 89 30 633 89 30 633 89 30 633 89 30 633 
Overstretch(%) 41 50 101 29 36 66 19 25 40 8 15 19 
Trefoil3 x 13 mm 97 32 745 97 32 745 97 32 745 97 32 745 
Overstretch (%) 54 60 137 41 45 96 29 33 65 18 23 40 
Trefoil3 x 14 mm 104 35 860 104 35 860 104 35 860 104 35 860 
Overstretch (%) 65 75 174 51 59 126 39 46 90 27 35 62 
Trefoil3 x 15 mm 111 37 989 111 37 989 111 37 989 111 37 989 
Overstretch(%) 76 85 215 61 68 160 48 54 119 35 42 86 
cf = circumference; II = length of free margin of leaflet 
Table 8 Comparison of aortic annulus circumference, leaflet length and area for annulus diameters 
of 20 to 26 mm in tricuspid aortic valves, with the same data for inflated balloons of increasing 
sizes. Percentage overstretch is the ratio of the three calculated parameters for the balloons 
and the aortic annulus -1 (x 100). The balloons above the drawn line in the table can be used 
with an overstretch of < 20% of the aortic annular circumference. 
The fact that we obtained a larger increase in valve area with bifoil 2 x 19 mm balloons 
is of some interest, but one has to keep in mind that these balloons were only employed 
in patients where trefoil 3 x 12 balloons gave unsatisfactory results. One has to weigh the 
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higher risk of an oversized balloon in each individual against an unsatisfactory 
valvuloplasty result. 
d) Incidental complications 
Other complications mentioned in the literature were mitral valve rupture by balloon 
inflation while the balloon was entrapped in the chordae tendineae (48) and in another 
case report, the rupture of an aberrant chorda, crossing the left ventricular outflow tract 
(49). 
Direct hemodynamic results 
In our experience balloon aortic valvuloplasty resulted in an increase in aortic valve 
area from 0.47 ± 0.14 to 0.75 ± 0.19 cm2 with an average increase of 63 ± 38% (fig 6). 
This increase in valve area resulted in a significant higher systolic aortic valve flow and 
a significant lower mean systolic pressure difference between the left ventricle and the 
aorta (fig 5). Larger series from Rauen (50) and Boston (23) reported increases in aortic 
valve area of 0.53 ± 0.18 to 0.97 ± 0.34 cm2 and from 0.6 ± 0.2 to 0.9 ± 0.3 cm2 
respectively, representing an increase of 83 and 50% respectively. These two series 
comprising 300 and 170 patients respectively of the same mean age as our series, also 
contained some younger patients, the youngest being 30 and 35 years old respectively. 
The technique of valvuloplasty used, was also comparable, the largest balloon used was 
no bigger than in our institution. Letac (50) like others, noticed a significant correlation 
between the initial and post dilatation valve area. He also found that patients with an 
increase in valve area of less than 75% were younger (mean age 71 years) than those 
with an increase :::::75 % (mean age 75 years). On the other hand Cribier, the pioneer 
from the Rauen group, states that "best results were usually obtained in younger 
patients" (34), a finding confirmed by Safian (23). Sex, etiology of valve disease, clinical 
symptoms, ejection fraction of the left ventricle or bi or tricuspidy were not predictive for 
a good result (50). Although the difference in the relative increase in valve area between 
Letac's and our own patient series is obvious (83 and 63%), we have no explanation for 
their better results, albeit that the Rauen group applied longer and more inflations than 
we did. Although this group calculates valve area from mean gradients between aorta 
and left ventricle, they never mentioned in their last or previous publications the actual 
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values of the mean gradients. If we had used peak systolic gradients across the aortic 
valve for our calculations as they did, the increase in valve area would have been about 
10% higher. 
Restenosis and clinical results 
After the initial enthusiasm for this new technique, Dancy was one of the first to point 
out the high frequency of early recurrence after balloon aortic valvuloplasty (20). Later 
reports confirmed this finding, Grollier (51) e.g. routinely recatheterized 24 out of 30 
patients 8 days after aortic valvuloplasty. Eight of these patients must be considered as 
failed valvuloplasties, with a less than 25% increase in aortic valve area, 9 had a 
persistent more than 25% increase while 7 had not. Of note is that 4 patients with failed 
procedures had a more than 25% increase in valve area at recatheterization. The same 
finding has been reported by Davidson, using echo Doppler measurements routinely 
in 20 consecutive patients 2-4 days after valvuloplasty. The 50% increase in aortic valve 
area directly after the procedure, had been reduced to 25% in a few days (52). Spielberg 
found signs of restenosis at recatheterization in all but one of 23 patients who had 
undergone valvuloplasty 6-9 months earlier (53). Letac, routinely recatheterized 45 
patients, at 5 months, but excluded 8 patients from his analysis, because they had 
incomplete dilatations, and thus could not be taken into account for restenosis (54). Of 
the 37 remaining patients, 9 (24%) showed restenosis. At 5 months follow-up, Bashore 
found signs of restenosis in 30 out of 44 patients, measured invasively (68%) (55). 
Desnoyers recorded a return to prevalvuloplasty measured aortic valve flow velocities 
in 52% of patients at 9 months follow-up (56). So the rate of restenosis whether 
measured invasively or not is very high, ranging from 24 to 96%, depending on the 
definition of restenosis and selection of patients. We did not routinely measure invasively 
the result of valvuloplasty at follow-up, mostly in view of the age and "brittleness" of these 
patients. Echo and Doppler measurements where available during follow-up will be 
discussed in a separate chapter (chapter 5). 
In contradistinction with these disappointing data, the functional improvement 
encountered in most of these patients is good. An improvement in functional class was 
noted in the series from Rauen in 84% of all patients, at a mean follow-up of 8 months 
(54). This improvement was reflected in a reduction of the severity of all symptoms, 
present before valvuloplasty: syncopal attacks from 26% to 0%; dyspnea class III-IV from 
96 PERCUTANEOUS BALLOON AORTIC VALVULOPLASTY 
69 to 12%; severe angina pectoris from 24 to 6%. In the series from Boston (23), 26% 
of patients had a recurrence of symptoms, treated with revalvuloplasty in 9%, aortic valve 
replacement in 10%, while 7% were managed on medical therapy, after a mean follow-
up time of 9 months. In our patient group improvement in clinical symptoms was present 
initially in all patients after a successful procedure (31 out of 35 hospital survivors). Event 
free improvement on the contrary persisted only in 26% of patients, at a mean follow-
up time of 22.5 months. Of the remaining 74% of patients, 10% died in hospital, 41% 
underwent aortic valve replacement after a mean of 13 months, 20.5% died out of 
hospital on average 15 months after valvuloplasty, while one inoperable patient is now 
waiting for revalvuloplasty. 
The literature (23,53,54,57.58,59,60,61 ,62) is summarized in fig 9 with data on event 
free and total survival. 
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Figure 9: Survival data from literature reports (with reference numbers) and present data, indicated by 
TC. Control data again derived from O'Keefe (ref 62). Total survival, including survival of patients who 
underwent aortic valve replacement after aortic valvuloplasty, and event free survival data are given. 
For comparison survival data are given from a group of 50 patients with severe aortic 
stenosis in whom operation was either declined by the patient or deferred by the 
physician. Survival at one, two and three years in this last group was 57,37 and 25% 
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respectively, with 5 patients having aortic valve replacement (62). All reported data show 
better total survival at any time of follow-up after balloon aortic valvuloplasty, but data 
beyond twelve months are scanty. 
Left ventricular function after valvuloplasty 
Three patients from our study population, in whom surgery was deferred on the basis 
of poor left ventricular function, had improved ejection fractions after valvuloplasty, and 
were operated on when symptoms recurred. Impaired left ventricular function is a 
common phenomenon in patients with long standing, severe aortic valve stenosis. This 
depression of the ejection fraction may be reversible after aortic valve replacement (63). 
Safian et al (64) noted a significant increase in ejection fraction after aortic valvuloplasty 
in almost half of 28 patients with low ejection fractions before valvuloplasty. The increase 
was from 34 to 58%, three months after the valve dilatation in these responders. These 
authors found no differences between responders and non responders with respect to 
aortic valve area after valvuloplasty. Berland et al published immediate results and one 
year follow-up in a group of 55 patients with ejection fractions < 40%, who subsequently 
underwent valvuloplasty. In hospital mortality was 5.5%, while at a mean follow-up of 11 
months, another 40% of patients died. Recatheterization was carried out in 20 patients 
from this study group. Ejection fraction rose only significantly in 11 patients without 
restenosis (65). 
The value of valvuloplasty in patients who have low ejection fractions and urgently 
need valve replacement is hard to establish. According to Fremes, urgent surgery and 
a low ejection fraction together, increase predicted probability of operative mortality in 
elderly patients by a factor 4 to 6 and in younger patients by a factor 6 (27). So it might 
be worthwhile performing valvuloplasty as an initial procedure, and make a subsequent 
operation less risky. A similar line of reasoning goes for coronary artery dilatation and 
the ultimate need for bypass grafting. But one has to add to the total risk, the risk of the 
valvuloplasty procedure itself, which is certainly not negligible (around 5-10%) in these 
patients. One has to individualize these decisions, also explaining to patients what the 
dilemmas and options are, because some of the preoperative variables that increase the 
surgical risk also increase the risk of valvuloplasty (Table 7). 
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Very old patients and indications 
In a consecutive series of 26 patients aged 80 years or older undergoing aortic 
valvuloplasty, Brady et al (66) determined the in hospital mortality as 7.5%, mortality at 
6 months at 32%, and functional improvement occurred in 63% of all patients. Letac 
reported in the same age group in 92 patients, a perioperative mortality of 6.5%, a late 
mortality at 13 months of 29%, and functional improvement in about 85% of patients (67). 
The improvement in symptoms is impressive in both studies, and it is the most 
important result obtained in these patients. While death is inevitable, and life expectancy 
is probably not changed in this very old age group, no comparative group with the same 
amount of disease and without valvuloplasty is available. We fully agree with Cheitlin (33) 
who wrote in a recent Editorial in Circulation: "In this elderly age group with severe aortic 
stenosis, the quality of the last months of life can be miserable, with unremitting 
congestive heart failure, angina and syncope and multiple hospitalizations. If balloon 
valvuloplasty can alter these last years and improve the quality of life for these patients, 
then the procedure, even though its benefits are temporary, should be used in at least 
this one group of patients as the primary procedure " From our own series of patients, 
11 were older than 80 years at the time of valvuloplasty. Five of these patients died a 
mean of 16 ± 4.5 months after the dilatation procedure. One patient underwent aortic 
valve replacement, while the other five all still experience an improvement in symptoms 
at a mean follow-up time of 24 ± ; 2 months. The same improvement in validity class has 
also occurred before the demise of those patients who died. So although we can 
probably not offer them a longer life, at least a better quality of their remaining life span 
is in perspective. 
Aortic valvuloplasty is also indicated in that group of patients who are initially denied 
cardiac surgery. It provides a bridge for non cardiac surgical procedures (68,69), and 
is also indicated as a palliative treatment during pregnancy (70). Finally we feel that the 
procedure could be used in all patients with urgent need for relief of aortic valvular 
stenosis, as well as those who present with poor left ventricular function, as a bridge to 
surgical aortic valve replacement. 
In conclusion, just as previous attempts at surgical aortic valvuloplasty with dilating 
instruments were only partly or temporarily successful (71) and recent intraoperative 
studies of balloon valvuloplasty showed only a minimal or moderate increase in the 
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functional aortic orifice in a minority of patients (72), percutaneous balloon aortic 
valvuloplasty remains a technique which is lifesaving in selected patients with an 
acceptable procedural risk and marked functional improvement at medium term follow-
up in the majority of patients. 
We would recommend percutaneous valvuloplasty in patients over the age of 80, in 
those considered too high at risk for open heart surgery, in those with unoperated or 
recently operated carcinoma and finally in all patients who are denied cardiac surgery 
for other reasons. In chapter 9 these recommendations will be detailed. 
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CHAPTERS 
EVALUATION OF PERCUTANEOUS BALLOON AORTIC 
VALVULOPLASTY IN ELDERLY PATIENTS WITH DOPPLER 
ECHOCARDIOGRAPHY 
(This chapter has been accepted in a slightly different format for publication in the 
Netherlands Journal of Cardiology, 1990. Authors are: van den Brand M, Bellerse L, 
Vletter WB, Plante S, Serruys PW, de Feyter PJ, Suryapranata H, Roelandt JR) 
SUMMARY 
From March 1986through December 1989,38 patients underwent39 percutaneous 
balloon aortic valvuloplasty (PBA V) procedures, for isolated severe aortic valve stenosis. 
Mean age of these patients was 75 years, range 63-88. Nineteen of these patients were 
considered to be inoperable either due to cardiac or extracardiac conditions. Five 
patients were classified as high risk cases (age over 80 years), while the remaining 14, 
although presenting with several operative risk increasing factors, were acceptable 
candidates for aortic valve replacement. Aortic valve area calculated by the Gorlin 
formula increased, from 0.47 (± 0.14) to 0.75 (± 0.19) cm2 after PBAV. Four patients died 
in hospital, eight patients died out of hospital 5-23 months after valvuloplasty (mean 15 
± 5 months). Sixteen patients underwent aortic valve replacement 6 days to 36 months 
after valvuloplasty (mean 13 ± 9 months), while 11 patients are still without events at a 
mean follow-up period of 23 ± 12 months. 
Thirty-one patients had maximal aortic valve flow velocity measured with echo Doppler 
techniques both immediate before and 24-48 hours after valvuloplasty. 
Conversion of this maximal velocity to millimeters mercury and comparing these 
values with the pressure difference between peak left ventricular and peak aortic 
pressure, when estimated hemodynamically, showed poor correlations both before and 
after valvuloplasty (r = 0.49 and 0.55 respectively). The Doppler technique tended to 
overestimate aortic valve pressure drops over 74 and 25 mm Hg, when 
hemodynamically derived, and to underestimate pressure drops below that value 
respectively before and after PBAV. After valvuloplasty the maximal velocity over the 
aortic valve was significantly reduced from 4.6 ± 0.7 mjsec to 4.1 ± 0.8 mjsec. 
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Twenty two patients had immediate Doppler evaluation after valvuloplasty as well as 
at a mean follow-up time of 10 ± 7 months. Maximal velocity over the aortic valve 
increased in that period from 4.1 to 4.4 mjsec (not significant), with the highest increase 
in velocity in the group of patients dying late, 4.0 to 4.5 mjsec (not significant). 
Comparing catheter derived aortic valve areas calculated by the Gorlin formula directly 
post PBAV, with echo Doppler derived areas calculated with the continuity equation at 
follow-up, showed a good correlation in 6 patients with persisting clinical improvement 
(r = 0.94). 
It is concluded that the echo Doppler derived aortic valve areas, show a better 
correlation with hemodynamically derived aortic valve areas, than maximal aortic valve 
flow velocities with peak to peak pressure aortic valve gradients. Although both 
techniques have their inherent limitations, the outcome of both estimations for aortic 
valve area is very similar. 
INTRODUCTION 
Percutaneous balloon aortic valvuloplasty is recently being performed with increasing 
frequency for the relief of severe calcified aortic stenosis in selected elderly patients. 
Most investigators now believe that aortic valvuloplasty is a palliative procedure, that 
should be limited to patients who are not surgical candidates for whatever reason (1-
5). In patients with severe congestive heart failure, balloon aortic valvuloplasty may 
improve the patient's condition, as a bridge to later aortic valve replacement. 
The procedure can produce moderate increases in aortic valve area, generally from 
0.4-0.6 before to 0.7 to 0.9 cm2 after valvuloplasty and can be performed with an 
acceptable periprocedural risk (1 ,2). 
Unfortunately, the mortality of these patients remains high after the procedure and 
mortality rates of 15 to 28% after 6 to 9 months have been reported (1 ,2). This high 
mortality is probably caused by restenosis, whose rate has been shown to be high both 
after invasive and non invasive assessment (6,7). Doppler echocardiography is a 
noninvasive method, especially convenient for elderly people with a low validity class, the 
population mostly referred for valvuloplasty. Symptomatic improvement and a non 
invasively measured reduction in the severity of aortic valve stenosis might indicate a 
persisting good result (8). 
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Previous studies using Doppler echocardiography have shown a fair or good 
correlation between pre and post valvuloplasty measured aortic valve areas, with 
catheterization data using the Gorlin formula (7,9-15). 
We studied the correlation between the drop in pressure across the stenotic aortic 
valve as well as valve area, measured during catheterization and estimated by Doppler 
echocardiography technique before and after aortic valvuloplasty. Long-term follow-up 
Doppler measurements were performed to correlate changes in maximal valve flow 
velocity with clinical events, mortality, aortic valve replacement, and functional status. 
PATIENTS AND METHODS 
From March 1986 through December 1989, 38 patients underwent 39 aortic 
valvuloplasty procedures. All patients were diagnosed as having severe aortic valve 
stenosis by physical examination, Doppler echocardiography and heart catheterization. 
All patients were discussed with the cardia-surgical team. Patients were acceptable 
candidates for a balloon valvuloplasty procedure if they fulfilled one of the following 
criteria: 
a) deemed inoperable in a combined cardia-surgical discussion 
b) classified as a high risk case 
c) classified as a normal risk patient, but with preference of the patient for balloon 
valvuloplasty instead of surgical valve replacement or surgical valvuloplasty. 
All patients and a relative had to give their informed consent, after explanation of the 
experimental character of the procedure, and the potential risks and benefits. No patient 
was acceptable if during diagnostic angiography aortic insufficiency more severe than 
grade II was demonstrated. 
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Clinical characteristics and the cardiac condition of these patients before valvuloplasty 
are summarized in tables 1 and 2. 
Nr of Patients 
Female sex 
Mean age (years) 
Inoperable 
High risk case 
Acceptable risk case 
Validity class IV 
Validity class Ill 
39 
24 
75.1 ± 7.1 
20 
5 
14 
14 
25 
Table 1 Clinical characteristics of balloon aortic valvuloplasty patients 
EF>0.55 
EF >0.40- 0.54 
>0.20 -0.39 
<0.19 
not assessed 
Aortic incompetence 
grade 0 
grade I 
grade II 
Coronary artery disease 
Absent 
1 vessel disease 
2 vessel disease 
3 vessel disease 
left main disease 
Number of patients 
22 
6 
5 
4 
2 
10 
20 
9 
24 
7 
2 
5 
Table2 Ejection fraction, severity of aortic incompetence and coronary artery disease in 39 
valvuloplasty patients 
CHAPTERS 109 
Table 3 summarizes the hemodynamic data of these patients before and after balloon 
aortic valvuloplasty. 
LVPSP LVEDP P-PSG MSG AF AVA %Increase 
B A B A B A B A B A B A AVA 
Mean 217 177 16 12 82 41 74 43 176 214 0.47 0.75 63 
.±.SO 37 34 9 9 24 15 19 10 50 49 0.14 0.19 38 
p value <0,05 <0.05 <0,05 <0,05 <0,05 <0,05 
AVA= aortic valve area (cm2); AF =systolic aortic valve flow (ml s-1); LVEDP =left ventricular end-diastolic pressure (mmHg); 
LVPSP = left ventricular peak-systolic pressure (mmHg); MSG = mean systolic aortic gradient (mmHg); P-PSG = peak to peak 
systolic gradient (mmHg); B = before; A = after. 
Table3 Hemodynamic data before and after 39 balloon aortic valvuloplasty procedures. 
The direct result of balloon aortic valvuloplasty, and the clinical follow-up of these 
patients are combined in table 4. 
Survivors operated 
(n = 16) 
Survivors not operated 
(n = 11) 
late deaths 
(n = 8) 
Early deaths 
(n = 4) 
Age M/F 
(years) ratio 
72.1:!: 5.6 6/10 
76.7:!: 6.6 4/7 
78.7:!: 9.5 3/5 
76.2:!: 1.5 2/2 
Follow-up time Aortic valve area (cm2) Aortic valve area Validity 
class 
(months) Before After Increase (%) Before 
Ill IV 
34:!: 8 0.51:!: 0.11 0.75:!: 0.15 52:!: 32 12 4 
23:!: 12 0.42:!: 0.11 0.73:!: 0.19 77:!: 31 7 4 
15:!: 5 o.4g:!: 0.18 0.76:!: 0.23 67:!: 48 6 2 
2:!: 3 days 0.42:!: 0.12 0 4 
Table 4 Clinical and hemodynamic data at the time of percutaneous balloon aortic valvuloplasty in 
patients with early and late mortality and in survivors, with and without aortic valve 
replacement. Data are given as mean values ± standard deviation 
Doppler echocardiography was performed in 34 patients within two weeks before and 
in 35 patients 24-48 hours after balloon aortic valvuloplasty. 1-27 months after 
valvuloplasty 24 patients were re-investigated (mean 10 ± 7 months). 
Patients were examined in the supine left lateral position. The continuous wave Doppler 
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examination was performed using a Toshiba SSH160 or a Diasonics Vingmed ultrasound 
unit. Peak aortic valve blood flow velocity was obtained by a non imaging continuous 
wave Doppler probe, placed in various positions to obtain apical right, left parasternal 
and suprasternal views. Spectral velocity traces were recorded on strip charts at a speed 
of 50 mmjs. 
The maximal instantaneous transvalvular pressure difference was estimated from the 
maximal aortic Doppler velocity by the modified Bernoulli equation: 
Pressure difference = 4 x max. velocity2 
Aortic valve area (AVA) was calculated from two dimensional echo and Doppler data 
with the continuity equation as follows: 
AVA= ALVOTx (TVI) LVOT, (11) 
------------------------------
(TV I) AV 
where AV = aortic valve, ALVOT = area of left ventricular outflow tract in cm2, AVA = 
aortic valve area in cm2, LVOT = left ventricular outflow tract and TVI =time velocity 
integral. Time velocity integrals were obtained by integrating the respective Doppler 
velocity spectra on a digitizing tablet, connected to an Olivetti c·omputer. Aortic valve 
area was calculated before and after valvuloplasty in one patient and in six other patients 
after valvuloplasty using echo and Doppler data. 
In two patients transoesophageal echocardiography was performed, in one during 
valvuloplasty under general anaesthesia, and in one other patient before and after 
valvuloplasty. The transoesophageal probe (5 MHz, single plane transverse transducer) 
was inserted through the oropharynx into the oesophagus. Two dimensional images 
were obtained in the standard transoesophageal echocardiographic planes. 
During catheterization the aortic valve area was calculated using the Gorlin formula 
(9). 
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RESULTS 
Gradients and flow velocity 
Comparison of the peak to peak systolic aortic valve pressure drop measured before 
and after valvuloplasty by catheterization, and maximal velocity over the aortic valve 
measured with Doppler, revealed poor correlations (fig 1 ). 
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Figure 1: Regression analysis of catheter and echo Doppler derived pressure drop over the aortic valve, 
(a) before and (b) after percutaneous balloon aortic valvuloplasty 
This proved also to be true for a regression analysis of the change in pressure drop. 
The maximal flow velocity over the aortic valve fell significantly after valvuloplasty from 
4.6 ± 0.7 to 4.1 ± 0.8 mjsec (p < 0.05) (fig 2). 
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Figure 2: Maximal flow velocity over the aortic valve, before and after balloon valvuloplasty and at late 
follow-up. The decrease in flow velocity after valvuloplasty is significant (p < 0.05), while the 
increase in flow velocity at late follow-up is not significant 
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The highest aortic valve flow velocity after valvuloplasty was recorded in the group 
with subsequent aortic valve replacement (fable 5). At a mean follow-up of 10 ± 7 months 
an increase in aortic valve flow velocity to 4.4 ± 0.6 mjsec was recorded (fig 2, table 5). 
This increase was not significant. The increase was on average highest in patients dying 
late, and lowest in patients who underwent late aortic valve replacement, although in 
none of the subgroups was this increase significant. 
All patients AVR Late mortality Uneventful FU 
(n = 39) (n = 16) (n = 8) (n = 11) 
Examined (n = 31) (n = 16) (n = 7) (n = 6) 
Max. Ao Velocity (mjsec) 
before mean 4.6 * 4.7 * 4.6 * 4.9* 
PBAV ± SD 0.7 0.5 0.5 0.9 
after mean 4.1 4.2 4.1 4.2 
PBAV ± SD 0.8 0.8 0.5 0.7 
(n = 22) (n = 11) (n = 5) (n = 6) 
Interval mean 10 8 8 16 
(months) ± SD 7 6 4 8 
after mean 4.1 4.3 4.0 3.9 
PBAV ± SD 0.7 0.8 0.4 0.3 
late mean 4.4 4.3 4.5 4.2 
FU ± SD 0.6 0.7 0.7 0.5 
* p < 0.05 
Table 5 Comparison between maximal Doppler measured aortic valve flow velocity before and after 
PBAVand at follow-up in all patients, and in three different outcomes: valve replacement (AVR), 
late mortality and uneventful follow-up (FU) 
Prevalvuloplasty aortic valve flow velocities were also compared between groups 
(Table 5). The values measured directly before and at late follow-up after valvuloplasty 
were not significantly different in the total group, nor in any subgroup. 
Echo Doppler estimated aortic valve area 
The only patient with prevalvuloplasty estimated echo Doppler aortic valve area 
showed an increase from 0.41 cm2 to 0.44 cm2 after valvuloplasty. If aortic valve area 
before and after valvuloplasty was measured with pressure difference and cardiac output 
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this increase was from 0.53 to 0.64 cm2. Six other patients had echo Doppler estimated 
aortic valve areas at a mean follow-up of 13 months after valvuloplasty. Aortic valve area 
varied from 0.47 to 1.22 (Table 6). 
Case number 2 3 4 5 6 
Catheter measured AVA 0.67 0.80 0.57 0.78 1.12 0.78 
post PBAV (cm2) 
Echo Doppler estimated AVA 0.75 0.96 0.47 0.85 1.22 0.96 
at follow-up (cm2) 
Follow-up period 22.5 21.0 12.5 9 6.5 5.5 
(months) 
Table 6 Echo Doppler estimated aortic valve area (AVA) at follow-up, and catheter measured 
aortic valve area directly after valvuloplasty 
Only patient nr 4 underwent aortic valve replacement, 4.5 months after this 
measurement, because of recurrent symptoms of angina pectoris. This patient had 
undergone coronary angioplasty for two vessel disease as well as aortic valvuloplasty. 
Regression analysis of echo Doppler estimated aortic valve areas at follow-up with aortic 
valve areas calculated from hemodynamic data at the end of the valvuloplasty procedure 
shows that AVA (cath) = 0.18 + 0.70 AVA (echo). There was a good correlation 
between both values, with a r value of 0.94. Below a hemodynamic derived AVA of 0.60 
cm2, echo Doppler measurements underestimated aortic valve area, while above a 
hemodynamic derived AVA of 0.60 cm2, echo Doppler tended to overestimate the AVA. 
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Transoesophageal echocardiography 
In two patients transoesophageal echocardiograms were performed. In the first 
patient a tricuspid heavily calcified aortic valve with very limited cusp mobility was 
documented before valvuloplasty. After valvuloplasty an improved mobility of 
predominantly the non coronary cusp was seen. Five months later, after recurrence of 
symptoms, the mobility of the non coronary cusp was similar to prevalvuloplasty. This 
patient subsequently underwent valve replacement. In the other patient 
transoesophageal echocardiographic monitoring was performed under general 
anaesthesia during valvuloplasty. A heavily calcified tricuspid aortic valve, with a big 
calcified lump in the left coronary cusp was present and valve opening was solely 
confined to the non coronary cusp. After valvuloplasty no apparent difference in cusp 
mobility was noted. This patient showed an increase in echo Doppler estimated aortic 
valve area from 0.4; cm2 to 0.44 cm2 and in hemodynamic derived aortic valve area 
from 0.53 to 0.64 cm2. These values are in agreement with the minimal changes 
observed during transoesphageal echocardiography. 
DISCUSSION 
Transvalvular pressure gradients 
Several studies have shown the usefulness of Doppler echocardiography in assessing 
the systolic transvalvular pressure drop in aortic stenosis (iO, 16-28). Although the 
systolic pressure gradient is an important determinant of aortic valve area, transvalvular 
flow is even more important. In our study a poor correlation was found between maximal 
Doppler estimated flow velocity and peak to peak systolic gradients measured at 
catheterization, both before and after aortic valvuloplasty. Doppler measured maximal 
instantaneous systolic transvalvular pressure differences before valvuloplasty were on 
average 7 mm Hg higher than catheter derived peak to peak systolic gradients. After 
aortic valve dilatation the mean difference between the two methods increased to 29 mm 
Hg, with again the higher values for Doppler derived pressure differences. Danielsen (29) 
comparing maximal Doppler and maximal catheter derived pressure differences, found 
these gradients both to be significantly higher than peak to peak systolic gradients, 
recorded during catheterization. Defined this way the Doppler technique systematically 
underestimated the maximum catheter derived pressure difference (29). 
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Both Doppler and catheterization measurements have several sources of inaccuracy 
for deriving the pressure drop over a stenotic valve. For catheterization derived values, 
the acquisition mode is very important. Calculations from left ventricle to aorta pull back 
tracings, can be misleading in failing to achieve a good superimposition of left ventricular 
and aortic pressure recordings (30). This is more the case if any irregularity of the heart 
rhythm exists. Also measuring pressure differences with tipmanometered catheters 
instead of fluid filled catheters might result in different values, because fluid filled 
catheters overestimate especially the left ventricular pressure, and lead to an 
overestimation of the catheter derived instantaneous maximal pressure difference. 
Danielsen (29) for example calculated in 80% of his patients pressure drops across 
the aortic valve from pull back tracings, while we always used simultaneous recorded 
pressures, derived mostly from fluid filled catheters. Introducing a catheter in the left 
ventricle through the aortic valve further reduces the aortic orifice. An 8F catheter for 
example occupies an area of 3.14 x (4F)2 = 5.6 mm2, reducing the actual aortic valve 
area in severe aortic stenosis by about 1 0%. An additional variability in the catheter data 
is introduced by the pressure recovery. In a region distal to an obstruction the pressure 
gradually increases. Clark (31) using aortic stenosis models, demonstrated that pressure 
recovery extended to 9 em downstream of the stenotic area. Pressure recovery is 
determined by the flow velocity at the site of the obstruction, and the ratio between the 
cross sectional flow area at the obstruction site, and that of the flow channel distal to the 
obstruction. In order to obtain a fully recovered pressure, the catheter must be 
positioned outside the turbulent area, which is at a variable distance from the stenotic 
valve. 
The application of the Bernoulli equation in its most simple form (pressure drop = 4 
x (fluid velocity)2) has also several assumptions as put forward by Rijsterborgh and 
Roelandt (32). 
It is assumed that the conversion of potential energy into kinetic energy takes place 
without energy losses. Also a uniform velocity distribution at the cross sectional flow 
area in the obstruction is assumed, which might not be the case. A standard Doppler 
instrument measures the maximum velocity at the site of the obstruction. It is 
conceivable that especially after valvuloplasty, non uniform flow velocities across the 
stenotic aortic valve exist, resulting in overestimation of actual velocities, by measuring 
only maximal velocities. Also the energy losses may not be negligible and vary with the 
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shape and size of the obstruction, underestimating the pressure drop by Doppler 
echocardiography. These two potential errors partly compensate for each other by 
operating in opposite directions. The simplified Bernoulli equation will overestimate the 
actual pressure drop in mild aortic stenosis and underestimate it in severe aortic stenosis 
(32). This theory is confirmed by the data of several reports. Below a peak 
catheterization pressure drop of 50 mm Hg, the simplified Bernoulli equation tends to 
overestimate the pressure drop, while above a pressure difference of 50 mm Hg the 
same equation underestimates the pressure difference obtained by catheter (16-28). 
One technical aspect of measuring maximal velocities across the aortic valve by Doppler 
echocardiography deserves attention. The Doppler beam must be derived as parallel as 
possible to the blood flow jet across the stenotic valve (24,29). This requires the use of 
a small non imaging transducer with multiple angulations from various positions. 
Nonetheless experienced echocardiographers can assess accurately aortic valve 
gradients (24). Finally the measured difference might well be real, because 
measurements were not made simultaneously. In the post valvuloplasty situation 
alterations in aortic valve flow might partly be responsible for the demonstrated 
differences. 
Aortic valve area calculations 
Data from previous studies indicate that for a given, catheter calculated valve area, 
a wide scatter of peak Doppler derived pressure gradients exists especially for mild to 
moderate aortic stenosis (29). This scatter is the result of variation in transvalvular flow, 
which is unknown. A peak aortic flow velocity of >4.5 mjsec for example was highly 
specific for severe aortic stenosis, but had a low sensitivity. Half of the 70 patients 
described by Oh with a peak aortic flow velocity of < 4.5 mjsec had severe aortic 
stenosis (15), by hemodynamic measurements. These authors found good correlations 
between catheter and Doppler derived mean gradients (r = 0.86; y = 0.89x + 2.3). 
With use of the continuity equation, relating the flow velocity with the cross sectional 
area of flow at a given flow volume, it was demonstrated in several studies that aortic 
valve area can be reliably estimated (11-13). The same equation has been applied to 
calculate aortic valve area both before and after aortic valvuloplasty (7, 14, 15). According 
to these authors the Doppler continuity equation can accurately predict the severity of 
aortic stenosis pre and post valvuloplasty. Pre valvuloplasty correlation coefficients 
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between catheter and Doppler derived aortic valve areas were 0.72, 0.71 and 0.80. Two 
of these studies also correlated postvalvuloplasty valve areas and found correlation 
coefficients of 0.61 and 0.85 respectively (7, 14). 
It is rather remarkable that two techniques, each with their inherent sources of errors, 
show such good correlations. Catheter measured aortic valve area, measured with aortic 
valve flow and mean transvalvular pressure gradient, has also been questioned, 
especially when assessing severe stenotic valves with low transvalvular flow rates 
(33,34). During dobutamine and isoproterenol infusion, aortic valve areas calculated by 
the Gorlin formula (9), increased from 0.67 to 0.81 cm2 and from 0.86 to 1.09 cm2 
respectively. In one of these studies, aortic valve area was calculated during dobutamine 
infusion in five patients simultaneously using the continuity equation. In these patients 
calculated aortic valve area echo Doppler derived changed from 0.69 ± 0.23 cm2 to 0.71 
± 0.21 cm2. 
These findings suggest flow dependence of the Gorlin formula. Come et al recording 
two sets of catheter derived aortic valve areas before valvuloplasty, found only a 
moderate correlation between the two sets of values (r = 0.42) (35). Catheter derived 
aortic valve area can therefore not be considered as the "gold standard" (32). 
Although there was a time delay of several months in our patients in whom aortic valve 
area was measured both with echo Doppler and with catheter derived methods, good 
agreement existed between the values calculated in this way. As all patients mentioned 
in table 6 were free of clinical symptoms of restenosis, we might assume that aortic 
valve areas measured at the end of the valvuloplasty procedure did not change much 
during the follow-up period. Moreover none of these patients showed an increase in 
maximal aortic valve flow velocity, measured repeatedly during this follow-up period. 
Transoesophageal echocardiography 
One literature report adresses the usefulness of transoesophageal echocardiography 
during aortic valvuloplasty (36). The potential advantages are: readily visible anatomy 
of the stenotic aortic valve, monitoring of left ventricular function during and after 
balloon inflation and assessment of aortic incompetence after dilatation. 
Transoesophageal echocardiography can be of help in deciding whether further valve 
dilatation with a larger balloon is warranted, evaluate directly the effect of balloon inflation 
on valve cusp mobility and space balloon inflations till left ventricular function has 
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returned to preinflation values. 
We feel that in patients with symptomatic aortic valve stenosis, echo Doppler 
evaluation with aortic valve area calculation is indicated. In surgical candidates, 
presurgical evaluation should include coronary angiography. In non surgical candidates 
coronary angiography and valvuloplasty could be performed in the same session. The 
procedure is preferably performed under general anaesthesia while transoesophageal 
echocardiography may become a major monitoring technique. After valvuloplasty, 
follow-up investigations should include echo Doppler aortic valve area measurements 
at regular intervals e.g. every three months. If recurrence of symptoms occurs and aortic 
valve area measured this way returns to prevalvuloplasty values, the mentioned 
investigation scheme should be repeated. In patients without symptoms, or with 
moderate symptoms and with signs of restenosis documented objectively by calculating 
aortic valve area with echo Doppler, a conservative attitude is justified, with more 
frequent follow-up visits, because asymptomatic patients with moderate to severe aortic 
stenosis are at relatively low risk for sudden death as recently documented by Kelly et 
al (37). If complaints persist or recur in patients without objective signs of restenosis, 
alternative explanations for the clinical deterioration should be sought before the patient 
is subjected to recatheterization. 
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CHAPTER 6 
AORTIC VALVULOPLASTY OF CALCIFIC AORTIC STENOSIS WITH 
MONOFOIL AND TREFOIL BALLOON CATHETERS: PRACTICAL 
CONSIDERATIONS 
(This chapter has been published in the lnt J Cardiac Imaging i990; 5:249. Authors 
are: Plante S, van den Brand M, van Veen L, di Mario C, Essed CE, Beatt KJ, Serruys 
PW) 
SUMMARY 
In order to evaluate the relation between balloon design (monofoil, trefoil) and 
valvular configuration, experimental aortic valvuloplasty was performed in four post-
mortem hearts with calcific aortic stenosis of various morphology. The degree of 
obstruction of the aortic orifice was assessed by computed axial tomography during 
inflation of monofoil i5 and i9 mm and trefoil 3 x i2 mm balloon catheters. We also 
evaluated the hemodynamic repercussion of balloon inflation (fall in systolic aortic 
pressure) in four elderly patients with acquired aortic stenosis who underwent a 
percutaneous transluminal aortic balloon valvuloplasty, with stepwise increasing balloon 
sizes of i5 mm, ;g mm and 3 x i2 mm, as during our in vitro experiments, and who 
underwent aortic valve replacement later on. In these patients, we correlated the 
anatomy of the excised aortic valves with the retrospective analysis of aortic pressure 
curves recorded during previous valvuloplasty procedures. 
Our experimental and clinicopathological observations showed that the degree of 
obstruction of the aortic orifice in post -mortem specimens and the tolerance to balloon 
inflation in live patients are dependent of the valvular configuration. Although trefoil 
balloons have the theoretical advantage to avoid complete obstruction of the aortic 
orifice during inflation, we observed that in presence of a tricuspid configuration, they 
could be potentially more occlusive than monofoil balloons since each of the 3 
individual components of the trefoil balloon occupied the intercommissural spaces 
while inflated. However, they offered more residual free space when inflated in aortic 
valves with a bicuspid configuration (i.e. congenitally bicuspid valves or tricuspid valves 
with one fused commissure). 
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In our opinion, these observations are relevant, since degenerative disease of the 
aortic valve (i.e. tricuspid valve without commissural fusion) is now recognized as the 
most common etiology of aortic stenosis in the elderly. 
INTRODUCTION 
Percutaneous transluminal balloon aortic balloon valvuloplasty (PBAV) for acquired 
aortic stenosis (AS) has been introduced a few years ago as an alternative for valve 
replacement. in patients with high surgical risk or for those who refused surgical 
intervention (1 ,2). Procedure-related complications, limited hemodynamic improvement 
and the high recurrence rate reported until now (3-16) have decreased the initial 
enthusiasm for this relatively new technique. 
Despite these current limitations, PBAV is currently regarded by many cardiologists 
as a palliative treatment in a subset of patients with prohibitive surgical risk. Some 
authors recently advocated PBAV as a "bridge" procedure to improve left ventricular 
function before aortic valve replacement or non-cardiac surgery (17, 18). 
However, other shortcomings of the procedure are 1) the largely unpredictable 
individual tolerance to balloon inflation (hypotension) and 2) the unpredictable 
immediate hemodynamic results in an individual patient. The incidence of non-
responding or poorly responding patients (aortic valve area still < 0.7 cm2 at the end 
of the procedure) is ranging from 18.7% to 38.2% (12). These facts suggest that some 
morphological aspects (bicuspid or tricuspid valve, fused or non-fused commissures) 
or other factors like the volume occupied by nodular calcifications and residual 
elasticity of some leaflets (19) can adversely influence the hemodynamic results of the 
procedure. Furthermore, it seems conceivable that balloon catheters of different 
shapes (monofoil, bifoil, trefoil) operate with distinct mechanisms of dilatation in the 
presence of a specific valvular morphology. 
To circumvent hypotensive responses during balloon inflation, trefoil balloon 
catheters have been introduced recently. Attractive advantages of this device have 
been demonstrated in animal experiments (20) and it has been effective in allowing 
continuous blood flow during inflation in the setting of pulmonary valvuloplasty in adults 
(21), aortic valvuloplasty in children and young adults (22), and in mitral and aortic 
valvuloplasty in adults (23-24). However, the degenerative, remodeling and calcifying 
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process peculiar to acquired AS in elderly patients differs largely from the pathological 
changes observed in congenital and rheumatic valvular diseases; this may explain why 
some of these patients still present abrupt and severe falls in aortic pressure, even 
when PBAV is performed with trefoil balloon catheters. 
In order to achieve better hemodynamic results and to obtain technical refinements 
in the valvuloplasty material, we have to improve our knowledge of the operational 
mechanisms of dilatation. Intra-operative, post-mortem and experimental studies on the 
mechanisms of aortic valvuloplasty have been reported until now, based mainly on 
visual inspection and low-energy x-ray techniques (19,25-27). In order to obtain 
detailed quantitative information on the intravalvular calcium distribution before and 
after valvuloplasty and to further elucidate the operational mechanisms of dilatation, we 
have performed thin-slice computed tomographic scanning in post-mortem hearts with 
calcific AS before, during and after balloon valvuloplasty (28). This technique avoided 
superimposition of structures and provided vastly superior density resolution compared 
to conventional x-ray techniques. In our study, fracture of nodular calcifications, 
commissural separation and central raphe splitting were the observed mechanisms of 
balloon valvuloplasty. However, calcium redistribution (27) could not be recognized as 
an operational mechanism, since no dilatation-related modification in density and 
volume of the calcific deposits was observed with computed tomographic scanning. 
Furthermore, computed axial tomography provided useful informations concerning the 
relations between balloon size and shape and valvular configuration. To our 
knowledge, few reports have focused on this particular aspect of aortic balloon 
valvuloplasty. 
In this chapter, we describe our experimental and clinicopathological observations 
related to aortic valvuloplasty performed with single circular (monofoil) and trefoil 
balloon catheters in human hearts with acquired AS. We will present a review of our 
previous experimental findings and we will correlate these results with our recent 
clinicopathological observations, based on retrospective analysis of valvuloplasty 
procedures performed in some patients who underwent subsequently a valve 
replacement and from whom excised aortic valves were available for 
anatomopathological evaluation. For more detailed information concerning our in vitro 
experiments, the reader is referred to our previous publication (28). 
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EXPERIMENTAL VALVULOPLASTY 
Material and methods 
Four hearts with calcific, stenotic aortic valves and intact aortic rings were selected 
from our collection of autopsy specimens (Pathology Department 1, Erasmus 
University). The mean heart weight was 583 .±. 78 g (range: 538-700 g). The average 
thickness of the left ventricular wall was 19.5 .±. 1.9 mm. 
Case 1: This specimen was obtained from a 67 year-old female who died suddenly. 
The aortic valve was tricuspid, with extensive nodular calcifications of the valve cusps 
projecting into the valve sinuses, but without commissural fusion. These findings were 
compatible with a degenerative etiology. 
Case 2: The second specimen came from a 71 year-old male patient in whom a pre-
mortem cardiac catheterization had shown a mean systolic aortic gradient and a valve 
area of 70 mm Hg and 0.6 cm2, respectively. Mild aortic regurgitation, moderate 
combined mitral valve disease and subocclusive stenoses of the left anterior 
descending and circumflex arteries were also present. This patient died after having 
sustained a large anterior myocardial infarction. At pathological examination, the 
coexisting mitral valve disease and the tight, heavily calcified commissural fusion 
between non-coronary and right coronary aortic cusps were in accordance with a 
rheumatic etiology. Although originally tricuspid, the aortic valve had a bicuspid 
configuration, owing to the tightly fused commissure. Nodular calcifications on the 
aortic aspects of the cusps were also observed. 
Case 3: Irreversible cardiogenic shock occurred in this 73 year-old male patient, as 
a consequence of a posterior myocardial infarction. Post-mortem examination revealed 
a congenitally bicuspid aortic valve. The larger anterior cusp was divided by a central 
calcified raphe, extending across the floor of the aortic sinus from aorta to the free 
edge. The valve had moderate nodular calcifications, but no commissural fusion. 
Case 4: The fourth heart was obtained from a 50 year-old female in whom a 
previous catheterization had demonstrated a mean systolic aortic gradient of 77 mm 
Hg and a calculated valve area of 0.7 cm2. This patient, while awaiting surgical 
correction, developed fatal acute pulmonary edema. At autopsy, the valve was also 
congenitally bicuspid, but with an almost symmetric configuration, a moderate bilateral 
commissural fusion, and diffuse calcifications confined to the leaflets. In the anterior 
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cusp, a calcified central raphe was also observed. 
Specimens were originally preserved in a 10% formalin solution but were kept in 
water for 30 days before the experiment. Cylindrical calipers of increasing diameter 
(range: 3-30 mm) were used to assess the aortic orifice area, while the aortic annulus 
diameter was measured directly. All specimens were examined on a Tomoscan 350 
clinical unit (Philips, Phillips Medical Systems, Best, Netherlands). Three radiopaque 
markers were sutured to the aortic wall at the leaflet level and used as reference points 
in the scanning procedures. Axial scan series, covering the entire aortic valve region, 
were performed with contiguous scans of 1.5 mm thickness. Off-line evaluation was 
performed on a Philips Stand Alone Viewing System, enabling sagittal reconstruction, 
contour detection of the region of interest, and calculation of volumes and mean 
computed tomographic attenuation values (Hounsfield Units) of calcium deposits. In 
all specimens the region of interest contour mode was used to determine the residual 
orifice area during each inflation. Evaluation of all the axial scans was used to assess 
the minimal free space between leaflets and balloon. 
Post-mortem aortic valvuloplasty was performed with balloons of increasing 
diameter, passed retrogradely from the aorta into the left ventricle. First, a monofoil 15 
mm balloon (inflated cross-sectional area: 1.8 cm2) was manually inflated across the 
aortic valve with a pressure of 3 atmospheres. Thereafter, a second and third dilatation 
were performed with a monofoil 19 mm (area: 2.8 cm2) and a trefoil 3 x 12 mm (3.4 
cm2) balloon catheter, both inflated to a pressure of 3 or 4 atmospheres. Balloons 
were inflated until complete disappearance of indentation of the valves on the balloons. 
Leaflet avulsion, valve ring disruption or liberation of valvular debris did not occur in 
any specimen. Experimental valvuloplasty with bifoil-designed balloon catheters was 
not assessed in this study, since they were not commercially available at that time in 
our institution. 
Measurement of the aortic valve orifice by cylindrical calipers was performed at the 
beginning and after each dilatation. Visual inspection, photographs and axial computed 
tomographic scans were obtained before, during and after each balloon inflation. 
Figure 1 provides an example of computed axial tomography scans obtained at the 
level of the aortic valve orifice during experimental valvuloplasty in a post-mortem 
specimen. 
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Figure 1: Axial scans of a post-mortem specimen (case 
#1) performed at the level of the aortic valve orifice, 
during inflation of 15 mm, 19 mm and trefoil 3 x 12 mm 
balloons (enlargement factor: 4 X). This valve was the 
most heavily calcified. The density is decreasing from 
white areas (calcium deposits, catheters, radiopaque 
markers), to the grey (heart and valve soft tissue, water 
in inflated balloons), and the black areas (air). During 
inflation, the 15 mm balloon was displaced towards the 
less calcified left aortic cusp (Fig.1 A). Minimal increment 
in valve area was achieved. The inflated 19 mm balloon 
occupied also an asymmetrical position in the aortic 
orifice, but the displacement of the free edges of the 
cusps was greater than with the previous dilatation, 
involving also the most heavily calcified leaflet (Fig.1 B). 
Fracture of nodular calcifications was noted at visual 
inspection. During inflation of the trefoil balloon (Fig.1 C), 
a rotating movement was observed. At the end of 
inflation, the three intercommissural spaces were 
occupied by the 3 individual components of the balloon, 
almost totally occluding the aortic orifice. At visual 
inspection, the increase in cusps mobility was 
associated with full-thickness fracture of the heavy 
nodular calcifications. L: left; R: right. 
Figure 1C 
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Results and comments 
Table 1 summarizes clinical data and macroscopic aspects of the four valves. Volumes and mean 
computed tomographic attenuation values of the calcific deposits are also tabulated. 
Calcium Deposits 
Valve Ring 
No Commissural Diameter Volume CT Value 
Case Sex Age Cusps Fusion (mm) (cm3) (HU) 
F 67 3 No 24 1.21 948 
2 M 71 3 Yes 24 0.29 132 
3 M 73 2 No 22 0.19 281 
4 F 50 2 Yes 20 0.17 121 
CT value = computed tomographic attenuation value; HU = Hounsfield Units; F = female; M = male 
Table 1 Clinical data, macroscopic aspects and computed tomographic evaluation of valve 
calcium deposits of the four post-mortem specimens. 
Table 2 shows the aortic valve area (AVA) obtained before and after dilatation with 
15 mm, 19 mm and 3 x 12 mm balloons in each case, as calculated by cylindrical 
calipers. 
Balloon Size 
BASAL 
15 mm 
19 mm 
3 x 12 mm 
Table 2 
Case 1 Case 2 Case 3 Case 4 
0.20 0.78 0.95 0.95 
0.28 1.76 0.95 0.95 
0.50 2.26 1.76 1.76 
0.95 3.14 2.83 2.54 
Aortic valve area (cm2) before experimental valvuloplasty and after dilatation with 15 
mm, 19 mm and 3 x 12 mm balloons, as calculated by cylindrical calipers. 
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Figure 2 represents the minimal free space (residual aortic orifice) observed during 
inflation, as determined by the region of interest contour mode. 
Residual Aortic Orifice ( cm2 ) 
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Figure 2: Computed tomographic evaluation of the residual aortic orifice (cm2) during inflation of 15 
mm, 19 mm and 3 x 12 mm balloons in the four post-mortem specimens, as determined by the region 
of interest contour mode. In cases where a bicuspid configuration was present (cases 2, 3 and 4), the 
trefoil 3 x 12 mm balloon allowed more free space between balloon and leaflets, while the monofoil 15 
mm and 19 mm balloons were both more occlusive, despite their smaller cross-sectional surfaces. 
Conversely, when the valve had a tricuspid configuration (case 1: tricuspid valve without fused 
commissure), the trefoil balloon was much more occlusive (residual aortic orifice: 0.09 cm2) than 
monofoil15 mm and 19 mm balloons (residual aortic orifice: 0.53 and 0.30 cm2, respectively). 
During inflation of the 15 mm balloon, a residual free space between the balloon and 
the aortic cusps of at least 0.30 cm2 was observed in cases 1 and 2. However, in 
presence of a congenitally bicuspid valve (cases 3 and 4), balloon inflation resulted in 
an almost complete obstruction of the aortic orifice (0.07 and 0.02 cm2, respectively). 
No gross fracture of nodular calcifications nor commissural or raphe splitting were 
observed in any specimen. A moderate increase in AVA occurred only in case 2, while 
minimal or no changes were achieved in the remaining cases (Table 2). It should be 
noted that in none of the specimens did the inflated 15 mm balloon occupy a central 
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position in the aortic orifice. The stretching induced by the balloon was more important 
on the less calcified, more flexible valve leaflets. 
Concerning the 19 mm balloon, a significant increment in AVA was achieved in all 
the specimens. Although the balloon still occupied an asymmetrical position in the 
aortic orifice, larger displacement of the free edges of the cusps were observed, 
involving the most heavily calcified leaflets. Except in case 1, which was a tricuspid 
valve without commissural fusion, this balloon was almost occlusive in the remaining 
cases. The better residual free space observed in case 1 (0.30 cm2) can be explained 
by a wider opening of the leaflets, which in turn created an increment in 
intercommissural spaces. Fracture of nodular calcifications were noted in cases 1 and 
2 at visual inspection. Partial commissural separation or central raphe splitting occurred 
in cases 2, 3 and 4. 
Conversely, despite the larger transverse diameter and cross-sectional area of the 
inflated 3 x 12 mm trefoil-shaped balloon, the residual orifice during inflation was 
paradoxically greater than with previous dilatations in all cases except in case 1, due 
presumably to the peripheral and central spaces generated by the trefoil configuration. 
This advantage of the trefoil shape was already known, but we remarked that it was 
mostly evident when a "bicuspid" configuration could be observed (case 2: tricuspid 
valve with one fused commissure; cases 3 and 4: congenitally bicuspid valves). 
However, in presence of a tricuspid morphology (case 1), the opposite effect was 
observed. This may be explained by the rigidity of the leaflets related to the 
degenerative process, which have oriented passively the individual parts of the inflating 
trefoil balloon to engage each of the three intercommissural spaces. 
CLINICOPATHOLOGICAL OBSERVATIONS 
In order to compare the results of experimental valvuloplasty to the clinical situation, 
we analysed retrospectively aortic pressure curves recorded during dilatation at the 
time of PBAV in patients who underwent subsequently a valve replacement and we 
have correlated these hemodynamic data with the anatomopathological evaluation of 
the surgically excised aortic valves. 
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Methods 
From March 1986 to October 1988, thirty-five elderly patients underwent PBAV in our 
institution. The technique of the valvuloplasty procedure itself in our institution has 
been described earlier by our group (10). Ten of these patients underwent 
subsequently an aortic valve replacement (7 for restenosis, 2 for a failed procedure 
and one patient for severe aortic regurgitation). In four of these surgical patients, a 
stepwise dilatation with 15 mm, 19 mm and trefoil 3 x 12 mm balloons had been 
performed, in the same sequence as during our in vitro experiments described above. 
Two of these patients underwent surgery for failed PBAV, since increments in AVA 
achieved by valvuloplasty were only minimal, without significant symptomatic 
improvements. The two other patients underwent valve replacement for recurrence 
of stenosis, defined as a clinical recurrence of symptoms with either a return of 
maximal aortic valve flow velocity to pre-valvuloplasty values on echo Doppler flow 
measurements, or an invasively measured AVA which was less than 25% larger than 
before PBAV. 
The hemodynamic repercussion of aortic orifice obstruction generated by balloon 
inflation was assessed by the systolic aortic pressure, continuously recorded 
throughout the procedure by a 7 F pigtail catheter positioned in the descending aorta. 
Systolic aortic pressure values were obtained by reviewing the aortic pressure tracings 
recorded on paper during the PBAV procedures. The pressure curves recorded during 
dilatation were analyzed and the lowest systolic aortic pressure values (nadir) were 
selected. Since the pressure scale on the recording paper grid was 4 mm Hg j mm, 
the lowest systolic aortic pressure value was arbitrarily rounded to 5 mm Hg (for 
example: 12 mm = 48 mm Hg; rounded to 50 mm Hg). In cases where more than one 
inflation was performed with the same balloon, the pressure curve showing the lowest 
systolic aortic pressure value was selected. Figure 3 gives an example of the aortic 
pressure curves recorded during a valvuloplasty procedure. 
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Figure 3: Patient B: Aortic pressure cuNes recorded at the time of percutaneous aortic valvuloplasty 
during dilatation with 15 mm, 19 mm and 3 x 12 mm balloon catheters. In this patient, 
anatomopathological evaluation revealed a congenitally bicuspid calcified aortic valve. Balloon inflation 
is represented by downward arrows (•) and deflation by upward arrows (r). The dotted lines show the 
point on the cuNes where the lowest systolic aortic pressure values were selected. During dilatation with 
the 15 mm balloon (upper tracing), blood pressure dropped rapidly to 60 mm Hg, but an increase to 80 
mm Hg was noted shortly after. However, the inflated monofoil19 mm balloon (center tracing) was very 
occlusive, resulting in a marked fall in blood pressure {30 mm Hg) and disappearance of the systolo-
diastolic waves. The balloon was rapidly deflated after 20 seconds and blood pressure returned almost 
immediatlyto 120 mm Hg (not shown). No loss of consciousness occurred. During inflation of the 3 x 
12 mm balloon {lower tracing), the lowest systolic pressure was 80 mm Hg and was well tolerated, even 
if that balloon had the largest inflated cross-sectional area. A transient decrease in blood pressure 
occurred at the time of deflation. This phenomenon is relatively common during deflation, although not 
completely understood. 
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Results and comments 
Table 3 summarizes clinical data, pathological findings related to the excised valves 
and hemodynamic data of the PBAV procedures. 
C Age (years) 
L 
I 
N Interval* 
I (months) 
c 
A Reason for 
L Surgery 
p Valve 
A Anatomy 
T 
H Commissural 
0 Fusion 
L 
0 Calcifications 
G 
y Tearing of 
Leaflets 
v 
A 
L Gradient 
v (mean) 
u 
L 
0 
p A.V~. 
L (em) 
A 
s 
T 
y 
Patient A 
65 
F 
T 
3+ 
PRE 48 
POST 41 
PRE 0.5 
POST 0.6 
Patient B Patient C Patient D 
73 64 74 
9 9 9 
F R R 
B B T 
+ ** 
3+ 2+ 3+ 
80 68 74 
58 41 47 
0.3 0.4 0.5 
0.4 0.6 0.7 
B - bicuspid;F - failed valvuloplasty; R = restenosis; T = tricuspid; A.V.A. = aortic valve area, 
calculated with the Gorlin's formula; PRE = before valvuloplasty;POST = after valvuloplasty 
* Time elapsed between aortic valvuloplasty and valve replacement 
** PBAV did not result in commissural separation in patient D 
Table 3 clinical data, pathological findings related to the excised valves and hemodynamic data 
obtained before and after PBAV, in patients who underwent valve replacement after 
PBAV. 
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Figure 4 illustrates the lowest systolic aortic pressure recorded in the four patients, 
when the different balloons were fully inflated. 
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Figure 4: Lowest systolic aortic pressure values recorded during inflation of monofoil 15 mm, 19 mm 
and trefoil 3 x 12 mm balloons in four patients who underwent elective percutaneous aortic valvuloplasty 
1 to 10 months before valve replacement. In cases where more than one inflation was performed with 
the same balloon catheter, the curve showing the lowest systolic pressure value was selected. In patients 
in whom a bicuspid configuration was present (B and C: congenitally bicuspid valves; D: tricuspid valve 
with one commissural fusion not separated by balloon valvuloplasty), the 19 mm balloon generated a 
more dramatic fall in blood pressure and was less tolerated than the larger trefoil 3 x 12 mm balloon (30 
vs 80 mm Hg, 25 vs 50 mm Hg, and 30 vs 60 mm Hg, respectively). Conversely, in patient A (tricuspid 
valve without commissural fusion), the trefoil balloon offered no advantage compared to the 19 mm 
balloon, as reflected by the slightly lower blood pressure observed during the 3 x 12 mm balloon 
inflation. 
The mean age was 69.0 years (range: 64-74 years) and the mean time interval 
between PBAV and valve replacement was 7.0 months (range: i-9 months). Despite 
the limited number of patients available, we noted that in patients in whom a bicuspid 
valve configuration was present (patients Band C: congenitally bicuspid valves; patient 
D: tricuspid valve with one fused commissure in which PBAV did not result in 
commissural separation), dilatation with the single circular ;g mm balloon was less well 
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tolerated than with the larger 3 x 12 mm trefoil balloon, as revealed by the systolic 
aortic pressure during inflation (Figure 4). These observations correlated well with our 
experimental findings, which have shown that inflated trefoil-shaped 3 x 12 mm 
balloons allowed more residual free space in presence of a bicuspid configuration. 
Conversely, pathological examination of the aortic valve in patient A revealed a 
calcified tricuspid valve without commissural fusion (i.e. tricuspid configuration), in 
accordance with a degenerative etiology. In this case, dilatation with the 3 x 12 mm 
balloon did not appear to offer any advantage, being as occlusive as the 19 mm 
circular balloon (Figure 4). These findings do not confirm but suggest strongly that 
intercommissural spaces may have been obstructed by each of the three individual 
parts of the trefoil balloon, as observed in our in vitro experiments. 
DISCUSSION 
In contrast with other valvular heart diseases in which balloon valvuloplasty has been 
applied, acquired AS in the elderly is characterized by a broad spectrum of valvular 
morphology. We have assessed qualitatively and quantitatively the effects of dilatation 
with different balloons in aortic valves of various morphology (bicuspid, tricuspid, fused 
and non-fused commissures) and etiology (degenerative, congenital and rheumatic), 
but the extrapolation of our experimental results to other cases with different anatomy 
should be made with caution. 
The increments in AVA achieved after experimental valvuloplasty were much greater 
than those reported in clinical trials. It seems unlikely that this discrepancy was related 
to the effects of formalin fixation. In fact, formalin preservation alters valvular fibrous 
proteins and leads to stiffening of the valve leaflets and reduction of the elastic 
properties of the aortic cusps, resulting in increased rigidity of the aortic valve leaflets. 
Thus, it seems conceivable that smaller increments in AVA would have been obtained 
after formalin fixation. However, it should be noted that previous reports (26) compared 
the effects of balloon dilatation on 27 calcific, stenotic aortic valves dilated after variable 
periods of fixation in formalin and on 12 non-preserved valves dilated either at post-
mortem examination or in the operating room and observed no apparent difference in 
results. In our experimental study, the greater increments in AVA, compared to those 
CHAPTER 6 137 
achieved in the clinical situation, are rather explained by: 1) easy and optimal 
positioning of the balloon in a non-beating heart, 2) the possibility to perform 
prolonged inflation time without creating adverse effects such as hypotension and 3) 
direct measurement of AVA by cylindrical calipers, which differs greatly from the 
Gorlin's formula used in live patients. 
Our experimental observations have demonstrated that use of balloons with 
diameter smaller than 19 mm resulted generally in minimal or no increment in aortic 
valve area. The radial forces of the inflating 15 mm balloon were initially applied on the 
less calcified and more flexible leaflets and the space occupied by the fully inflated 
balloon was not sufficient to displace substantially the free edges of the more rigid 
leaflets. This was depicted by the asymmetrical position of the inflated 15 mm balloon 
observed in all the experimental cases. Clinical experience has also shown that better 
hemodynamic improvements can usually be achieved with balloons of larger diameter 
(29). Some authors advocate the use of oversized balloons (i.e. larger than the aortic 
ring) to obtain better hemodynamic results (30) but some controversies still exist, 
based mainly on the fear of producing catastrophic complications such as tearing of 
aortic leaflets or aortic wall dissection, resulting in major aortic regurgitation, cardiac 
tamponnade or fatal aortic rupture (31 ,32). Furthermore, acquired aortic stenosis is 
frequently associated with extensive calcific vegetations, protruding into the valve 
sinuses. During balloon inflation, this calcium bulk may prevent the complete 
apposition of the aortic leaflets against the aortic wall. If oversized balloons are used 
in this situation, the trapped calcific vegetations can further increase the mechanical 
stress generated by the inflating balloon on the aortic wall, which may lead to 
disastrous consequences. Extensive calcifications may also provide additional 
explanations on the limited hemodynamic improvements achieved by PBAV in a non 
negligeable proportion of patients (19). For instance, the lowest obtained AVA in our 
experimental study occurred in the most heavily calcified valve (case 1), reflected by 
the largest volume and the highest density on computed tomographic scanning (Table 
1). In our clinical observations, the failed PBAV procedures occurred in patients A and 
B, in whom aortic valves were also heavily calcified. 
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Trefoil balloons have been developed in attempt to avoid complete interruption of 
blood flow during inflation and to reduce the frequency of marked hypotension during 
valvuloplasty procedures. This advantage has been observed during inflation across 
the aortic valve in dogs, in pulmonary valvuloplasty in adults, aortic valvuloplasty in 
children and young adults, and in mitral and aortic valvuloplasty in adults (20-24). Our 
experimental and clinical observations suggest that trefoil balloons allow a larger 
residual orifice and can provide a better blood flow during inflation in presence of a 
bicuspid configuration, despite its superior inflated cross-sectional area (3.4 cm2) 
compared to the circular 19 mm balloon (area: 2.8 cm2); on the contrary, the trefoil-
shaped balloon does not appear to offer the same advantages in presence of a 
tricuspid aortic configuration. In order to compare the trefoil 3 x 12 mm balloon with 
a single circular balloon of equivalent diameter, experimental valvuloplasty using a 
monofoil 25 mm balloon would have been interesting, but this size was not 
commercially available at the time of our in vitro experiments. Nevertheless, it seems 
conceivable that the obtained results would have been similar in cases where a 
bicuspid configuration was present, since the 19 mm balloon was already almost 
completely occlusive. 
Balloon catheters with a bifoil design have also been introduced recently. As 
mentioned previously, bifoil balloons were not assessed in our study, since they were 
not commercially available in our institution at the time of our in vitro experiments and 
they have not been used during valvuloplasty procedures in patients from whom our 
clinicopathological observations were derived. In a recent report of Voudris et al. (33), 
it has been stated that bifoil balloons offered better hemodynamic results and a better 
tolerance during inflation than monofoil and trefoil balloon catheters. The balloon 
catheters assessed in that study were monofoil19 mm (inflated. area: 2.8 cm2), bifoil 
2 x 15 mm (area: 3.5 cm2) and trefoil 3 x 10 mm (area: 2.4 cm2). The better 
hemodynamic results achieved may be related simply to the greater inflated area of the 
bifoil balloon used in that study. They also reported a higher rate of marked 
hypotension in the group of patients in which a 3 x 10 mm trefoil balloon was used. 
However, this subgroup had the more depressed left ventricular function before PBAV; 
thus, the relatively poorer tolerance of inflation observed might not be entirely related 
to the trefoil design. Furthermore, since the valvular configuration was not known, it 
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may be speculated that some of these patients had indeed aortic valves with tricuspid 
configuration and according to our observations, use of trefoil balloons in this situation 
can lead to an almost complete interruption of aortic flow and severe hypotension. 
Further experimental studies with monofoil, bifoil and trefoil balloon catheters of 
equivalent inflated cross-sectional areas, assessed in different valvular configurations, 
would certainly be very useful for improving our knowledge of the balloon - leaflets 
relationship in PBAV. 
CONCLUSION 
Our experimental and clinicopathological observations have shown that the degree 
of aortic orifice obstruction during inflation of a monofoil or a trefoil balloon is 
dependent on the underlying valvular morphology. In our opinion, these observations 
are relevant, since degenerative disease of the aortic valve is now recognized as the 
most common etiology of aortic stenosis in the elderly, based on the knowledge of the 
changing natural history of aortic stenosis observed since a few decades (34). Some 
authors have also reported that heavily calcified congenitally bicuspid aortic valves 
were at higher risk for complications from PBAV, such as irreversible hypotension 
(35). These findings demand that, in clinical practice, a careful assessment of the 
valvular anatomy should be attempted in patients in whom PBAV is planned, in order 
to individualize the choice of the valvuloplasty material and to optimize the tolerance 
of the procedure. Unfortunately, accurate characterization of the valvular morphology 
of stenotic aortic valves in elderly patients can be often misleading, due to the 
remodeling of the valve architecture by the degenerative process and calcium 
deposition. Until now, conventional techniques such as contrast angiography and 
precordial echocardiography have not been proved to be reliable for assessing 
accurately the valvular morphology of acquired AS. Transoesophageal (36) or 
intravascular echocardiography (37) can be valuable techniques to provide useful 
images of valvular anatomy and represent promising solutions to this diagnostic 
problem, especially in obese or emphysematous patients. Fiberoptic angioscopy can 
also provide diagnostic informations on aortic valvular morphology (35), but probably 
with a lesser degree of accuracy and applicability, compared to transoesophageal and 
intravascular ultrasound imaging. 
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However, all these techniques have the major disadvantage to be relatively invasive. 
But recently, ultrafast computed tomography has been used in the diagnosis of aortic 
valve stenosis and assessment of its severity in a small number of patients (38,39). 
Good correlations with catheterization-derived AVA have been obtained and in some 
patients, heavily calcified bicuspid and tricuspid aortic valves were clearly identified. 
Even if the overall accuracy is not yet defined, this noninvasive technique seems very 
promising as a diagnostic adjunct to improve the safety of PBAV. 
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CHAPTER 7 
ASSESSMENT OF THE "LONG SHEATH" TECHNIQUE FOR 
PERCUTANEOUS AORTIC BALLOON VALVULOPLASTY 
(This chapter has been published in Cathet and Cardiovasc Diagn i990; i9: i29. 
Authors are: Plante S, Beatt KJ, van den Brand M, di Mario C, Meier B, Serruys PW) 
SUMMARY 
A i 00 em long i 6.5 F valvuloplasty catheter introducer was assessed as an adjunct 
for percutaneous transluminal aortic valvuloplasty (PBAV) via the femoral artery in 3i 
patients with severe aortic stenosis. Observed improvements in peak systolic gradient 
(8i .6 ± 29.9 mm Hg vs 35.5 ± i6.0 mm Hg, p < O.OOOOOi) and aortic valve area (0.6 
± 0.4 cm2 vs i .0 ± 0.6 cm2, p < O.OOOOi) were similar to those achieved in a control 
group (C) of i 7 patients in which no femoral sheath was used. However, a shorter 
procedure duration (2i i ± 8i min. vs i i7 ± 30 min., p < O.OOi) and a reduced rate 
of vascular complications at the femoral puncture site (4i% vs 6.5%) were observed 
in patients in whom the long sheath (LS) technique was used. The frequency of other 
PBAV-related complications was comparable (C = 35%, LS = 29%, p = n.s.). 
Other technical advantages of this device are: i) prevention of looping and bending 
of the balloon catheter in tortuous vessels and easy positioning of the balloon across 
the aortic orifice provided by the LS trackability, 2) stabilisation of the balloon during 
inflation, 3) monitoring of supravalvular aortic pressure provided by the side-arm of the 
LS and reliable measurement of systolic gradient and 4) the ability to perform 
aortograms without the need of another catheter in the ascending aorta. Thus, in our 
experience, the long sheath technique is a valuable adjunct for PBAV. 
INTRODUCTION 
Percutaneous transluminal aortic balloon valvuloplasty (PBAV) is ct •rrently regarded 
as a palliative treatment for elderly patients with critical aortic stenosis (AS) not suitable 
for open-heart surgery (i ,2). Although the limited immediate hemodynamic 
improvement, inherent procedure-related complications and possible development of 
late valve restenosis have decreased the initial enthusiasm for this alternative technique 
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(3-6), PBAV remains the only therapeutical tool availp.ble for severely symptomatic 
patients with unacceptably high or prohibitive surgical risk. These current limitations 
of PBA V demand simplification of the technique, in order to decrease the duration of 
the procedure and the rate of vascular complications, and to facilitate passage of 
balloon catheters through tortuous vessels and across severely narrowed aortic 
orifices. The device described here has been developed in an attempt to achieve these 
objectives. 
Long sheaths are currently used in catheterization laboratories for trans-septal 
catheterization and myocardial biopsy by the femoral vein. Recently, they have been 
used to help the performance of PBAV (7). In a previous report (8), we have presented 
results of PBAV performed in 12 patients with severe AS, using this 100 em long 
introducer especially designed for retrograde PBAV via the femoral artery. In this 
article, we report the results of PBAV procedures performed with this device in 31 
patients and we compare the observed results and complications with our previous 
experience with the conventional percutaneous femoral artery approach. 
METHODS 
Introducer design 
The introducer consists of a polyurethane inner dilator and a 100 em long Teflon 
sheath (Schneider AG) with a 15 F internal lumen and a 16.5 F external diameter, 
connected to a proximal valve system to prevent retrograde bleeding. This proximal 
adjustable adaptor is formed by a self-sealing diabolo-shaped silicon valve and a 
proximal screw-seal. A side-arm, connected to the transparent chamber in which the 
silicon valve is located, allows intermittent flushing of both the silicon valve and the 
internal lumen of the sheath and enables the recording of the hydraulically transmitted 
pressure from the distal tip of the sheath. 
Patients 
From March 1986 to April 87, 17 patients (47% male; mean age ± SO: 73.2 ± 6.8 
years) underwent PBAV in our institution, using a conventional technique of direct 
percutaneous introduction of the valvuloplasty balloon catheters through the femoral 
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artery, as previously described (2). These patients, in whom no femoral sheaths were 
used, served as our control group. 
Thereafter, PBAV was performed with the use of the long sheath technique in 31 
patients (42% male; mean age ± SO: 66.5 ± 22.5 years) from two catheterization 
centers. The AS etiology was presumed degenerative in twenty-four patients (77%) and 
congenital (bicuspid) in the remaining cases. Informed consent was obtained before 
each procedure. 
Technique 
In the 17 patients who served as our control group, a conventional approach was 
used, consisting of direct introduction and removal of various balloon catheters 
through the femoral artery. In the long sheath group, the valvuloplasty introducer was 
inserted through the femoral artery, following adequate positioning of a 0.035 inch, 300 
em exchange guidewire across the aortic valve orifice. The guidewire is designed with 
a stiff proximal part to facilitate the insertion of the introducer and to provide a better 
trackability when attempting to cross the aortic orifice with the balloon catheter. The 
distal tip of the guidewire (7-12 em) is soft and flexible to prevent ventricular wall 
trauma. The gradual tapering of the tip of the inner dilator combined with the support 
provided by the stiff guidewire allowed easy introduction into the femoral artery. 
Progression up the ascending aorta and positioning of the distal end of the sheath just 
above the aortic valve is also facilitated, despite the frequently tortuous iliac and 
femoral vessels commonly seen in elderly patients. After removal of the inner dilator, 
multiple balloon catheters were easily positioned across the aortic valve orifice, over 
the exchange guidewire with its tip in the left ventricular cavity. The side-arm was used 
for pressure monitoring, performance of aortograms and for irrigation and intermittent 
flushing with heparinized solution; this was mandatory since blood clots can form 
rapidly in the large dead space of the sheath (Figure 1 ). At the end of the procedure, 
after reversal of the residual effect of heparin, the sheath was removed and hemostasis 
achieved by careful inguinal compression. 
In the control group, the largest balloon catheter used was 15 to 20 mm in 8 
patients, trefoil 3 x 9 mm in one patient and 3 x 12 mm in the remaining cases. In the 
long sheath group, the largest balloon catheter used was 23 to 25 mm in two cases, 
trefoil 3 x 8 in one, 3 x 9 mm in four and 3 x 12 mm in 19 patients. In two cases, the 
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bifoil 2 x 19 mm balloon was the largest balloon used. 
Figure 1: Blood clots in the lumen of the long sheath. After two balloon dilatations, the contrast injector 
was connected to the side-arm of the long sheath, for the performance of an aortogram. During pre-
filling by contrast medium, large clots were observed in the lumen of the long sheath (arrows). The 
screw-seal was removed, allowing spontaneous expulsion of the thrombi. After, the sheath was irrigated 
with heparinized solution and a supplementary dose of I.V. heparin was given. The procedure was 
continued without complications. 
Statistical analysis 
Means and standard deviations were calculated for each group of data. Unpaired 
and paired Student's t test, Chi square test and Fisher's exact test were used 
whenever appropriate. 
RESULTS 
Table i shows the hemodynamic variables measured immediatly before the 
procedure and after the last balloon dilatation in the two groups. The procedure 
duration is also tabulated. The two groups were comparable for age, sex, peak systolic 
gradient and aortic valve area before and after the procedure. Significant improvements 
in peak systolic gradient and aortic valve area were achieved in both groups. However, 
the mean procedure duration was much shorter in the long sheath group (117 ± 30 
min. vs 21; ± 81 min., p < 0.001), as reliably assessed in 14 patients (82%) of the 
control group and in 23 patients (74%) of the long sheath group. This was calculated 
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as the time elapsed from femoral puncture to the last recorded intra-aortic pressure, 
just before removal of the sheath and catheters. This included the time required for 
complete diagnostic catheterization (control group: 5 cases; long sheath group: 4 
cases) and transluminal coronary angioplasty (long sheath group: 2 cases) in the 
same session. To achieve hemostasis after removal of the long sheath, the mean 
inguinal compression time was 43 minutes (range 30-70 min., as assessed in the first 
14 patients), which was comparable to the time usually required to achieve hemostasis 
after a conventional PBAV procedure. 
Control Group Long Sheath Group 
No. Patients 17 31 
Age (years) 73.2 ± 6.8 66.5 ± 22.5 (p = n.s.) 
Sex{% Male} 47% 42% (p = n.s.) 
Peak Systolic Gradient {mm Hg) 
Before 83.8 ± 28.8 81.6 ± 29.9 (p = n.s.) 
After 39.6 ± 17.0 35.5 ± 16.0 (p = n.s.) 
Aortic Valve Area {cm2) * 
Before 0.5 ± 0.1 0.6 ± 0.4 {p = n.s.) 
After 0.7 ± 0.2 1.0 ± 0.6 {p = n.s.) 
Duration of Procedure {min.) ** 211 ± 81 117 ± 30 p <.001 
* Assessed with the Gorlin's formula 
** The procedure duration (minutes) was calculated as the time elapsed from femoral puncture to 
the last recorded intra-aortic pressure, just before removal of the sheath and catheters. 
Table 1 
For some patients {see text), this included the time required for complete diagnostic 
catheterisation or transluminal coronary angioplasty in the same session. 
Age, sex, hemodynamic data and procedure duration 
In the control group, unsuccessful introduction of a 3 x 12 mm trefoil-shaped balloon 
catheter into the femoral artery or across the aortic valve occurred in 3 patients 
(17.6%), mainly due to tortuous vessels and lack of pushability. Such unsuccessful 
attempts were not encountered in any patient of the long sheath group; in only one 
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case, we experienced a relatively difficult retrieval of a 2 x 19 mm bifoil-shaped balloon 
after rupture. The use of the long sheath technique in patients with tortuous vessels 
has facilitated the manipulation of the catheters and the exchange procedures, by 
preventing looping and bending of the balloon catheters. A good example of facilitated 
positioning of the balloon catheter across the aortic valve provided by the long sheath 
is shown in Figure 2. 
Figure 2a Figure 2b 
Figure 2: Fig.A: This 80 year-old female patient with severe aortic stenosis (aortic valve area: 0.4 cm2; 
peak systolic gradient: 66 mm Hg) was scheduled for an elective PBAV. After introduction of a 23 em 
16.5 F sheath into the right femoral artery, a 0.035 inch exchange guidewire was positioned in the left 
ventricle. However, multiple attempts at crossing the stenotic valve with a 3 x 8 mm trefoil balloon 
catheter were unsuccessful, due to bending of the catheter in the descending aorta. The procedure was 
aborted, but the short sheath was left in place and irrigated with a heparinized solution. We urgently 
ordered a long sheath, which was provided by the manufacturer within 24 hours. (Thick arrows: bendings 
of the shaft of the 3 x 8 mm trefoil balloon catheter in the descending aorta; thin arrow: Swan-Ganz 
catheter; black dot: exchange guidewire in the left ventricle.) 
Fig.B: The following day, a second PBAV was attempted. After positioning of the guidewire into the left 
ventricle, the short sheath was removed and replaced by a 100 em long sheath. The aortic orifice was 
easily crossed and consecutive dilatations with trefoil-shaped 3 x 8 mm and 3 x 12 mm balloon catheters 
were performed, without bending of the balloon catheters. The procedure was uncomplicated and 
satisfactory (aortic valve area: 0.7 cm2; peak systolic gradient: 47 mm Hg). (Thick arrows: shaft of the 
3 x 8 mm trefoil balloon catheter inside the long sheath; open arrows: distal tip of the long sheath above 
the inflated balloon; thin arrow: Swan-Ganz catheter; black dot: exchange guidewire in left ventricular 
cavity.) 
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The procedure-related complications observed in the two groups are summarized 
in Table 2. 
CONTROL GROUP 
Femoral pseudoaneurysm 
Surgical removal of 
balloon remnant 
Groin hematoma 
Total 
CONTROL GROUP 
Left hemiplegia 
Left hemianopia 
Grade 3 Aortic insufficiency 
Ventricular fibrillation 
Total 
VASCULAR COMPLICATIONS AT PUNCTURE SITE 
( 2) 
( 1 ) 
( 4) ** 
LONG SHEATH GROUP 
Surgical repair of damaged 
femoral artery 
Femoral intimal dissection 
with mural thrombosis 
7 (41 %) Total 
( 1 ) 
( 1 ) * 
2 (6.5 %) 
p < 0.05 
OTHER PBAV-RELATED COMPLICATIONS 
LONG SHEATH GROUP 
( 1 ) 
( 2) 
( 1 ) 
( 2) 
6 (35 %) 
Procedure-related death 
Pericardia! tamponnade 
Third degree AV block 
Grade 3 Aortic insufficiency 
Stroke 
Acute pulmonary edema 
Embolic myocardial infarction 
Ventricular tachycardia 
Total 
( 2) * 
( 1 ) 
( 1 ) 
( 1 ) * 
( 1 ) 
( 1 ) 
( 1 ) 
( 1 ) 
9 (29 %) 
p = n.s. 
* 
** 
These complications occurred in the same patient (see text for details). 
Large groin hematomas requiring multiple blood transfusions in two patients. 
Table 2 Procedure - related complications 
Seven patients ( 41%) of the control group developed vascular complications at the 
femoral puncture site: three required surgical intervention (2 for pseudoaneurysm 
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formation and one for removal of a balloon remnant after balloon rupture) and large 
groin hematomas developed in 4 patients, requiring multiple blood transfusions in two 
cases. 
Vascular complications occurred only in 2 patients (6.5 %) of the long sheath group. 
A 22 year-old male patient needed surgical repair of the femoral artery for severe 
bleeding after unsuccessful attempts at introducing the long sheath over a conventional 
guidewire. The other vascular complication occurred in a 73 year-old female patient in 
functional class IV (N.Y.H.A.). The procedure was uncomplicated with a single circular 
19 mm balloon (2 inflations) and a 23 mm balloon (3 inflations). In an attempt to 
achieve better hemodynamic results, the balloon catheter was exchanged for a 2 x 19 
mm bifoil-shaped balloon. After the second inflation with the latter, an aortogram 
showed severe aortic regurgitation with evidence of contrast extravasation around the 
left main coronary artery. In the following hours, her clinical condition deteriorated and 
she died one day after the procedure in a state of irreversible cardiogenic shock. 
Before death, signs of right leg ischemia were noted, suggesting a procedure-related 
complication. Post-mortem examination showed congested lungs and liver, along with 
signs of hypoperfusion in both kidneys. Examination of the heart revealed a 
hypertrophied and dilated left ventricle, moderate atherosclerosis of the coronary 
arteries and a calcified tricuspid stenotic aortic valve showing severe iatrogenic aortic 
insufficiency. An aortic intimal dissection was found, originating at the junction of the 
right and left coronary cusps, with extension to the proximal part of the left coronary 
artery. Inspection of the right leg vasculature revealed a mural dissection with occlusive 
thrombosis originating at the level of the right femoral artery puncture site. 
The rate of other PBAV-related complications (cardiac, neurological, etc.) was similar 
in the two groups (35% vs 29% for the long sheath group, p = n.s.). One intra-
operative death (long sheath group) occurred in a 77 year-old patient, with coexistent 
severe stenosis of the left main coronary artery, an occluded right coronary artery and 
a left ventricular ejection fraction of 14%, who developed irreversible cardiogenic shock 
at the end of the first inflation. Post-mortem examination did not reveal any cardiac or 
vascular damage that could have been related to the procedure itself. 
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DISCUSSION 
Cribier et al (1) reported that tortuosity of the iliac arteries or aorta impeded balloon 
exchanging procedures in 16 of 82 patients (19.5%) in whom the femoral route was 
used, preventing further dilatations with larger sized balloons, and possibly leading to 
suboptimal results. Drobinski et al. (4) atso reported that a right axillary percutaneous 
arterial approach has to be used in 4 of 37 patients (11%) for the same reasons. We 
observed a similar rate of unsuccessful attempts in our control group (17.6%), but 
such difficulties were not encountered in the long sheath group. 
It should be noted that, although many patients had tortuous iliac and femoral 
vessels, none of them had severe narrowings or subtotal occlusions, a condition which 
appears less amenable to the proposed technique. Nevertheless, the combined use 
of a stiff guidewire and a long sheath was able to straighten the vessels, allowing more 
easy passage of balloon catheters up to the ascending aorta. Stiffer guidewires were 
introduced almost simultaneously with the use of the long sheath and may have had 
an independent effect in facilitating negotiations of tortuous vessels and passages of 
balloon catheters across the aortic valve orifice. 
The improvement in procedure duration observed in the long sheath group was 
mainly related to the facilitated balloon catheters manipulations and exchange 
procedures, especially in presence of tortuous vessels. However, other factors may 
have influenced these results. For instance, the long sheath technique has been 
introduced after the performance of 17 conventional PBAV procedures in our 
institution. Therefore, the operators's previous experience (the "learning curve" effect) 
may have influenced favorably and independently the duration of the PBAV procedures 
in the long sheath group. Another bias may also arise from the small number of 
patients in the study and the incomplete data collection, since it was not possible to 
reliably assess the procedure duration in all cases, for various reasons. Other groups 
have reported procedure duration of less than 2 hours with a standard approach (4,9), 
but the time interval used for the assessment of the procedure duration was not clearly 
defined. Nevertheless, we observed a dramatic reduction in the time required for 
performing PBAV with the long sheath technique in our institution. It should be 
emphasized that patients undergoing PBAV are often severely ill or in poor general 
condition and improvement in procedure duration with easier and quicker access to 
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the ascending aorta may be crucial in reducing the inherent complication rate. 
Since the introduction of PBAV for calcific AS, the most frequently reported 
procedure-related complication has been related to local damage at the femoral 
puncture site, due to multiple insertions and removals of large balloon catheters and 
to the use of larger balloons required to achieve better hemodynamic results. The 
rate of vascular complications reported in the literature varies from 11.7% up to 32%, 
depending upon the severity of complications described (10-13). According to data 
obtained from the French Registry (more than 600 patients) (14), this rate was 
approximately 12%. In the present series, we observed a rate of 41% in patients 
treated with the standard approach, compared to only 6.5% when the long sheath was 
used. A shorter sheath, of course, would suffice for reducing the rate of vascular 
complications at the femoral puncture site, since others have reported a reduction from 
14.8% to 4.9%, using a shorter 14 F femoral sheath (9). 
The observation of such a low frequency of vascular complications with a 16.5 F 
arterial sheath may be unexpected, since the reported incidence of peripheral vascular 
damage related to the use of insertion sheaths of similar size for intraaortic 
counterpulsation balloons varies from 10% to 20% (15). However, this may be more 
related to the duration of use rather than the size of the catheter itself. On the other 
hand, the potential damage to the artery wall caused by multiple insertions and 
removals of balloon catheters frequently presenting irregular shapes andjor sharp 
edges after several inflations or after balloon rupture may be greater than that induced 
by the single insertion of a long sheath over its well-tapered inner dilator. Long sheaths 
with 14, 11.5 and 10 F diameter were also available at the time of our study. A 16.5 F 
sheath was selected in order to accommodate easily the shafts of the largest balloon 
catheters commercially available, to avoid difficult retrieval of deflated or ruptured 
balloons and to avoid damping of the aortic pressure tracing when deflated balloon 
catheters were pulled back in the lumen of the sheath. In some cases, a 14 F sheath 
might have been of sufficient size, but after having experienced a relatively difficult 
retrieval of a ruptured 2 x 19 mm bifoil balloon in one of our first patients, it was 
decided not to use sheaths smaller than 16.5 F. 
Other advantages of the long sheath technique should be emphasized. First, the 
long sheath provides stability during inflation (Figure 3), allowing the use of shorter 
balloons and preventing the to-and-fro motion of the balloon across the aortic valve, 
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which is frequently observed during inflation and may be implicated as a factor of 
ventricular perforation. 
Figure 3: Trefoil-shaped 3 x 12 mm, 40 mm long balloon (Schneider AG) inflated across the stenotic 
aortic valve. The presence of the distal end of the sheath (arrows), just above the balloon, prevents 
possible to-and-fro motion during inflations. 
Second, the side-arm located in the proximal part of the sheath enables recording 
of the hydraulically transmitted supravalvular aortic pressure, allowing reliable 
measurement of the aortic gradient. Even during balloon inflation, high quality pressure 
tracings were obtained. In a few cases, damped pressure curves were observed and 
obstruction of the distal tip of the sheath by the the inflated balloon was suspected. In 
those cases, immediate injection of contrast via the side-arm revealed that the distal 
end of the sheath was free and that the recorded aortic pressure, which correlated with 
patients's symptoms, was rather related to aortic orifice obstruction by the inflated 
balloon. Third, iatrogenic aortic valve regurgitation can be assessed easily, since good 
quality aortograms can be obtained by contrast injection either by the side-arm or via 
a pigtail catheter inserted through the long sheath. Finally, as with the use of shorter 
sheaths, the exchange procedures are performed without bleeding or the need of a 
second person to compress the punctured artery throughout the procedure. 
A major disadvantage of the long sheath is the fact that its position in the ascending 
aorta provides a potential source for cerebral/peripheral air or clot embolism, although 
we observed more cerebrovascular complications in the control group (3 patients) than 
in the long sheath group (I patient) (Table 2). In the latter, air embolism from the 
balloon itself was more likely, since the patient had a stroke almost immediatly after 
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balloon rupture. This patient was discharged a few days later, after partial recovery. In 
another patient however, a clot embolization in the left circumflex coronary artery, 
resulting in a non-fatal myocardial infarction, was probably related to the use of the 
long sheath. Meticulous purging and adequate heparinization are thus crucial. 
CONCLUSION 
In our experience, the long sheath technique provides easier and quicker access to 
the aortic orifice, especially in patients with tortuous vessels. It gives additional support 
for the passage of the balloon catheters and offers a better stability during balloon 
inflation. In our hands, the long sheath technique has been associated with a decrease 
in the number of unsuccessful attempts, a decrease in procedure duration and a 
reduction in the frequency of vascular complications at the femoral puncture site. 
However, since the two groups have been compared in a sequential way, a direct 
comparison with our previous experience may be misleading, as the improvements 
observed with the long sheath technique may be related in part to the "learning curve" 
effect. 
With the commercially available balloons catheters, the long sheath technique is a 
valuable adjunct for the performance of PBAV, despite its large diameter. Technological 
improvements are needed for manufacturing balloon catheters with smaller shafts and 
with effective balloon cross-sectional area, in order to use femoral sheaths with a 
smaller diameter and eventually further decrease the rate of vascular complications 
related to the performance of PBAV. 
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CHAPTER 8 
AORTIC VAlVE REPlACEMENT AFTER FAilED OR COMPliCATED 
BALLOON AORTIC VALVULOPLASTY, OR AFTER RESTENOSIS. 
IMMEDIATE RESUlTS, FOllOW-UP COURSE AND 
HISTOlOGIC FINDINGS 
(Part of this chapter has been submitted for publication to the American Journal of 
Cardiology under the title: Histologic changes in the aortic valve after balloon aortic 
valvuloplasty: evidence for a delayed healing process. Authors are: van den Brand M, 
Essed CE, Plante S, Mochtar B, de Feyter P, Suryapranata S, Serruys PW). 
SUMMARY 
Out of a consecutive series of 39 elderly patients who underwent percutaneous 
balloon dilatation of a severely stenotic aortic valve, 4 died within 28 days. In four other 
patients a less than 25% increase in valve area was achieved. Two of them underwent 
surgery at i and 9 months after valvuloplasty, the third patient died i9 months after 
valvuloplasty, while the fourth patient is in validity class II without operation. One other 
patient had severe aortic incompetence due to tearing off of one aortic valve leaflet, 
and was operated on within one week. Of the remaining 30 patients, ; 3, showing signs 
of restenosis, after an initial increase in valve area of at least 25%, have also been 
operated on 3 to 36 months after valvuloplasty (mean i7 months). None of the i6 
operated patients died, the in hospital postoperative course being mostly 
uncomplicated, with a mean hospital stay of i6.9 days (range i0-62 days). At a mean 
follow-up of 22.0 months after operation (range 3-39 months) none of the patients died. 
Macroscopic inspection of previously dilated aortic valves showed a tear off of the 
aortic wall of 7 mm in one case. In all other valves no macroscopic changes 
attributable to previous valve dilatation could be detected. Histology of the resected 
valves was available in i 2 patients and was compared with histology of resected non-
dilated aortic valves from iO patients in a matching age group. Microscopically the 
dilated aortic valves showed small tears or lacerations of the collagenous valve stroma, 
fractures in the calcifications and splitting of commissures that were all filled up by 
young scar tissue. This scarification may play a role in the development of restenosis. 
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However, it seems that organization and collagenisation of the scar tissue takes 
longer to develop in these aortic valves as compared to other tissues. Young scar 
tissue without collagenisation was still seen 24 months after dilatation. It is suggested 
that due to this belated collagenisation of scar tissue, restenosis might develop more 
slowly than is expected. 
INTRODUCTION 
Balloon valvuloplasty of the aortic valve has been advocated by several authors as 
an alternative for aortic valve replacement in patients with high surgical risk, or as an 
intermediate procedure to improve left ventricular function, before aortic valve 
replacement (1-8). A recent Editorial by Block stated that one has to weigh the 
benefits of a single intervention with a higher risk (operation) against a palliative 
procedure with a high recurrence rate and cumulative risks (valvuloplasty) (9). 
Recurrence rates, both clinically defined and measured invasively or noninvasively are 
indeed high, varying from 24 to 67% (6-1 0). With this high restenosis rate, subsequent 
procedures are numerous. Two recently published series reported reinterventions in 
about a quarter of the patients, after a mean follow up of six months, while another 
quarter did not survive this follow-up period (6,8). As the vast majority of patients 
undergoing balloon valvuloplasty for aortic valve stenosis are poor surgical candidates, 
operative mortality and postoperative course should be documented in these patients, 
both after unsuccessful or complicated procedures, as well as after restenosis of the 
dilated valve. 
The mechanisms and effects of aortic valve dilatation by inflated balloons depend on 
the underlying anatomy. "Calcific aortic stenosis" is applicable to all varieties of aortic 
stenosis in adults, but is usually reserved for the late calcification of bicuspid or 
tricuspid aortic valves (11). In these forms the principal mechanism of dilatation might 
be fracture of nodular calcifications, with an increased leaflet mobility. In the types of 
aortic stenosis where there is concomitant fusion of commissures, like in rheumatic 
valvular disease, separation of these commissures at dilatation might have a beneficial 
effect (12, 13). Little is known about the effects of balloon dilatation at a microscopical 
level and possible change in microscopic anatomy with time (1 0, 14, 15). To obtain an 
insight into the frequency and magnitude of these potential changes and the alterations 
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these induced damages undergo in time after dilatation, 12 valves excised during valve 
replacement were histologically examined and compared with histology of resected 
non-dilated aortic valves of patients in a matching age-group. 
PATIENTS AND METHODS 
From March 1986 through December 1989, 39 elderly patients underwent 
percutaneous balloon dilatation of the aortic valve (PBAV). Sixteen of these later 
underwent aortic valve replacement. Characteristics of all patients undergoing aortic 
valve dilatation and of the group with subsequent aortic valve replacement are 
summarized in Table 1. 
Number 
Male/female 
Mean age (years) 
Range 
Ejection fraction :::0,55 
0.40-0.54 
0.20-0.39 
<0.19 
not assessed 
Aortic valve area before dilatation 
(cm2) 
Aortic valve area after dilatation 
Aortic valve area increase (%) 
BAV 
39 
15/24 
75.1 
58-88 
22 
6 
5 
4 
2 
0.47 ± 0.14 
0.75 ± 0.19 
63.0 ± 38.0 
AVR 
16 
6/10 
72.1 
63-85 
10 
2 
2 
0.51 ± 0.11 
0.75 ± 0.15 
52.0 ± 32.0 
non AVR 
19 
7/12 
77.3 
58-88 
12 
4 
2 
1 
0 
0.45 ± 0.15 
0.74 ± 0.21 
64.0 ± 33.0 
Table 1 Characteristics of all patients undergoing balloon aortic valvuloplasty (BAV) and of patients 
with and without subsequent aortic valve replacement (AVR). Data are given as mean values 
± standard deviation. 
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Valvuloplasty procedure 
The technique of the valvuloplasty procedure itself in our institution has been 
described earlier (i6). All procedures were performed using a percutaneous femoral 
approach. After recording of baseline values to calculate on line aortic valve area, by 
measuring mean transvalvular pressure gradient and aortic valve flow, balloons of 
increasing size were introduced to increase the aortic valve area by at least 50%. The 
maximal balloon diameter employed in the first 29 patients was a trefoil 3 x i 2 mm 
balloon, while in the last i 0 patients a bifoil 2 x i 9 mm balloon was used in six 
(manufactured by Schneider-Shiley, Zurich). The bifoil balloons were employed after 
examination of the results obtained with these larger balloons in other institutes (i7-
i9). In the first seventeen patients a balloon was positioned in the aortic valve area 
over a 260 em long 0.038" diameter guide wire with a soft tip (Cordis Corporation, 
Miami). In the last 22 patients a 0.035" diameter, 300 em long back up guide wire was 
used (Schneider-Shiley, Zurich). Over this wire a iOO em long, i6.5 French diameter 
valvuloplasty balloon introducer (Schneider-Shiley, ZOrich) was positioned immediately 
above the aortic valve. This introducer sheath facilitates the exchange of balloon 
catheters, restricts the balloon movement during inflation, enables a check for aortic 
incompetence by injecting contrast through it after dilatation, and reduces the trauma 
of multiple balloon insertions (20) (see also chapter 7). A successful procedure was 
arbitrarily defined as an increase in aortic valve area of at least 25%, without death or 
major complications necessitating urgent surgery. Restenosis was defined as a clinical 
recurrence of symptoms with either, on echo Doppler flow measurements, a return of 
maximal aortic valve flow velocity to pre valvuloplasty values, or an invasive measured 
aortic valve area which was less than 25% larger than before valvuloplasty. 
Hemodynamic data before and after valvuloplasty are summarized in Table 2. 
LVSP LVEDP MSG SAVF AVA AVA 
(mmHg) (mmHg) (mmHg) (mljsec) (cm2) increase(%) 
Before (N = 39) 218 ± 37 16 ± 9 74 ± 19 176 ±50 0.47 ± 0.14 
After (N = 34) 177 ± 34 12 ± 9 43 ± 10 214 ± 49 0.75 ± 0.19 63 ± 38 
LVSP = left ventricular systolic pressure; LVEDP - left ventricular enddiastolic pressure; MSG- mean 
systolic aortic valve gradient; SAVF = systolic aortic valve flow; AVA = aortic valve area 
Table 2 Hemodynamic data of 39 patients before and after balloon aortic valvuloplasty 
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In five patients no valve area could be calculated after the procedure: two patients 
died after the first balloon inflation, two patients had severe aortic regurgitation after 
valvuloplasty, which precluded aortic valve area calculation, while in a fifth patient data 
were not recorded due to neurological complications. 
Mortality and procedural failure 
Four patients died within 28 days after balloon valvuloplasty. Two patients in severe 
failure died during the procedure after the first balloon inflation. One other patient, also 
with severe failure, had a successful procedure but died one week later due to 
progressive failure. The fourth patient had signs of aortic base dissection after inflation 
of a bifoil2 x 19 mm balloon, and died 24 hours after the procedure. One patient was 
operated on within one week after the procedure, because of severe aortic 
incompetence (Table 3, nr 7). Of the remaining 34 patients, 4 must be considered as 
failures, with an increase in valve area after dilatation of less than 25% (see chapter 4). 
Two of these patients have been operated upon (Table 3, nr 3,4). One was operated 
on within one month, the other one experienced some relief of symptoms and was 
operated on 10 months later. Of the other two with failed procedures, one died 19 
months after the procedure, while the last patient is in validity class II, 6 months after 
valvuloplasty. Of the remaining 30 patients, 13 cases with clinical signs of restenosis, 
i.e. recurrence of symptoms such as angina andjor syncope andjor dyspnoea which 
were present before dilatation and had improved afterwards were acceptable for 
operation. Six of these 13 cases had been classified as inoperable before valvuloplasty, 
three for poor left ventricular function (Table 3, nr 5, 6, 13), one for possible dementia, 
one for unoperated carcinoma uteri and one for advanced age combined with intestinal 
angiodysplasia. Another six had been classified as increased risk candidates and one 
patient preferred valvuloplasty. They all exhibited an increase in Doppler measured 
aortic valve velocities at the time of recurrence of symptoms compared with post 
valvuloplasty measurements. Hemodynamic and clinical details of these 16 operated 
patients are given in table 3. 
Nr Age Sex EF LVEDP Maximal 
(mmHG) Balloon size 
B B A (mm) 
1 63 M 0.42 31 16 20 
2 76 M 0.65 24 11 20 
3 74 F 0.63 12 2 3 X 12 
4 5 F 0.56 23 23 3 X 12 
5 75 M 0.27 25 13 20 
6 64 M 0.19 40 39 3 X 12 
7 72 F 0.72 13 22 19 
8 74 F 0.60 11 14 3 X 12 
9 85 F 0.55 11 20 2 X 19 
10 73 M 0.64 28 n.a. 3 X 12 
11 64 F 0.63 15 2 20 
12 75 M 0.60 13 8 20 
13 75 F n.a. 27 3 3 X 12 
14 72 F n.a. 5 4 15 
15 71 F 0.43 8 4 '23 
16 77 F 0.60 12 17 3 X 12 
AVA %AVA 
(cm2) Increase 
B A 
0.59 0.81 37 
0.53 0.88 66 
0.34 0.36 6 
0.49 0.57 16 
0.71 0.96 35 
0.37 0.64 73 
0.66 AI grade Ill 
0.46 0.70 52 
0.57 0.71 30 
0.59 n.a. 
0.33 0.80 142 
0.57 0.95 67 
0.39 0.71 82 
0.62 0.85 37 
0.41 0.71 73 
0.53 0.78 47 
Interval 
Valvuloplasty 
Operation 
(months) 
13 
6 
10 
1 
7 
9 
6 days 
8 
3 
13 
36 
24 
27 
20 
6 
13 
Concomitant 
Disease 
Coronary artery disease 
diabetes, nephrolithiasis 
Rheumatoid arthritis, anemia 
Mitral prosthesis, COPD 
COPD 
Usual interstitial pneumonitis 
Rheumatoid arthritis, anemia 
..... 
Ol 
~ 
Hypertension, ulcus duodeni, polyposis recti 
Coronary artery disease, intestinal anglodysplasla 
Epllepsia tarda 
Cholelithiasis, dysbasia, hypertension 
Intestinal angiodysplasia and bleeding 
Congestive heart failure 
COPD, hypertension, coronary artery disease 
SjOgren's disease, dementia?, coronary artery 
disease 
Adenocarcinoma uteri 
EF = ejection fraction of the left ventricle; LVEDP =left ventricular enddiastolic pressure; AVA= aortic valve area; B = before valvuloplasty; A= after valvuloplasty; COPD = chronic 
obstructive pulmonary disease; n.a. = not assessed; 
Table 3 Clinical characteristics and outcome of balloon aortic valvuloplasty in 16 patients subsequently operated on 
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Surgical procedure 
All patients operated on in our hospital (n = 14) were treated according to the same 
standard surgical protocol. Extracorporeal circulation was started combined with 
moderate (28°C) hypothermia and hemodilution. After aortic cross clamping cold 
crystalloid potassium cardioplegia was infused either in the aortic root or directly into 
the coronary ostia. Topical cooling was applied. Left ventricular venting was routinely 
instituted via the right upper pulmonary vein. After incision of the aortic root special 
attention was given to macroscopic inspection of the previously dilated valve, 
specifically looking for tearing of valve leaflets, fracture of calcific deposits and rupture 
of previously fused commissures. The underlying valve anatomy was established as 
mono-, bi- or tricuspid. The amount of calcification was scored as + to + + +, 
indicating, minimal, moderate or extensive involvement. After inspection, the valve 
leaflets were excised and stored for microscopic examination in twelve cases. Optimal 
decalcification of the valve ring was performed. Eleven valves were replaced by St 
Jude Medical bileaflet valves ranging in size from 21 to 25 mm. (St Jude Medical Inc., 
Minnesota, USA). Three valves were replaced by Carpentier-Edwards bioprostheses 
size no 23. (Edwards Laboratories AG, Switzerland) in one case a Mitroflow 
bioprosthesis no 23 was implanted (Symbiom Inc, Arizona, USA), while in the last 
patient surgical debridement of the tricuspid aortic valve was performed. All devices 
were implanted with interrupted Ticron 2-0 sutures. In four cases concomitant coronary 
artery bypass grafting was carried out. Mean cardiopulmonary bypass time was 122 
minutes (± 32, range 72-192) while mean aortic cross-clamping time was 90 minutes 
(± 24, range 48-135). 
Histological technique 
The fragmented resected valves from patients 2 through 12 and 15 (Table 3) were 
fixed in I 0% formalin and decalcified in rapid bone decalcifier (ROO: Dupage Kinetic 
Laboratories Inc, Plainfield, USA). Subsequently a routine paraffin processing cycle was 
applied and 51Lm sections were stained with hematoxylin and eosin and elastic-van 
Gieson stain. 
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RESULTS 
Operation and postoperative course 
As can be concluded from Table 3, one of these patients (nr 7) had aortic valve 
replacement after a complicated valvuloplasty procedure, resulting in severe aortic 
incompetence. Two other patients must be considered as failed procedures, with less 
than 25% aortic valve area increase, while the last 13 patients had restenosis. 
Nr. Valve Commissural Calcifi- Tearing Implanted In hospital In hospital 
anatomy fusion cations of leaflets valve stay rehabilitation 
(days) (weeks) 
1 B No 3 + No StJ 25 12 
2 B No 3 + No StJ 23 11 4 
3 B No 3 + No StJ 21 14 2 
4 T No 3 + No StJ 21 12 
5 B No 3 + No StJ 23 16 3 
6 B No 2 + No StJ 23 11 
7 BfT YesjNo 2+ Yes StJ 19 21 
8 T Yes 3 + No StJ 21 14 2 
9 T No 3 + No CE 23 11 3 
10 B No 3 + No CE 23 11 
11 T No 3 + No StJ 21 13 
12 T No 3 + No CE 23 10 
13 n.a n.a 3 + n.a StJ 21 15 
14 T No 3 + No surgical 11 
valvuloplasty 
15 T No 3+ No StJ 21 62 10 
16 n.a n.a 3+ n.a M 23 26 
B = Bicuspid aortic valve; T = Tricuspid aortic valve; StJ = St Jude Medical valve prosthesis; 
CE = Carpentier Edwards biological valve prosthesis; M = Mitroflow biological valve prosthesis; 
Table 4 Peroperative findings and early postoperative course after inadequate valvuloplasty and 
subsequent aortic valve replacement 
Gross anatomical findings and in hospital course in these 16 operated patients are 
summarized in Table 4. Six patients had an, in origin bicuspid valve, seven a tricuspid 
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valve and in 1 patient bicuspidy or tricuspidy could not be established with certainty. 
Two patients were operated on in another hospital. In these cases macroscopy (and 
microscopy) was not available(nr 13 and 16). Macroscopic findings attributable to the 
previous valve dilatation could be demonstrated in one patient only. In this case (nr 
7, Table 4), the original valvular anatomy could not be established with certainty. There 
were two cusps, the one posteriorly situated was thickened and heavily calcified. The 
other cusp, probably a fusion of the left and the right cusps, was remarkably 
unaffected by the degenerative process, but exhibited a tearing off of the aortic wall 
over 7 mm on the right side. It must be assumed that, through the rigidity of the 
posterior cusp, all radial balloon force had been exerted on the more pliable cusp, with 
subsequent tearing. 
Fracturing of calcific deposits was not macroscopically noticed in any case. 
The in hospital course of all patients was favorable. No patient died after the 
procedure, while the post-operative course was uncomplicated in eleven patients. In 
four patients the postoperative recovery was prolonged, once due to a sternal 
hematoma, once due to pneumonitis, once due to urinary tract infection, mental 
confusion and a Calles fracture, and in one patient due to intrathoracic bleeding 
necessitating rethoracotomy 5 days after the operation. One other patient had a 
rethoracotomy on the day of operation for intrathoracic bleeding, which did not prolong 
the recovery period. After discharge 6 patients were rehabilitated in a convalescent 
home for 2 to 10 weeks, mainly due to the social situation of these patients (older, 
unattached people). 
At a mean follow-up of 22.0 months after operation (range 3-39) no patient has died. 
Eleven patients are in validity class I (NYHA), four are in class II, and one is in class 
Ill. Thirteen patients are taking anticoagulants, three digoxin and six diuretics. The 
other medication of these patients is mainly determined by coexistent disease, such 
as hypertension, rheumatoid arthritis and epilepsia. 
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Microscopy 
The control group consisted of 4 female and 6 male patients. They underwent aortic 
valve replacement for critical aortic stenosis. Microscopically the valves basically 
presented the picture that is seen in calcific aortic stenosis (21 ). They showed marked 
fibrosis, with nodular calcifications in a hypocellular dense collagenous connective 
tissue stroma (Fig 1 ). 
Figure 1: Histologic segment of non dilated aortic valve leaflet after excision, shows nodular 
calcifications (C), in a hypocellular collagenous tissue stroma (*). 
Lymphocytes, plasmacells and capillaries could be present in the more loose 
connective tissue stroma surrounding the collagenous stroma. Where calcifications 
eroded the valve surface fibrin deposits were present between the protrusions. Small 
hemorrhages and iron laden macrophages were present subendothelially. The 
hemorrhages are considered to be an effect of manipulation during valve excision. 
All resected dilated valves showed the basic histologic changes that were also seen 
in the control group (Table 5). In two patients degenerative bone formation was 
present in the calcifications. However, a few striking differences with the control group 
are noticed. In 11 of the 12 patients, young scar tissue, consisting of a rather cell-rich 
Patient 
Nr. 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
15 
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2 
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R 
F/R? 
R 
R 
R 
'Pre-existent' pathology 
collagenary calcifi- bone superficial superficial 
stroma cation formation fibrin deposits hemorrhages 
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++ ++ + -- + 
++ ++ + -- + 
++ ++ -- -- --
++ ++ + 
++ ++ + + 
++ ++ -- --
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++ ++ + + 
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pathology as result of valvuloplasty 
young scar in young scar in calcium fragments Iron laden hemorrhages Interstitial 
collagenous stroma calcified nodule In scar macrophages deep In stroma fibrin 
+ 
++ 
++ 
++ 
+++ 
+ + with sealed commissure 
+ 
+ superficial 
++ 
++ 
++ 
++ 
++ 
+ 
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++ 
+ 
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+ + histiocytic infiltrate 
++ 
++ 
+ 
++ 
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-- + 
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+ 
C = Complicated valvuloplasty F = Valvuloplasty Failure 
Table 5 Histologic findings in 12 excised aortic valves operated on after PBAV 
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pattern of fibroblasts, capillaries and an inflammatory infiltrate composed of 
lymphocytes, plasmacells and histiocytes was present. This scar tissue seemed to fill 
up small tears or lacerations in the dense collagenous tissue stroma (11 patients) (Fig 
2a) and it also filled up fractures in the calcified nodules (7 patients) (Fig 2b). 
Figure 2a: Histologic segment of aortic valve leaflet after balloon dilatation. 
Small laceration in the dense collagenous tissue stroma (*), filled up with scar tissue (S). 
Figure 2b: Histologic segment of aortic valve leaflet after balloon dilatation. 
Scar tissue (S) filling up fractured calcified nodule (C). 
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Fragments of calcium embedded in the young scar tissue were seen in 10 patients 
(Fig 2c). 
Figure 2c: Histologic segment of aortic valve leaflet after balloon dilatation. 
Calcium fragments embedded in young scar tissue. 
In one patient a commissure was identified to be sealed together again with recent 
scar tissue. Hemorrhages and fibrin, more deeply in the valve stroma were seen in 6 
patients. Superficial fibrin deposits and hemorrhages might very well be, but were not 
considered as an effect of dilatation because they were also seen in the control group. 
One patient only showed the basic pathology of calcified aortic stenosis and no recent 
scar tissue. However, this patient was operated on 36 months after dilatation and it 
may very well be that by that time the scar tissue is completely organized and not 
recognizable as "new". There was no clear difference in microscopical appearance 
between the successfully and the 2 non-successfully dilated patients, although 1 of the 
non-successfully dilated patients showed, in addition to the presence of young scar 
tissue in the collagenous valve stroma, an extensive histiocytic reaction around 
severely fragmented calcifications (nr 3). The second patient only showed scar tissue 
between fragmented calcifications (nr 4). 
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DISCUSSION 
The reasons not to operate on these sixteen patients as a first choice were manifold. 
One patient, 85 years old, who had recently undergone hemicolectomy for 
angiodysplasia, had angioplasty of the left anterior descending artery in a previous 
session, without much improvement of her predominantly anginal symptoms. After 
valvuloplasty as a second procedure she experienced no improvement of her 
symptoms and she underwent a second angioplasty of the left circumflex artery in a 
third session. When symptoms did not improve afterwards, she was ultimately 
operated on, despite her age. 
Three other patients were declined surgery for poor left ventricular functions with 
ejection fractions of respectively 0.19 and 0.27 (one not assessed). After valvuloplasty 
their ejection fractions were respectively 0.38 ,0.42 and 0.37 and after recurrence of 
symptoms they were subsequently operated on. Two other patients were declined 
surgery, one for unoperated carcinoma and one for possible dementia. After operation 
in the former, and reevaluation in the latter case they both were accepted for surgery. 
Another nine patients all had concomitant disease such as diabetes, nephrolithiasis, 
coronary artery disease, previous mitral valve replacement, lung disease, epilepsia, 
arthritis and hypertension, or a combination of these, which together with advanced 
age made surgery less desirable. However, after recurrence of symptoms or after 
unsuccessful valvuloplasty they were nevertheless accepted for surgery. The last 
patient preferred valvuloplasty as a first choice, but underwent valve replacement after 
restenosis. 
Without intervention life expectancy is limited in patients with symptomatic aortic 
valve stenosis. Natural history data are only available from the pre-surgery era and 
show a life expectancy of 3 to 4.7 years in the presence of angina andjor syncope 
(21-23). In patients with cardiac failure the expectancy is from less than one year to 
two years (21-23). 
None of the patients died after surgical replacement of the severely stenotic aortic 
valves. The risk of valve replacement is hard to establish in this heterogeneous group 
of patients. Acar reported a 19% early mortality in patients operated on for aortic 
stenosis with or without aortic incompetence over the age of 65 in the period from 
1968 to 1979 (24). Jamieson collecting his data in the same period found a 4.7% thirty 
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day hospital mortality in aortic valve replacements for all causes in the age group over 
65 (25). In his overview of the literature an overall operative mortality was found of 
13.3% for aortic valve replacement over the age of 60 in the sixties. In the seventies 
this figure dropped to 7% for the same condition in the same age group. Deloche 
reported a 12% operative mortality in a group of 101 patients over the age of 70 with 
aortic valve replacement for aortic stenosis, between 1970 and 1980 (26). Duren 
reported a 10% hospital mortality in a comparable group of 20 patients, operated on 
between 1977 and 1985 (27). More recently Magovern reported a 4.3% operative 
mortality for aortic valve replacement in the age group over 70, while it was 26,7% 
when combined with bypass surgery for the same age group (28). In the age group 
over 80 a 30% early mortality ( < 90 days) has been reported (29). Preoperative 
selection must be the most important determinant of peri-operative mortality as stated 
correctly by the last author. So it is at least remarkable that in this group with more 
than average risk factors no in hospital mortality occurred, and the post-operative 
course was so favorable. This is the more the case as these operations were 
performed in three different hospitals, with five surgeons operating. Two authors 
reported in hospital mortality after aortic valve replacement in patients with previous 
balloon aortic valvuloplasty, the mortality being 13 and 14% respectively (30,31). 
After aortic valve replacement the prognosis for patients with severe aortic valve 
stenosis is considerably improved. An annual mortality after operation of 2.0% to 11.3% 
has been reported (25). In our series at a mean follow-up of 22 months after operation 
no patient who had undergone previous balloon aortic valvuloplasty died. It is very 
unlikely that this group of patients constituted a selected group with a more favorable 
prognosis with or without surgery, because they were all but one considered high risk 
candidates for aortic valve replacement. 
Several reports mention the percentage reinterventions after balloon aortic 
valvuloplasty after different follow-up periods. After 7 to 10 months percentages are 
noted from 12 to 29% (6,31,32). At a longer follow-up period of 17 and 24 months 
these percentages were 36 and 48% respectively (33,34). Revalvuloplasty is less 
influenced by the time of follow-up, and varies between 10 and 18% (7,33), probably 
more reflecting local policy, or different patient populations, than differences in 
restenosis percentages. Our proportion of patients operated upon after valvuloplasty 
was 41% at a mean of 17 months after valvuloplasty, while one patient underwent 
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revalvuloplasty after 14 months. Combining the operation and revalvuloplasty numbers 
yields a 44% reintervention rate. It has been our policy to refer patients for surgery in 
case of restenosis, if they are operable. Of five inoperable patients presenting with 
signs of restenosis all but one refused redilatation. 
It is difficult to appreciate these outcomes in different hospitals. Selection of patients, 
definition of inoperability, and acceptability for (re)valvuloplasty must at least in part be 
responsible for these divergencies. Also local and national logistics and availability of 
cardiac surgery might influence operative mortality. In our country with excellent 
cardiac surgical facilities, balloon aortic valvuloplasty seems only justified in very old 
patients, patients with untreatable infections, patients with unoperated or recently 
operated carcinoma, while it is open for debate whether patients with very poor left 
ventricular function should undergo balloon aortic valvuloplasty first as a bridge to 
surgery. 
The morphologic substrate of calcific aortic stenosis in the elderly is, irrespective of 
the mechanism initiating it, represented by severe fibrosis and heavy calcifications of 
the valve leaflets sometimes in combination with commissural fusion. These pathologic 
changes render the valve rigid and immobile (35,36). 
As was seen in our study, and supported by other workers (12,14,37) the effect of 
balloon valvuloplasty lies in decreasing this immobility in three ways: 
1. Cleavage or tearing of the dense collagenous valve stroma. 
2. Fracture andjor fragmentation of calcifications. 
3. Cleavage of fused commissures. 
It seems that the final outcome of PBA V mainly depends on the severity of the basic 
pathologic changes in the valve and the extent of the injury the balloon is able to 
create. In the 2 patients that had insufficient dilatation procedures with an increase of 
the aortic valve area of less than 25%, we indeed saw some injury in the valve leaflets, 
but apparently it was not extensive enough. Commeau et al (1 0) made a comparable 
observation in a peroperative study. They noticed, that when the valve was extensively 
calcified, dilatation macroscopically hardly showed any effect. On the other hand, a too 
extensive injury, holds the risk of creating too severe a damage to the valve with a 
chance of aortic insufficiency, as happened in one of our patients, where a valve leaflet 
was actually torn off the aortic wall. 
The injury inflicted to the aortic valve, appears to be followed by a scarring reaction. 
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We saw that small tears or lacerations in the collagenous valve stroma and fractures 
in the calcifications as well as cleavages of commissures were filled up with young scar 
tissue. Our observations find support in literature (14,37). Scarification is recognized 
as a possible mechanism for restenosis (14,15). Indeed, development, organization 
and collagenisation of the young scar tissue, in the tears and fractures in the valve, will 
in the course of time restore the valve's immobility, and so have the potential to lead 
to restenosis. 
However, from our study it appears that organization and collagenisation of the scar 
tissue in these valves takes longer to develop as compared to other tissues. We saw 
non-collagenous scar still present in the valves 24 months after dilatation. Normally a 
scar should be completely organized and collagenised within 6 weeks. This 
observation shows the potential for restenosis to develop slowly, so that the patient 
may expect to enjoy an acceptable complaint-free episode. 
Another conclusion that could be drawn from our observations is that the per- and 
post-operative risk of surgery in valvuloplasty patients might be overestimated. After 
all, one of the more important spin offs of the introduction of balloon valvuloplasty, so 
far has been a more liberal attitude of surgeons to operate on patients with an 
increased but acceptable risk. 
We feel that PBAV still has a place in relieving aortic stenosis in the inoperable 
elderly with severe aortic stenosis, albeit on strict indications. 
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CHAPTER 9 
MECHANISMS, NEWER TECHNIQUES AND INDICATIONS FOR 
PERCUTANEOUS BALLOON AORTIC VALVE DILATATION 
MECHANISMS 
Several mechanisms for successful dilatation have been proposed. These 
mechanisms include fracture of nodular calcifications, separation of fused 
commissures, or stretching of rigid valve leaflets, all with the aim of restoring some of 
the valve's normal mobility (1-3). Most data have been derived from inspection after 
balloon dilatations in the operating theatre (1 ,4), after postmortem dilatations (1 ,3,5), 
or from inspection of aortic valves which have previously undergone balloon 
valvuloplasty (2,6, 7). Our own histologic observations, described in chapter 8, suggest 
fragmentation of calcific deposits, also on a microscopic level, with filling of the 
cleavage line with fresh scar tissue. This scarring reaction may play a role in the 
development of restenosis, although organization and collagen deposition of the scar 
tissue occurs over a prolonged period. Becker and Hoedemaker state that the nature 
of the damage inflicted on these valves, almost by necessity dictates that restenosis 
must occur (8). 
Kennedy et al. noted in five postmortem examinations· of aortic valves previously 
subjected to balloon dilatation that in the two tricuspid valves increase in cusp mobility 
was greater than in the two bicuspid valves (9). Here the difference in outcome could 
be explained by the underlying anatomy. Unfortunately the exact anatomy of a stenotic 
aortic valve can only be ascertained before operation in a minority of patients. The 
creation of hinge points by fracturing calcific deposits by the inflated balloon, might be 
one of the more important working mechanisms of successful percutaneous 
valvuloplasty. If correct, more mobility of the valve leaflets might be achieved, by 
applying more force on the calcified, scarred valve leaflets. 
NEWER BALLOON TECHNIQUES 
Balloons with larger diameters and inflated to higher pressures, exert a greater stress 
on the wall than smaller balloons. On the other hand, oversized balloons have the 
intrinsic disadvantage of possibly dissecting the aortic wall, resulting in less support of 
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the valve leaflets on the aortic wall, with ensuing aortic valve leaflet incompetence. A 
recent publication from Dorros et al. showed a greater valve area increase after 
employment of double balloons than after the use of single balloons (1 0). The number 
of complications appeared not to increase with this alternative method although 
medium term results were not much better than with single normal sized balloons. So 
while a slightly better direct result is obtained with these larger balloons, the procedure 
is potentially more hazardous, and the medium term outcome is still at its best, only 
fair, with a high mortality and high recurrence rate after the procedure. It might be 
inferred that overstretching accelerates the restenosis process. 
Recently a new device has been described for valvuloplasty in calcified aortic 
stenosis (11). The system consists of 3 expandable prongs mounted on a freely 
movable catheter tip. The prongs can be manipulated into an expanded position from 
outside of the body. No obstruction of bloodflow occurs as with conventional balloon 
dilatation. Use of this instrument in the operating room in 10 patients, just prior to 
aortic valve replacement, yielded a substantial increase in planimetered aortic valve 
area, primarily due to improved splitting of fused commissures. Unfortunately 
commissural fusion is encountered only in a minority of cases of calcified aortic valve 
stenosis in elderly patients. Evenso, the instrument has certain potential by virtue of 
the fact that it does not obstruct aortic valve flow during expansion. Its disadvantage 
is that it fractures calcific deposits to a lesser extent. The design of the instrument has 
a high resemblance to the instruments developed around 1950 by the surgeons Brock, 
Bailey and Larzelere, as discussed in chapter 3. 
Other techniques have been advocated to create a greater cusp mobility by 
fracturing calcific deposits, retained within leaflets. Worley et al (12) described a 
technique to decalcify aortic valves by electrohydraulic shock waves. They reported 
their experiences with a lithotripsy electrode in four postmortem specimens and in five 
living patients undergoing aortic valve debridement valvuloplasty for severe aortic 
stenosis. Under both circumstances the hand held lithotriptor fragmented the 
calcifications contained within the valve leaflets, leading to less rigidity of the valve as 
estimated by palpation. In the surgical cases subsequent removal of calcific deposits 
was facilitated after the lithotriptor had been used, by creating a cleavage plane 
between fragmented calcifications and the surrounding valve tissue. No perforations 
of valve cusps were seen. One patient was operated on at 6 months follow-up for 
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severe aortic incompetence, the other four still experienced a measurable 
improvement, with mild or moderate aortic incompetence in all patients. Potential 
problems in the application of this technique in the operating theatre include 
perforation in the area of previously existing ulcerations, or burning and distortion of 
aortic valve cusps by direct contact between spark and tissue. 
The use of electrohydraulic shock waves is not necessarily the optimal means of 
decalcification. The use of ultrasonic destruction and aspiration of calcium fragments 
from the valve cusps, might improve the results of surgical debridement techniques, 
and decrease aortic cross-clamp time. Other energy sources will undoubtedly be 
introduced and might make the procedure safer (12). 
Erny and Waller (13) constructed a balloon catheter which incorporated an 
electrohydraulic lithotripsy probe at its tip. In three of five postmortem human 
specimens with severe aortic valve stenosis, a slight increase in valve area was 
apparent after utilization of this device. _No apparent increase in calcium nodule 
fracturing over a conventional balloon technique was noted, nor was there a 
perceptible ~elease of calcific fragments from the valves. In a calcified porcine aortic 
valve this lithotripsy balloon catheter resulted in massive release of calcific fragments, 
when compared to conventional balloon dilatation. 
Laser balloon valvuloplasty has also been tried recently in normal canine aortic 
valves (14). Simultaneous application of pressure and heat might be more effective 
than pressure alone to prevent elastic recoil. For this purpose two optical fibers were 
inserted in the central portion of a balloon catheter, terminating in a cylindrical diffuser. 
During balloon inflation and laser activation in vitro, a 70°C temperature was measured 
at the aortic adventitial surface. Laser balloon valvuloplasty increased (normal) aortic 
valve area more than balloon valvuloplasty. No loss of integrity of valve leaflets and 
aortic wall or charring was evident. We must point out, however, that normal aortic 
valves are hard to compare to severely stenotic valves, especially in in vitro 
experiments. The temperature recorded in this experiment will certainly be lower during 
in vivo balloon valvuloplasty, by the cooling effect of the bloodstream. And finally if 
recoil is prevented by heat application, severe valve insufficiency might ensue. 
Nevertheless experiments which aim at preventing recoil after aortic valve dilatation, 
should continue. After all, during a 20 mm balloon inflation, without a visible waist, 
aortic valve area is temporarily 3.14 cm2. Research should be directed to develop 
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instruments to stent the aortic valve area, which might ultimately lead to percutaneous 
implantable artificial aortic valves. 
NEWER INTRODUCTION TECHNIQUES 
As described in chapter 4, arterial complications at the balloon insertion site are 
numerous. With the introduction of long and short arterial sheaths, as described in 
chapter 7, arterial complication rate dropped from 41 to 6.5 %, due to less trauma from 
smooth surface sheaths, rather than sliding multiple, uneven balloons over a wire 
through the femoral artery wall. The availability of polyethylene balloons, which deflate 
to a lower profile, and pass through 12 French (4.0 mm) sheaths, has also diminished 
the arterial introduction complication rate (15). Another approach to reduction of 
vascular complications of percutaneous valvuloplasty has been reported by Cole and 
Krone (16). They advise placement of the large-bore arterial sheath in the common 
femoral artery, and to confirm this by introducing first a 5 French catheter, and inject 
8-10 cc of non ionic contrast through this catheter. Should the catheter be in the 
superficial femoral artery, than a more cephalad puncture site is selected, and the 
angiogram repeated. Puncturing the common femoral artery however, bears a 
potentially higher risk of retroperitoneal bleeding, especially if the posterior wall of the 
common femoral artery above the inguinal ligament is perforated during the puncture. 
NEWER MONITORING TECHNIQUES 
The usefulness of transoesophageal echocardiography, has been mentioned in 
chapter 5. The advantages are: readily visible anatomy of the stenotic aortic valve, 
monitoring of left ventricular function during and after balloon inflation, assessment of 
aortic incompetence after balloon inflation, and measurement of the aortic annulus and 
inflated balloon diameter (17). Especially when the procedure is performed under 
general anaesthesia, this method of monitoring the patient is without problems in our 
experience of three cases. Afterload reduction during general anaesthesia by injecting 
nitroglycerin intravenously just prior to balloon inflation, has also proven in our 
experience to make balloon inflations better tolerated, with the option of longer 
duration of balloon inflation, and quicker return to pre inflation left ventricular function. 
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Also recently the use of a percutaneously introduced intravascular ultrasound catheter 
during percutaneous balloon valvuloplasty has been reported (18). These investigators 
were able to record not only the nature of the underlying anatomy of the stenotic aortic 
valve, but also the improved mobility of the aortic valve leaflets post valvuloplasty, with 
visualisation of a crack in a calcific aortic valve nodule post valvuloplasty. Also the 
extent of the atrial septal defect after mitral balloon valvuloplasty, was clearly visible 
with this new instrument. Thus transoesophageal echocardiography and intravascular 
ultrasound catheters, may become important adjunctives to monitor valve anatomy 
before and after balloon valvuloplasty. 
NEWER CIRCULATORY SUPPORT 
Balloon valvuloplasty for the management of aortic valvular stenosis is generally 
performed in patients who are high risk operative candidates, or in whom surgery is 
actually contraindicated. Unfortunately these patients are also at high risk during 
valvuloplasty, because balloon inflation across the aortic valve is linked with a 
substantial reduction in cardiac output, leading to hypotension. 
Recently percutaneous cardiopulmonary support systems have been introduced, and 
the use of this technique during aortic valvuloplasty has been reported (19). The long 
valvuloplasty sheath and a venous sheath are introduced on one side, as described 
in chapter 4. The femoral vein and artery in the other groin were used for introducing 
20 French sheaths. Via the femoral venous sheath on this side, an 18 or 20 French 
multihole catheter was passed over a guidewire into the right atrium. Via the arterial 
sheath an 18 or 20 French catheter was positioned in the distal abdominal aorta. Both 
cannulae were then connected to the cardiopulmonary support system, which 
consisted of a pump and oxygenator. Cardiopulmonary support was achieved by 
pumping blood from the right atrium to the distal aorta at a maximal flow rate of 5.0 
liters/min. After attaining satisfactory cardiopulmonary support, valvuloplasty was 
performed in the usual manner. Vogel (19) reported 6 patients undergoing aortic 
valvuloplasty with such an approach. Aortic valve areas increased as a result of 
valvuloplasty at least twofold in all patients. In two patients self terminating ventricular 
tachycardia lasting 10 seconds was noted. No other major problems were encountered 
during these support procedures. Declining filling pressures during cardiopulmonary 
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support required fluid administration. At the termination of the procedure approximately 
1.5 liters of blood remained in the bypass system, which could not be pumped back 
into the patient. Consequently blood transfusions were required in all patients to 
compensate for this blood loss. The femoral vein and artery were closed by suture 
after removal of the cardiopulmonary support catheters at the end of the procedure. 
One patient died 12 hours after valvuloplasty following sudden ventricular fibrillation. 
Such support during aortic valvuloplasty could extend the application of aortic 
valvuloplasty to patients with severely diminished left ventricular function and 
hemodynamic instability. It also permits the use of extended balloon inflation times, 
which might improve the results of valvuloplasty. We agree with Vogel's statement 
(19): "As interventional cardiology advances into the treatment of more complex and 
advanced coronary and valvular disease, circulatory support procedures are likely to 
bridge the gap between standard transcatheter interventions and open heart surgery". 
Moreover, cardiopulmonary support, installed in the interventional catheterization room, 
also allows for less urgency during transfer of the patient to the operating room, should 
the need arise. Nevertheless these decisions depend on local policies and the 
willingness of the surgical team to accept patients for valve replacement, even if they 
are in a poor cardiac condition. It has not been demonstrated that supported 
valvuloplasty, eventually followed by aortic valve replacement offers these patients a 
more favorable outlook for the future, than direct aortic valve replacement. 
INDICATIONS FOR PERCUTANEOUS BALLOON AORTIC VALVULOPLASTY 
It should be stressed that at least in the group of elderly patients described in this 
thesis, the valve area increases only minimally, and can not compete with the effects 
achieved by aortic valve replacement. Looking at these heavily calcified, fibrous, 
scarred valves in the operating theatre, makes this conclusion hardly unexpected. But 
as pointed out in chapter 4, even minimal or temporary improvements in valve area 
can lead to a better quality of life and to a better hemodynamic situation, albeit 
temporary, by diminishing the afterload which an already severely hypertropied 
ventricle has to overcome. Minor improvements have yielded major effects. So the 
paradoxical fact presents itself that elderly patients, who are at high risk during aortic 
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valve replacement, are also the very patients who by the nature of their disease might 
expect to benefit the least from a percutaneous balloon dilatation. Balloon dilatation 
creates a greater valve area, especially if the commissures are fused. Unfortunately this 
is only the case in a minority of the elderly population described here. This is in 
contradistinction with congenital aortic stenosis, where commissural fusion is rather the 
rule than the exception. In such patients better results have been obtained. A particular 
matter of discussion could be the group of adult patients with congenital aortic 
stenosis, who are not yet symptomatic. It could be expected that in this group of 
patients, the best results could be obtained by reducing effectively and early on, the 
pressure overload on these ventricles. As hypertrophy is a process which is only partly 
reversible as shown by Krayenbuhl and coworkers (20), it might be worthwhile to 
prevent the more severe forms of hypertrophy, by dilating these valves in younger 
patients at the right moment. If the procedural risk were to become negligible, then 
even presymptomatic patients might be candidates for this procedure. 
For the elderly age group the procedure should be restricted to severely 
symptomatic patients who for whatever reason, are inacceptable for aortic valve 
replacement. These reasons could include recently operated, or inoperable 
malignancies, provided such patients are not in a terminal phase of their malignant 
disease, or very advanced age with diminished cerebral function. Infectious diseases 
precluding the implantation of an artificial valve, the necessity of performing major non 
cardiac surgery, and very poor left ventricular function are other reasons. In the last 
instance one has to weigh the risk of the palliative valvuloplasty procedure itself, 
against the diminished risk of valve replacement, once left ventricular function has 
improved. 
As most risk factors and the relative importance of these individual risk factors for 
aortic valve replacement are well known, a more accurate risk profile should be 
calculated in each patient before making an individual decision for aortic valve 
replacement or percutaneous balloon aortic valvuloplasty. These considerations should 
be discussed with the patients and their relatives in a frank and open manner. 
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SAMENVATTING 
Aortastenose is een term die algemeen gebruikt wordt voor de aandoening, waarbij 
de aortaklep vernauwd is. De aortaklep bevindt zich tussen de linker kamer en het 
opstijgende deel van de lichaamsslagader, en heeft als functie het terugstromen van 
bloed uit de lichaamsslagader naar de linker kamer te bel etten. 
Ongeveer 500 jaar geleden maakte Leonardo da Vinci schetsen van deze klep en 
trachtte hij zich met glasmodellen een inzicht te verwerven in de stroompatronen die 
optreden als het bloed vanuit de linker hartkamer deze klep passeert. 
Een eerste beschrijving van vernauwde aortakleppen vinden we terug in 1647 in het 
werk van Riverius. 
Ongeveer 200 jaar later vinden we de eerste min of meer complete beschrijving van 
aortastenose en de invloed die deze aandoening uitoefent op het overige deel van de 
bloedsomloop. Toen reeds werd vastgesteld dat een normale aortaklep, die ongeveer 
tot 3 a 4 cm2 oppervlakte kan openen, ernstig vernauwd moet zijn aleer deze 
vernauwing leidt tot een vermindering van de bloedstroom door deze klep. 
In het algemeen kan het ziektebeeld samenhangend met vernauwing van de 
aortakleppen ingedeeld worden in twee hoofdgroepen: de aangeboren en de verworven 
aortastenose. Bij de aangeboren vorm is de meest voorkomende onderliggende 
anatomie een aortaklep die bestaat uit een of twee slippen, in plaats van de normale drie 
slippige klep. Be halve dat deze aangeboren afwijking al kan lei den tot vernauwing van 
de klepopening bij de geboorte, kan een aangeboren afwijking in het aantal klepslippen 
oak met een normale wijdte van de opening gepaard gaan, en pas op latere leeftijd 
aanleiding geven tot een vernauwing. Naast deze aangeboren vorm door een te gering 
aantal klepslippen, kan het dus oak voorkomen dat deze aangeboren afwijking in de 
aanleg van de normaal voorhanden zijnde drie klepslippen, pas op latere leeftijd leidt tot 
aortastenose. In het algemeen geldt dat hoe geringer het aantal klepslippen, hoe eerder 
de verschijnselen van aortastenose zich zullen manifesteren. De verkregen vorm van 
aortastenose kan zowel bij een abnormaal aantal klepslippen als oak bij een in aanleg 
drieslippige klep optreden. De meest voorkomende oorzaak van vernauwing van een in 
aanleg normale klep was acuut rheuma, maar door een verminderd voorkomen van dit 
ziektebeeld in westerse Ianden, is nu een degeneratieve afwijking van de aortaklep, die 
zich manifesteert op oudere leeftijd, de meest voorkomende oorzaak in onze 
samenleving, doordat de bevolking steeds ouder wordt. In aile drie de ziektebeelden die 
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zich op latere leeftijd voordoen, dus vernauwing van congenitaal misvormde 
aortakleppen, rheumatische ontsteking van de aortakleppen en degeneratieve 
vernauwing van in aanleg "normale" aortakleppen kunnen verkalkingen optreden, die de 
reeds verdikte en vergroeide klepslippen nog minder beweeglijk maken. Dit proces van 
verdikking en verkalking leidt to een verhoogde weerstand voor de uitstoot van bloed uit 
de linker hartkamer, hetgeen weer leidt tot een verdikking van de spierwand van de 
hartkamer. In een later stadium kan deze voortdurende overbelasting leiden tot een 
verminderde samentrekking van de hartkamer. Verschijnselen samenhangend met een 
vernauwde aortaklep treden meestal pas laat op in het beloop van de ziekte en bestaan 
uit pijn op de borst, aanvankelijk vooral bij inspanning, duizeligheid en flauwvallen, terwijl 
kortademigheid meestal pas optreedt bij falen van de linker hartkamer. Het optreden van 
plotse dood is zeldzaam als eerste symptoom van aortastenose. Symptomen doen zich 
voor als de aortaklepopening tot minder dan 1.0 cm2 is teruggebracht, terwijl de 
meerderheid van aile patienten zelfs zonder verschijnselen blijft zolang de klepopening 
meer dan 0.7 cm2 bedraagt. Het natuurlijke beloop van deze ziekte is moeilijk vast te 
stellen, omdat de mogelijkheid tot het vaststellen van de ernst van de aortaklepafwijking 
door middel van hartcatheterisatie samen vie! met de eerste pogingen een dergelijke 
afwijking door middel van een hartoperatie te behandelen. Toch wordt algemeen 
aangenomen, onder andere door retrospectief onderzoek van overleden patienten, dat 
de levensverwachting van patienten met symptomen wijzend op aortastenose beperkt 
is tot enkele jaren. Omdat vooral oudere mensen in onze westerse samenleving 
getroffen worden door dit ziektebeeld, is het begrijpelijk dat een groat aantal patienten 
in de oudere leeftijdscategorie, ook afwijkingen aan de kransslagaderen vertonen. Het 
zichtbaar maken van de kransslagaderen door middel van hartcatheterisatie en 
selectieve coronaire angiografie behoort dan oak routine matig te geschieden bij deze 
groep patienten. 
In 1913 werd door Tuffier voor het eerst een paging gedaan een vernauwde aortaklep 
op te rekken door met de vinger de aortaklepopening te verwijden door instulpen van 
een dee! van de aortawand, juist boven het klepniveau. In de vijftiger jaren werden door 
chirurgen vaak ingenieuze instrumenten ontwikkeld om een vernauwde aortaklep in te 
snijden of op te rekken. Tegelijkertijd werden pogingen ondernomen tot het verwijderen 
van kalkneerslagen in de aortaslippen en het losmaken van aan elkaar vergroeide 
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klepslippen, welke techniek verder werd verfijnd na de invoering van de hart-long 
machine, waardoor de operatie tijd aanzienlijk kon worden verlengd. Deze techniek 
aangeduid met de Franse term " debridement", bestaat nag tot op de dag van vandaag 
en wordt toegepast bij patienten met drieslippige kleppen, redelijk behouden normale 
anatomische verhoudingen, zonder aortaklep lekkage en bij wie behandeling met 
antistollingsmiddelen, zeals gebruikelijk na implanteren van een kunststofklep, minder 
gewenst is. 
In i95i werd door Hufnagel voor het eerst een kunststofklep in de afdalende aorta 
ge"implanteerd bij een patient met aortaklep insufficientie. Deze kunstklep bestond uit 
een metalen ring met een kooi, waarin een metalen bal op en neer kon bewegen. Dit 
antwerp werd later vervolmaakt door Starr en Edwards door gebruik te maken van een 
siliconen bal en beklecing van de stalen paten van de kooi. Oak werden in dezelfde 
periode kunststof klepprothesen ontwikkeld, gelijkend op de natuurlijke aortaklep, welke 
terplaatse van de insufficiente aortaklep werden ingehecht. 
In dezelfde periode werd door Murray in Canada en D. Ross in Europa voor het eerst 
gebruik gemaakt van klepsegmenten van humane oorsprong. Later werden deze donor 
kleppen eerst gesteriliseerd, ingevroren en gedroogd, welke techniek vooral door Barratt 
Boyes in Nieuw Zeeland werd ontwikkeld. Oak niet-humane kleppen werden voor 
transplantatie gebruikt, alsook andere humane of dierlijke weefsels, al of niet met 
gebruikmaking van een frame waarop deze klep vervangende weefsels · werden 
gemonteerd. Oak prothesen uit kunststof vervaardigd ondergingen de afgelopen 40 jaar 
vele veranderingen, aile bedoeld om de kunstklep minder thrombogeen te maken, 
duurzamer en minder belemmerend voor de bloedstroom. 
Momenteel worden zowel de "debridement" techniek, verschillende homo- en 
heterografts, als kunststof kleppen gebruikt om zieke vernauwde aortakleppen te 
remodelleren of te vervangen. De controverse of biologische kleppen van humane of 
dierlijke oorsprong beter zijn dan kunstkleppen is niet in het voordeel van een van beide 
beslecht. Biokleppen hebben ongetwijfeld het voordeel dat na implantatie geen 
antistollingstherapie vereist is, maar het nadeel dat de duurzaamheid in de tweede 
decade na implantatie mogelijk minder is dan van artificiele kleppen. 
Hoe dit oak zij, vast staat dat chirurgische vervanging van de aortaklep, met welke 
prothese dan oak, nag steeds een niet anaanzienlijke kans op sterfte met zich 
meebrengt, vaaral bij audere patienten, met een verminderde linker kamerfunctie. Het 
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risico van overlijden ten gevolge van het chirurgisch vervangen van de aortaklep kan 
varieren van 5 tot 25% afhankelijk van de aanwezigheid van een aantal risicofactoren 
die door retrospectief onderzoek van geopereerde patienten konden worden 
vastgesteld. Hoewel de vooruitzichten zowel wat betreft de levensduur als de kwaliteit 
van dit resterende Ieven na een succesvolle operatie zeer gunstig zijn, heeft met name 
het risico van overlijden ten gevolge van de operatie er toe geleid dat alternatieve 
behandelingsmethoden werden aangewend, vooralsnog in de groep patienten die zich 
presenteren met ernstige symptomen van aortaklepstenose, en bij wie het operatie risico 
of door de chirurg of door de patient zelf als onaanvaardbaar hoog werd ingeschat. 
In 1966 werd door Rashkind voor het eerst een catheter met een ballon aan het distale 
einde gebruikt om een levensreddende behandeling toe te passen in pasgeborenen met 
een volledige transpositie van de long en de lichaamsslagader om een betere menging 
van beide bloedsomlopen te creeren. De ballon werd in lege toestand door het nag 
open zijnde foramen ovale van de rechter in de linker voorkamer gebracht, en na gevuld 
te zijn met contraststof teruggetrokken naar het rechter atrium om zo door een grotere 
opening tussen beide voorkamers de menging tussen beide bloedstromen te 
verbeteren. Na de introductie door Gruntzig in 1978 van kleinere opblaasbare ballonnen 
om kransslagadervernauwingen op te rekken, werd hetzelfde concept oak toegepast om 
aanvankelijk longslagader en later aortakleppen te dilatateren, vooral bij aangeboren 
vernauwingen van deze kleppen, met een bevredigdend resultaat. En hoewel pogi'lgen 
van 30 jaar geleden vooral door chirurgen ondernomen om vernauwde en verkalkte 
aortakleppen op te rekken meestal tot een onbevredigend resultaat leidden, en werden 
achterhaald door betere chirurgische technieken, is het concept van het oprekken van 
vernauwde aortakleppen nu door percutaan ingebrachte ballon catheters bij 
volwassenen in 1985 door Cribier uit Rouaan opnieuw geTntroduceerd. Zijn inspanningen 
richtten zich vooral op de groep patienten met een onaanvaardbaar hoog operatie risico, 
zoals zeer oude mensen. 
In maart 1986 hebben wij met Cribier samen de eerste patient door middel van deze 
techniek, die in de internationale literatuur de naam: percutane ballon 
aortavalvuloplastiek heeft meegekregen (PBAV), behandeld. Tot januari 1990 hebben 
wij 39 van dergelijke procedures uitgevoerd in 38 patienten, 23 vrouwen en 15 mannen. 
De gemiddelde leeftijd van deze patienten bedroeg 75 jaar. Van deze groep patienten 
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werden 25 beschouwd als inoperabel of zij vertegenwoordigden een zeer hoog operatie 
risico. Deze inschatting was gebaseerd op de leeftijd van de patienten, hun linker 
kamerfunktie en het bestaan van andere bijkomende, vaak de levensverwachting 
ernstige beperkende ziekten, zoals de aanwezigheid van een geopereerd of met 
geopereerd carcinoom, ernstige longfunctie stoornissen of infecties. De overige 13 
patienten werden niet als inoperabel beschouwd, maar hadden een aantal bijkomende 
afwijkingen die operatie minder gewenst maakten, of de patienten gaven zelf de 
voorkeur aan ballondilatatie. Van deze groep patienten zijn er vier in het ziekenhuis 
overleden, twee tijdens de procedure na een eerste ballon inflatie, een derde patient 
overleed een dag na de procedure ten gevolge van ernstige aortainsufficientie 
veroorzaakt door een dissectie van de aortabasis na ballondilatatie, terwijl de laatste 
patient 8 dagen na de procedure is overleden aan onomkeerbaar hartfalen. Een 
toeneming van de aortaklep opening met tenminste 25% kon worden bereikt in 31 van 
de overige 35 patienten. Bij de patienten die het ziekenhuis konden verlaten nam het 
klepoppervlak toe van 0.47 cm2 voor tot 0.75 cm2 na de dilatatie, terwijl het gemiddelde 
drukverval over de aortaklep afnam van 7 4 naar 43 mm Hg. 
Bij 3 patienten vond binnen 3 maanden een chirurgische vervanging van de aortaklep 
plaats, bij een van hen wegens ernstige aortainsufficientie na de procedure, bij een 
wegens een onvoldoende resultaat van de ballondilatatie, terwijl de derde patient al snel 
tekenen van restenose vertoonde. De overige patienten ondervonden allen een 
symptomatische verbetering na aortaklepdilatatie, syncopale aanvallen bijvoorbeeld, 
die tevoren bij acht patienten voorkwamen, deden zich na dilatatie niet meer voor. Oak 
klachten van angina pectoris en kortademigheid waren bij de meeste patienten 
verdwenen of verminderd na de procedure, resulterend in een betre validiteitsklasse. 
Vooral in de beginperiode ging de procedure vaak gepaard met soms ernstige 
complicaties. Complicaties ten gevolge van het invoeren en wisselen van ballon 
catheters in de arteria femoralis kwamen frequent voor, voordat een lange invoerschede 
werd gebruikt. Deze lange schede werd opgevoerd tot juist boven het aortaklepniveau 
en verhinderde dat de opgeblazen ballon uit de aortaklep opening kon schieten. Een 
ander voordeel van deze lange schede was een aanzienlijke vermindering van 
plaatselijke complicaties in de lies. Het opvoeren van ballon catheters door deze schede 
geeft aanzienlijk minder beschadiging van het gepuncteerde vat, dan het wisselen van 
balloncatheters over een ingebrachte voerdraad. Het aantal plaatselijke arteriele 
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complicaties verminderde dan oak van 41 naar 6,5%, zeals in een onderzoek in 
samenwerking met de universiteitskliniek van Geneve werd aangetoond. Oak de tijd 
benodigd voor een procedure verminderde aanzienlijk van 211 maar 117 minuten, nadat 
gebruik werd gemaakt van deze invoermethode. Zeals vermeld konden 35 patienten het 
ziekenhuis verlaten, na een gemiddelde opname duur van 6 dagen. Acht van dezen zijn 
overleden gemiddeld 15 maanden na de dilatatie, voor een groat dee! ten gevolge van 
hun hartlijden, voor een deel ten gevolge van andere ziekten, welke andere ziekten een 
aortaklepvervanging minder gewenst maakten. De gemiddelde leeftijd van deze 
overledenen bedroeg 79 jaar. Behalve de drie eerdergenoemde patienten, ondergingen 
nag 13 anderen een aortaklep vervanging, gemiddeld 17 maanden na de klepdilatatie, 
ten gevolge van het opnieuw optreden van ernstige klachten en tekenen van restensose. 
De gemiddelde leeftijd van aile geopereerde patienten bedroeg 72 jaar. Van de dertien 
patienten geopereerd drie maanden of meer na valvuloplastiek, waren 6 in eerste 
instantie als inoperabel beschouwd, 3 vanwege een sterk verminderde linker 
kamerfunctie, een vanwege een niet geopereerd uterus carcinoom, een wegens 
dementie, en een wegens hoge leeftijd gecombineerd met angiodysplasieen. Niettemin 
werden zij in tweede termijn geaccepteerd voor operatie. Een inoperabele patient met 
tekenen van restenose onderging een revalvuloplastiek. De zeven overige geopereerde 
patienten werden in eerste instantie geaccepteerd voor ballondilatatie vanwege 
bijkomende ziekten, of een voorkeur van de patient voor deze ingreep in plaats van 
operatie. Van aile zestien geopereerde patienten is er geen enkele overleden tijdens het 
ziekenhuisverblijf, noch gedurende een vervolg periode van gemiddeld 22 maanden. 
Het feit dat het hier een oudere groep patienten betreft met een grater of kleiner aantal 
risicofactoren voor sterfte tijdens of na de operatie, en de omstandigheid dat deze 
patienten door minstens vijf verschillende chirurgen in drie ziekenhuizen werden 
geopereerd, maakt dit uitstekende resultaat nag opmerkelijker. 
Een groep van 11 patienten tenslotte, met een gemiddelde leeftijd van 77 jaar is 
gemiddeld 23 maanden na een eenmalige klepdilatatie nag steeds in Ieven, en op een 
na, met aanzienlijk minder klachten. 
Van de gehele groep patienten was 87, 68 en 68% in Ieven na respectievelijk een, 
twee en drie jaar, terwijl deze percentages 62, 28 en 25% bedroegen indien aileen 
patienten die geen vervolg ingrepen ondergingen, worden beschouwd. Alles bijeen 
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verdient chirurgische therapie de voorkeur boven klepdilatatie bij patienten bij wie het 
operatierisico aanvaardbaar laag wordt ingeschat (bv. < 10%). Voor ernstig 
symptomatische patienten die niet voor operatie geaccepteerd worden, vanwege hun 
algemene, cardiale of extracardiale conditie, verdient valvuloplastiek overwogen te 
worden, omdat deze ingreep tot symptomatische verbetering leidt, ondanks het frequent 
optreden van restenose, welke dan opnieuw met valvuloplastiek behandeld kan worden, 
indien patienten nag steeds inoperabel worden geacht. 
De beslissing om tot operatie of valvuloplastiek over te gaan bij een groep patienten 
met een hoog operatierisico, zoals te verwachten is bij zeer oude patienten of patienten 
met een sterk verminderde linker kamerfunctie, dient genomen te worden in een overleg 
tussen patient, cardiochirurg en cardioloog. Oak kan valvuloplastiek bij sommige 
patienten leiden tot een verbetering van de verminderde linker kamerfunctie, hetgeen 
een latere klepvervanging minder riskant maakt. Deze beslissingen zullen mede bepaald 
worden door plaatselijke omstandigheden, zoals de beschikbaarheid en de kwaliteit van 
chirurgisch handelen. 
Doppler echocardiografie is een niet invasieve methode om de ernst van 
aortaklepstenose vast te stellen. Vooral bij hogere bloedstoomsnelheden over de 
aortaklep is deze methode specifiek voor het vaststellen van ernstige aortaklepstenose, 
bij lagere snelheden is een ernstige aortastenose niet uit te sluiten indien tevens een 
verminderde linker kamerfuctie bestaat. De stroomsnelheid kan via de vereenvoudigde 
Bernoulli formule omgerekend worden tot millimeters kwik en zo vergeleken worden met 
het tijdens hartcatheterisatie gevonden drukverval over de vernauwde aortaklep. 
Metingen bij 31 patienten voor en na ballonvalvuloplastiek, toonden een matige correlatie 
tussen de met Doppler techniek gemeten maximale stroomsnelheid en het piek 
systolische drukverschil tussen linker kamer en aorta, hemodynamisch geevalueerd. 
lndien met behulp van echo Doppler en catheterisatie technieken het resterende 
aortaklep oppervlak wordt berekend ton en deze waarden een zeer goede correlatie, al 
heeft elk van beide technieken zijn specifieke tekortkomingen. Niettemin daalde de 
maximale stroomsnelheid over de aortaklep met Doppler techniek gemeten van 4,6 tot 
4,1 meter per seconde onmiddellijk na ballondilatatie. Bij Doppler meting en gemiddeld 
10 maanden na ontslag uit het ziekenhuis nam deze snelheid weer toe tot 4,4 meter per 
seconde, wijzend op een partiele restenose. Evaluatie van patienten na aortaklepdilatatie 
door middel van Doppler stroomsnelheid metingen, gecombineerd met het registreren 
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van veranderingen in het klachtenpatroon, lijkt de aangewezen methode om deze 
patienten te vervolgen. 
De eerste catheters die gebruikt werden om aortakleppen te dilateren, bevatten aan 
het einde een enkele ballon, van verschillende lengte en met verschillende doorsneden. 
Modificaties in dit antwerp leidden tot de ontwikkeling van twee of drie parallel geplaatste 
ballonnen aan het einde van de catheter. In hoofstuk zes hebben wij getracht nadere 
informatie te verkrijgen omtrent de relatie tussen het model van de toegepaste ballon en 
de onderliggende anatomie van de te dilateren aortaklep. De mate van de theoretische 
belemmering van de bloedstroom door opgeblazen enkelvoudige en drieweg ballonnen 
werd door middel van computer tomografie gemeten in vier vernauwde aortakleppen van 
overleden patienten. Het bleek dat drieweg ballonnen, die theoretisch het voordeel 
hebben enige bloedstroom langs de opgeblazen ballonnen toe te Iaten, in deze 
experimenten tot een meer complete afsluiting van de aortaklepopening konden leiden 
dan enkelvoudige ballonnen, indien de te dilateren aortaklep drieslippig was. Deze 
theoretische beschouwingen werden geextrapoleerd naar de werkelijkheid door 
metingen van de daling van de aortadruk bij opblazen van verschillende ballonontwerpen 
in vier aortakleppen die twee- of drieslippig waren. De anatomie van deze kleppen was 
bekend doordat deze vier patienten na aortaklepdilatatie later een aortaklep vervanging 
ondergingen. Deze observaties toonden een goede correlatie met onze in vitro 
experimenten, in die zin dat dilatatie van tweeslippige kleppen met een drieweg ballon 
beter werd verdragen en tot minder aortadruk daling leidde dan oprekking door 
enkelvoudige ballonnen, en omgekeerd het gebruik van drieweg ballonnen geen 
voordeel opleverde ten opzichte van enkelvoudige ballonnen bij drieslippige 
aortakleppen. 
In hoofstuk acht worden naast de resultaten behaald met operatie van patienten die 
eerder een ballondilatatie hadden ondergaan, en die eerder zijn besproken in deze 
samenvatting, macroscopische en microscopische bevindingen bij geopereerde 
patienten gerapporteerd. Voor deze evaluatie waren 12 kleppen, die bij operatie waren 
verwijderd, beschikbaar. Slechts bij een patient werden macroscopisch afwijkingen 
gevonden die toegeschreven kunnen worden aan de voorafgaande klepdilatatie. Bij 
deze patient was een klepslip over een lengte van 7 mm losgescheurd van de 
aortawand, resulterend in ernstige aortaklep insufficientie, welke spoedoperatie 
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noodzakelijk maakte. Histologische afwijkingen in de gereseceerde kleppen, werden 
vergeleken met afwijkingen bij een controle groep van 10 patienten die tevoren geen 
klepdilatatie hadden ondergaan en oak werden geopereerd vanwege een ernstige 
aortaklepstenose. De niet tevoren met ballondilatatie behandelde kleppen toonden een 
aanzienlijke fibrose, met knobbelige verkalkingen ingebed in een celarm dicht collageen 
bindweefsel. Bij aile kleppen die verwijderd werden na voorafgaande percutane 
valvuloplastiek werden de afwijkingen die oak in de controle groep werden gezien, 
waargenomen, en bovendien in 11 van de 12 verwijderde kleppen een celrijk Iitteken 
weefsel, welk weefsel de breuklijnen in kalkophopingen en scheurtjes in het collagene 
bindweefsel opvulde. Dit Iitteken weefsel werd tot 24 maanden na voorafgaande dilatatie 
aangetroffen, en was bij een patient, 36 maanden na valvuloplastiek niet meer 
aantoonbaar. Dit zou de suggestie kunnen wekken dat organisatie van dit Iitteken 
weefsel laat optreedt en dat deze vertraagde omzetting van Iitteken in collageen weefsel 
het opnieuw optreden van vernauwing van de aortaklep vertraagt. Fragmentatie van 
kalkneerslagen in de klepslippen, het losmaken van aanelkaar vergroeide klepslippen 
en oprekking van starre klepbladen zijn waarschijnlijk gezamenlijk verantwoordelijk voor 
een grotere klepopening na dilatatie door middel van een ballon catheter. 
Diverse technieken zijn de laatste jaren aangeprezen om de resultaten van percutane 
dilatatie te verbeteren. Naast ballonnen met een grotere diameter in opgeblazen 
toestand, welke het gevaar van overrekking en verscheuring van klepslippen of de 
aortawand met zich meebrengen, werd recent een metalen dilatator geintroduceerd. Dit 
instrument, dat veel gelijkenis vertoont met de in vroeger tijden door chirurgen a vue 
gebruikte dilatator, bestaat uit drie ijzeren armen die van buitenaf geopend kunnen 
worden. Het voordeel van dit instrument is dat het minder belemmerend werkt op de 
bloedstroom en dat een grotere kracht kan worden uitgeoefend op de verkalkte en soms 
vergroeide klepslippen. Een nadeel is dat het minder invloed heeft op het kraken van 
kalkophopingen in de klepbladen. Andere methoden om de kleppen op te rekken maken 
gebruik van een vergruizer tip op een catheter gemonteerd, of catheters met een laser 
tip welke plaatselijk de opgerekte aortaklep kunnen verhitten, om zo een betere 
fragmentatie van kalkneerslagen te verkrijgen of elastische recoil na dilatatie te 
voorkomen. Voorlopig lijken deze technieken geen betere resultaten op te leveren dan 
ballon catheters. 
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Het gebruik van een lange invoerschede is reeds besproken, en biedt naar ons idee 
aanzienlijke voordelen, zowel om het aantal complicaties van ballonvalvuloplastiek te 
verminderen, als oak om de duur van de ingreep te bekorten. Behalve het voordurend 
meten van de aortadruk om het effect van ballondilatatie op de bloedstroom langs de 
opgeblazen ball on te kunnen vaststellen, verdient transoesophageale echocardiografie 
overweging tijdens de procedure. Naast een beter inzicht in de anatomie van de 
aortaklep en de invloed die ballondilatatie uitoefent op de beweeglijkheid van de 
klepslippen, kan deze methode ons een goed inzicht verschaffen in de samentrekking 
van de linker hartkamer. Met een volgende balloninflatie zou dan gewacht kunnen 
worden, totdat de linker kamertunctie zich weer hersteld heeft. Oak de toepassing van 
een hart-long machine in het catheterisatie laboratorium tijdens percutane valvuloplastiek 
is recent gerapporteerd. Het voordeel hiervan is dat de bloedcirculatie op peil blijft tijdens 
afsluiting van de aortaklepopening met een opgeblazen ballon, en de ballon dus Ianger 
opgeblazen kan blijven, zonder dat de patient bewusteloos raakt. Deze techniek kan 
overwogen worden als tijdelijke ondersteuning van de circulatie, vooral bij patienten met 
een sterk verminderde linker kamertunctie. Dit houdt wei in dat de hulp van een 
perfusionist in de catheterisatie kamer onontbeerlijk wordt, hetgeen tot wrijvingen met 
de afdeling cardiochirurgie, het normale werkterrein van perfusionisten, kan leiden. 
Concluderend zijn wij van mening dat percutane ballon valvuloplastiek een nuttige 
aanvulling kan zijn op de reeds zijn waarde bewezen hebbende chirurgische 
klepvervanging, indien patienten om wat voor reden dan oak niet aanvaardbaar zijn 
voor operatie. De techniek biedt deze groep patienten een redelijke kans op een betere 
kwaliteit van het resterende Ieven, al wordt de levensduur door deze ingreep 
waarschijnlijk vooralsnog niet verlengd. Ballondilatatie kan oak overwogen worden bij 
patienten met een sterk verminderde linker kamerfunctie, omdat zelfs minimale 
vergroting van het aortaklepoppervlak kan leiden tot een verbeterde linker kamerfunctie, 
en zo een latere aortaklep vervanging minder riskant kan maken. 
In ieder geval dient het risico van operatie en ballondilatatie vrijelijk met de patienten 
besproken te worden, om zo tot een beslissing te geraken welke ingreep bij deze 
individuele patient de voorkeur verdient. 
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